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ABSTRACT OF DISSERTATION 
 
 
OPIOID CODRUGS FOR PAIN MANAGEMENT 
 
Pain is an unpleasant sensory and emotional experience associated with actual or 
potential tissus damage or described in terms of such damage. Opioids are effective in 
treating moderate to severe pain, but opioid alone therapy is associated with several 
adverse effects, development of tolerance and addiction potential. One way to solve these 
problems is to administer opioids with adjuvant drugs. In this project several opioid 
molecules were combined with other adjuvant drugs in a single chemical entity to form a 
codrug.  
A series of codrugs were prepared by conjugation of an opioid with S-(-)-nornicotine, 
ketamine, norketamine and gabapentin. Several of the synthesized codrugs were 
evaluated for analgesic activity in the rats after oral administration. Codeine-S-(-)-
nornicotine, 3-O-acetylmorphine-S-(-)-nornicotine, and N-ethoxycarbonylgabapentin-
codeine codrugs showed greater effectiveness as well as prolonged pain management 
properties as compared to the parent drugs. Stabilities of several synthesized codrugs 
were studied in aqueous solutions from pH 1.3-7.4, in simulated gastrointestinal fluids, in 
rat plasma and in brain homogenate. Only the ester-linked codrugs showed sign of 
hydrolysis in different solutions. Carbamate-linked codrugs didn’t cleave under any 
hydrolytic condition. Pharmacokinetic study was performed on the following three 
codrugs: 3-O-acetylmorphine-S-(-)-nornicotine, N-acetylgabapentin-codeine, and N-
ethoxycarbonylgabapentin-codeine. The carbamate linkage in 3-O-acetylmorphine-S-(-)-
nornicotine codrug did not cleave in vivo to produce parent drugs. The ester linkage in N-
acetylgabapentin-codeine codrug cleaved in vivo to produce codeine and N-
acetylgabapentin, but N-acetylgabapentin did not undergo hydrolysis to produce 
gabapentin. The ester linkage in N-ethoxycarbonylgabapentin-codeine codrug hydrolyzed 
slowly in plasma to produce N-ethoxycarbonylgabapentin and codeine and then the 
carbamate linkage in N-ethoxycarbonylgabapentin hydrolyzed even slowly to produce 
gabapentin. Produced codeine also metabolized to generate some amount of morphine. 
Thus, the design and synthesis of an opiate and gabapentin codrug was achieved which 
was stable enough in the gastrointestinal tract, showed enhanced analgesic effects as 
 
compared to the physical mixture of the parent drugs, and also produced the two parent 
drugs in blood plasma. 
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Chapter 1 
Background, Literature Review and Object of the Study 
 
1.1 Pain 
According to International Association for the Study of Pain, pain is defined as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage” (Merksey, 1979). Pain is always 
subjective. We learn the application of the word „pain‟ through experiences related to 
injury in our early lives. Without any doubt, pain is a sensation in part of the body, but 
also it is unpleasant, and thus also an emotional experience. Many times, pain is reported 
even in the absence of any tissue damage or any likely pathophysiological state; this 
usually happens for psychological reasons. Pain is the most common symptomatic reason 
for seeking medical attention (Besson, 1999). Pain affects every one of us at some point 
of our lives, whether it is from headache, bruises and cuts or more severely resulting from 
surgery. Following is the summary of some major findings from the “1999 National Pain 
Survey” and “Pain in America: A Research Report” carried out in 2000: 
 Roughly 48 million people (24% of the Americans) in US suffer from pain lasting 
for six months or longer (chronic pain). 
 An additional 25 million of Americans suffer from acute pain resulting from 
surgery or accident. 
 Approximately 66% of these pain sufferers have been living with pain for more 
than five years. 
 Around 21.6 million American adults (11% of the Americans) regularly take 
prescription pain medication to manage chronic pain. 
 42% of pain sufferers are unable to work due to severity of pain. 
 63% of pain sufferers experience such severe pain that they are unable to engage 
in routine activities of daily living. 
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 Approximately 4.9 million people sought medical attention for chronic pain 
treatment in the year of 1999. 
 According to physicians‟ belief, about 40% of chronic pain patients could not 
engage in social activities due to sufferings of pain. 
 80% of - Americans believe that pain is a part of getting older. 
 60% of Americans believe that pain is just something that they have to live with. 
 28% responded that there was no solution to pain. 
 40% of - patients suffering from moderate to severe pain were unable to find 
adequate pain relief. 
 25% of pain patients had changed doctors at least three times due to insufficient 
pain relief. 
 36 million Americans missed work due to pain in the year of 1999. 
 Pain affected 83 million Americans‟ participation in various activities. 
 The most common types of pain are reported to be arthritis, lower back pain, 
bone/joint pain, muscle pain and fibromyalgia. 
These reports show that pain is a silent epidemic in the US. It is also clear that pain 
remains grossly undertreated and many times mistreated. Also, the loss of productivity 
and daily activity due to sufferings from pain is significant. Approximately US$1 trillion 
is spent every year in developed countries in direct health-care expenditure, lost work 
time and disability payments (Melnikova, 2010). Untreated pain substantially impacts 
pain sufferers and their family. A sufferer‟s quality of life is negatively impacted by pain 
and it diminishes his/her ability to concentrate, work, exercise, socialize, perform daily 
routines, and sleep. All of these negative impacts ultimately bring depression, isolation, 
and loss of self-esteem. Pain as a whole is a very active research area for pharmaceutical 
R&D mainly because of its under-treatment and frequent mistreatment. Another reason is 
that the older and still widely used analgesics can cause harsh adverse side-effects 
(Melnikova, 2010). Global pain and inflammation market sales together accounted for 
US$25 billion in the year of 2001 (Melnikova, 2010). Currently, management of pain 
depends substantially on analgesics that have been known for a long time. Non-narcotic 
analgesics (acetaminophen and aspirin), narcotic analgesics (opioids) and non-steroidal 
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anti-inflammatory drugs (NSAIDs) are the mainstays for pain management (Melnikova, 
2010). More recently, analgesic adjuvants and selective COX2 inhibitors have been 
added to the list of compounds for treatment of pain. Analgesic adjuvants are a class of 
compounds that include antidepressants, local anesthetics, and anticonvulsants. 
Inflammation-related pain is mostly treated by traditional NSAIDs, which have varying 
degrees of analgesic, anti-inflammatory and anti-pyretic activity (Scholz and Woolf, 
2002). NSAIDs are effective in treating inflammation-related pain, rheumatic disorders, 
and are useful as multipurpose pain killers (Melzack and Wall, 1965). NSAIDs inhibit 
both cyclooxygenase-1 (COX1) and COX2 enzymes. Both of these enzymes are the key 
targets in the inflammation pathway (Flower, 2003). Use of NSAIDs is limited by their 
serious gastrointestinal (g.i.) toxicity. NSAIDs containing free carboxylic acid 
functionalities cause g.i. irritation, bleeding, ulceration, and perforation. 16,500 NSAID-
related deaths are estimated in the US alone and 75,000 patients are hospitalized due to 
unacceptable side effects of NSAIDs every year (Flower, 2003). Other adverse effects of 
NSAIDs include nephrotoxicity, bronchospasm, skin rash and other allergies. Selective 
COX2 inhibitors were developed as analgesics due to their ability to retain analgesic/anti-
inflammatory effects with less toxicity, as they do not inhibit the gastro-protective COX1 
enzyme (Flower, 2003). Pfizer‟s celecoxib (Celebrex) and Merk & Co‟s rofecoxib 
(Vioxx) were approved by the FDA and launched as selective COX2 inhibitors (Renfrey 
et al., 2003). The combined total sales of these two selective COX2 inhibitor drugs in the 
year 2000 were US$4,774 million (Flower, 2003). Unfortunately, concern over the 
potential cardiovascular safety of the more selective COX2 inhibitors has risen, and this 
has led to a continuous decline in their market share in favor of NSAIDs and opioids 
(Melnikova, 2010). 
 
1.2 Opioids  
  Opioids are considered to be most effective therapeutic option in our arsenal for 
fighting serious pain (McQuay, 1999). They hold the major share of the pain market. The 
global pain market was estimated to be over US$50 billion in 2009. The pain market in 
seven major economies (the US, Japan, France, Germany, Italy, Spain and the UK) was 
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valued at US$27 billion in 2009.  A thirty six percent share of the pain market was held 
by opioid analgesics in 2009 (Melnikova, 2010).  
The term opium refers to a mixture of alkaloids obtained from the plant Papaver 
somniferum. Morphine is one of the 25 alkaloids isolated from opium poppy. Opiate 
refers to any natural or synthetic agent derived from or structurally related to morphine. 
Opioids, on the other hand, are compounds having morphine-like pharmacological 
activity. Opioids are divided into four broad groups:  
1) Endogenous opioid peptides produced by our body. Examples are the enkephalins 
and endorphins.  
2) Naturally occurring opioid alkaloids, for example morphine and codeine. 
3) Semisynthetic opioids, such as hydrocodone and oxycodone. 
4) Synthetic opioids, for example fentanyl and methadone. 
Radiolabeled morphine has been used to evaluate the location of the sites of action of 
morphine in mice, and it was found that the drug attaches to very specific areas in mouse 
brain. Those specific areas were classified as “morphine receptors” (Pert and Snyder, 
1973). Subsequent investigations have determined that endogenous compounds exist that 
stimulate morphine receptors and were termed endogenous morphines or endorphins 
(Hughes et al., 1975). Many of the clinically relevant opioids bind to morphine receptors 
or mu receptors and are thus called mu agonists. 
Opioid receptors are mostly found in CNS but are also ubiquitous throughout the 
peripheral tissues. Endogenous peptides are produced by noxious stimulation and they 
normally stimulate these opioid receptors. There are four major types of opioid receptors: 
mu, kappa, delta and sigma (Trescot et al., 2008). 
Mu receptors are mostly found in the brainstem. Some well-known agonists at the mu 
receptor are enkephalins, morphine, meperidine, fentanyl and codeine (weak agonist). 
Naloxone and naltrexone, on the other hand, are antagonists at mu receptors. Mu 
receptors produce supraspinal analgesia, respiratory depression, euphoria, urinary 
retention, sedation, constipation, and physical dependence (Trescot et al., 2008).  
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Kappa receptors are mostly found in brainstem and spinal cord. Dynorphine A is an 
agonist of the kappa receptor, while morphine is a weak agonist. Naloxone and 
naltrexone both act as antagonists at kappa receptors. Kappa receptors are responsible for 
spinal analgesia, dysphoria, sedation, and respiratory depression (Trescot et al., 2008).  
Delta receptors are mostly found in the brain and are responsible for supraspinal and 
spinal analgesia, respiratory depression, urinary retention, and physical dependence. 
Enkephalins and meperidine are examples of two agonists of delta receptors (Trescot et 
al., 2008). 
Sigma receptors are no longer considered as opioid receptors. They are responsible 
for dysphoria and psychomimetic effects.  
The following section is a brief description of the three opioids used in this current 
project. 
 
1.2.1 Morphine 
Morphine is a phenanthrene derivative and the prototypical mu receptor agonist. It 
is the gold standard opioid against with which all others are compared. It is a Schedule II 
substance, and is used to control moderate to severe pain. Morphine is mainly used for 
the treatment of non-cancer pain. Osteoarthritis is also treated with morphine rather than 
with NSAIDs as the latter therapeutic agents may cause gastrointestinal injury (Loeser 
and Melzack, 1999).  
After oral administration of morphine, only 40-50% of the administered dose 
becomes available to central nervous system. The reason for this poor bioavailability is 
morphine‟s poor lipid solubility, avid protein binding, and rapid conjugation and 
metabolism. Morphine is metabolized mostly by N-demethylation and O-glucuronidation. 
65% of a dose of morphine is metabolized to morphine-3-O-glucuronide (M3G) and 
morphine-6-O-glucuronide (M6G) primarily in the liver by the enzyme uridine-5‟-
diphosphate glucuronosyltransferase. M6G and M3G are produced in vivo in a ratio of 
1:5, and approximately 5% of morphine is N-demethylated to form normorphine. M6G is 
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believed to be an opioid agonist with a potency that is 2-4 times greater than that of 
morphine. M3G has very low affinity for mu opioid receptors and appears to be devoid of 
any significant analgesic activity (Coller et al., 2009). 
 
1.2.2 Codeine 
Codeine is a weak opioid analgesic with weak affinity for mu opioid receptors. 
Pure codeine is a Schedule II substance; however, when given in combination with other 
analgesics, it is considered as a Schedule III substance. Codeine is used for the treatment 
of mild to moderately severe pain. Codeine is also commonly used for postpartum pain 
associated with episiotomy and cesarean section (Trescot et al., 2008). The analgesic 
potency of codeine is approximately 50% of morphine potency. Studies have shown that 
80% of codeine is converted in vivo to codeine-6-O-glucuronide and 2-3% or less of 
codeine is metabolized to morphine. The rest of the molecules are metabolized to 
norcodeine (Vree et al., 2000). Some people believe that the analgesic action of codeine 
is due to its conversion to morphine, but recent studies have shown that the codeine 
metabolite codeine-6-O-glucuronide is also an active analgesic (Armstrong and Cozza, 
2003). 
 
1.2.3 Oxycodone 
Oxycodone is also a phenanthrene class opioid and a Schedule II substance. It is a 
powerful opioid analgesic and has affinity for multiple opiate receptors. Oxycodone is 
used for the treatment of moderate to severe pain. Unlike codeine and hydrocodone, 
oxycodone is a very potent analgesic. Oxycodone is metabolized in vivo to mainly 
noroxycodone and oxymorphone (Poyhia et al., 1992). Oxymorphone is an active 
metabolite and also an analgesic drug in its own right (Poyhia et al., 1992). 
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1.3 Problems Associated with Opioid Therapy 
Even though opioids are the most widely used analgesics for the treatment of 
moderate to severe pain, their use in postoperative care, and in the treatment of pain 
associated with life-shortening illnesses, such as cancer, is complicated by numerous 
side-effects associated with opioid therapy. The following is a summary of the major 
adverse effects produced by opioid analgesics. 
Constipation and nausea are the most common opioid side effects, and usually 
occur with very high incidence. Constipation occurs in 40-90% of opioid-treated patients 
and can occur even with a single dose of morphine (Berde and Nurko, 2008). Opioids 
cause bowel dysfunction through several effects, including blockade of propulsive 
peristalsis, inhibition of secretion of intestinal fluids, and increase of intestinal fluid 
absorption (Kurz and Sessler, 2003). Constipation is often dismissed as a trivial side-
effect, but the long term consequences of chronic constipation have an adverse effect on 
patient quality of life. Chronic constipation can cause hemorrhoid formation, rectal pain 
and burning, bowel obstruction and potential bowel rupture and death. Severe 
constipation can also lead to dose reduction for the opioids, resulting in decreased and 
inadequate analgesia. Unlike many other side effects, tolerance does not develop to the 
constipatory effects of opioids (Benyamin et al., 2008). 
Cellular immune suppression and decreased resistance to bacterial infection has 
been observed in guinea pigs treated with morphine. Opioids are believed to be the cause 
behind the increased incidence of infection in heroin addicts. Although exogenous 
opioids create immunosuppression, endogenous opioids are believed to induce 
immunoactivation (Benyamin et al., 2008). 
Opioids are known to cause hormonal changes in human body. Various studies 
have shown that opioids affect a variety of hormones, such as testosterone, estrogen, 
luteinizing hormone, dehydroepiandrosterone, andrenocorticotropin, and cortisol. Men 
taking prescribed or illicit opioids frequently suffer from several adverse side effects, 
including erectile dysfunction, decreased libido, depression, and decreased energy levels 
(Benyamin et al., 2008). 
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Opioid induced sedation is a very common side effect in opioid-naïve patients. 
Over time, tolerance to this side effect often develops. Dose initiation and rapid dose 
escalation in opioid therapy may cause sedation leading to reduced quality of life. Also, 
opioids exert negative effects on psychomotor/driving performance, especially in opioid-
naïve patients. After initiation of opioid therapy for pain management, a patients‟ ability 
to operate heavy machinery may be diminished and the patient may not be able to drive 
automobiles properly. After reaching a stable opioid analgesic regimen, patients are 
generally allowed to drive (Pud et al., 2006). 
Opioid-induced bladder dysfunction is a well-known complication in 
postoperative patients. Some studies have demonstrated urinary retention in 3.8-18.1% of 
patients taking opioids for post-operative pain management (Benyamin et al., 2008).  
Some opioids are believed to have cardiovascular side effects, although the 
occurrence is not very common. Morphine is known to release histamine in the human 
body causing vasodilation and hypotension (Benyamin et al., 2008). 
Development of tolerance and physical dependence are some of the very critical 
issues associated with opioid therapy. Tolerance refers to a phenomenon in which 
exposure to a drug results in the diminution of an effect, or the need for a higher dose to 
maintain an effect, and is one of the most common side-effects of opioid therapy. 
Tolerance causes decreasing effectiveness of opioids over time and ever-increasing dose 
requirements to provide adequate analgesia. Tolerance can be both pharmacokinetic and 
pharmacodynamics in origin. Pharmacokinetic tolerance is caused by changes in the 
metabolism of opioids after repeated administration, whereas pharmacodynamic 
tolerance is represented as the decreased analgesic effectiveness of opioids over time. 
One of the major clinical concerns when starting a patient on long term opioid therapy is 
the maintenance of analgesic efficacy of the opioid over time. Tolerance to some of the 
adverse side-effects of opioids also occurs, and this has positive benefits. Physical 
dependence is represented by development of an altered physiological state that is 
revealed by an opioid withdrawal syndrome following abrupt dose reduction, 
discontinuation of the drug, or administration of an antagonist drug. Physical dependence 
on opioids is a very common phenomenon and is expected to occur in all individuals 
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during continuous use of opioids for therapeutic or non-therapeutic purposes. Symptoms 
and signs of withdrawal syndrome include craving for opioids, restlessness, irritability, 
increased sensitivity to pain, nausea, abdominal cramps, insomnia and anxiety 
(Ballantyne, 2006). 
Addiction to opioids is a complex phenomenon involving several components, 
such as genetic, environmental, psychological, and the inherent properties of the drug 
itself. Addiction in the context of pain management with opioid therapy is characterized 
by a persistent pattern of dysfunctional opioid use that may include: adverse 
consequences associated with the use of opioids, loss of control over the use of opioids, 
and/or preoccupation with obtaining opioids despite the presence of adequate analgesia. 
Studies have shown that, after a treatment period, drug craving was observed in 8.7% of 
the patients on morphine compared to 4.3% on placebo (Moulin et al., 1996). In another 
study, 16% of the active patients were found to be abusing their opioid medications 
(Okie, 2010). 
Among all the complications associated with opioids, respiratory depression and 
death are the most feared ones. In the eyes of many patients, opioids are essentially legal 
heroin. In-between 1979 and 1990 the average drug poisoning death rates were 5.3% 
every year; however from 1990 to 2002 the death rates increased to 18.1% per year 
(Okie, 2010). During the same period of time, the number of deaths caused from opioid 
poisoning increased 91.2%. In 2007 there were 11,499 deaths caused by overdose of 
opioids, which is more than the number of deaths due to heroin and cocaine combined. 
Visits to the emergency department for opioid abuse more than doubled from 2004 to 
2008. Admission to substance abuse treatment programs increased by 400% between 
1998 and 2008, with prescription opioids being the second most prevalent type of abused 
drug after marijuana (Okie, 2010). 
In addition to all of these complications, opioids are also associated with other 
side effects, which include dizziness, cognitive dysfunction, urinary retention, vomiting, 
loss of appetite, pruritus, and ileus. 
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In addition to the adverse effects, opioids are not effective for the treatment of all 
types of pain syndromes. Pain is broadly divided into two categories: nociceptive and 
neuropathic pain. Nociceptive pain occurs as a result of activation of nociceptors (free 
nerve endings) by noxious stimuli, such as heat, pressure, and inflammatory mediators 
(Loeser and Melzack, 1999). Examples of nociceptive pain include postsurgical pain, 
inflammatory pain and low back pain. Nociceptive pain is often described as being 
constant, dull and aching in nature. Nociceptive pain is responsive to opioids. On the 
other hand, neuropathic pain occurs as a result of damage to the peripheral or central 
nervous system. Examples of neuropathic pain include diabetic neuropathy, pain from 
stroke, and pain from spinal cord injury. Neuropathic pain is described as burning, 
tingling and shooting in nature. Neuropathic pain is much less responsive to opioids 
(Foley, 2003). 
 
1.4 Combination Therapy for Pain 
Due to the above discussed complications related to opioid therapy and the 
ineffectiveness of opioids-alone therapy in treating neuropathic pain, it is well established 
that opioids should not be used in isolation to treat pain, and that the goals of treatment 
will commonly require additional medications, such as anticonvulsants, antidepressants, 
NSAIDs and other adjuvant analgesics (Gilron and Max, 2005). The theory behind this 
combination therapy for pain is to lower the dose to avoid side-effects, in addition to 
covering a broad spectrum of pain, i.e., to treat both nociceptive and neuropathic pain. 
The amplification of the desired pain relief effect while decreasing, or at least not equally 
increasing, the adverse side-effects inherent to the individual analgesics, is the main goal 
of combination therapy. A logical way to achieve this target is to combine agents that 
have complimentary mechanisms of action (Kalso, 2005). By combining two such agents, 
both mechanisms are expected to contribute in additive fashion to the analgesic effect, or 
may even be synergistic, and the adverse effect profile is expected to be more favorable 
than using individual agents to achieve the same level of analgesia (Raffa et al., 2003). 
There may be several advantages to using combination therapy over using a single 
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analgesic agent, and some of the advantages are discussed below, in addition to some 
disadvantages of combination therapy. 
 A combination strategy for pain management can produce increased efficacy in 
two ways. First, individual analgesic agents may not always produce complete 
pain relief, whereas addition of another analgesic or adjuvant may produce better 
efficacy. This is particularly beneficial if the combined agents are synergistic. 
Even if the drug combination produces just additive analgesia but there is less 
additivity of side-effects, the drug combination could still be clinically favorable. 
Secondly, a broader spectrum of pain relief can be achieved by combining 
analgesics of two different classes and mechanisms (Lussier et al., 2004). 
 If additivity or synergism leads to maximal efficacy at lower doses, a decreased 
opioid dose can be achieved. This will also result in less side-effects generated 
from opioids use. Also, adjuvant drug may antagonize some of the opioid adverse 
side-effects (Raja and Haythornthwaite, 2005). 
 A common aim for combination therapy is to reduce side-effects. By achieving an 
equivalent analgesic efficacy with reduced amounts of individual analgesic 
agents, combination therapy offers the potential benefit of a reduced side-effect 
profile for each agent (Raffa, 2001). 
 Development of tolerance to opioids can be prevented by using an effective 
analgesic drug combination. 
 Combination therapy may reduce the number of doses and may simplify the 
dosing schedule compared to dosing with individual analgesic agents. Greater 
convenience will produce greater patient compliance. 
 The use of combination therapy using individual agents may increase the cost of 
treatment, but the decreased cost of treating adverse effects may actually decrease 
the overall cost of treatment. 
 Concern over dose inflexibility comes into picture when agents are administered 
individually in a combination therapy. In case of a fixed ratio product, increasing 
the dose of one component without increasing the dose of the other component is 
not possible. 
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Four different combination strategies were chosen for this project based on current 
literature. In each of these approaches, opioids were combined with other agents having 
analgesic action but belonging to drug classes with different mechanisms of action. The 
following list represents four different combination strategies that were studied in this 
current project. 
 Combination of opioids and nicotinic receptor agonists 
 Combination of opioids and NMDA receptor antagonists 
 Combination of opioids and anticonvulsants 
 Combination of opioids and cannabinoids 
The following section describes the rationale for choosing each of the above 
combination therapies. 
 
1.4.1 Opioid-Nicotinic Receptor Agonist Combination 
Given the clear indication that current analgesic drugs may not provide adequate 
analgesia without causing adverse side-effects, a great deal of research emphasis has been 
placed on identification of novel molecular targets that might form the basis for the 
development of new analgesic agents. Neuronal nicotinic acetylcholine receptors 
(nAChRs) are among these new series of molecular targets (Vincler, 2005). Nicotinic 
receptors are located in the central nervous system at sites known to be important in pain 
processing. Neuronal nicotinic receptor agonists are effective in a broad spectrum of 
animal pain models, including acute thermal pain models (tail-flick, hot plate) and 
neuropathic pain assays (spinal or sciatic nerve ligation) (Flores, 2000). Both anti-
hyperalgesic and anti-allodynic effects have been observed in neuropathic pain models 
using nicotinic receptor agonists (Flores, 2000). Hyperalgesia refers to an exaggerated 
response to a noxious stimulus. Allodynia is represented by a painful response to a 
normally non-noxious stimulus. Neuropathic pain is characterized by several abnormal 
sensations. Hyperalgesia and allodynia are two of these kinds of abnormal sensations. 
Varieties of preclinical studies have shown that activation of neuronal nAChRs produces 
antinociception in various pain models and drugs acting at nicotinic receptors can be 
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expected to have analgesic properties (Arneric et al., 2007). Nicotine has been known to 
have weak analgesic activity for more than sixty years. Nicotine produces its analgesic 
effects by activating the neuronal nAChRs (Lippiello et al., 2007). Antinociceptive effect 
of nicotine in animals is typically of limited duration and is attenuated with repeated 
dosing. Moreover nicotine has a number of side-effects that preclude its use as a 
therapeutic agent. Side-effects of nicotine include adverse effects on autonomic function, 
its addictive nature, cardiovascular, gastrointestinal, and respiratory toxicity and tolerance 
(Decker and Meyer, 1999). Also, nicotine has a narrow therapeutic window and lacks 
selectivity for neuronal nicotinic receptors. The major issue for the successful 
development of analgesic agents from the class of nicotinic receptor agonists appears to 
be separation of efficacy from toxicity (Holladay et al., 1997). 
Nornicotine is an active metabolite of nicotine. It is the N-desmethyl derivative of 
nicotine. It might be a feasible candidate to investigate as a nicotinic receptor agonist and 
novel analgesic agent. Nornicotine is pharmacologically and pharmacokinetically 
different from nicotine in several aspects; i.e., nornicotine has:  
 Better oral bioavailability than nicotine (Ghosheh et al., 1999, 2001) 
 A longer half-life in brain and plasma (Ghosheh et al., 1999, 2001) 
 Greater brain accumulation upon repeated administration (Ghosheh et al., 1999, 
2001) 
 Less toxicity relative to nicotine (Papke et al., 2007) 
 Less potent compared to nicotine in dependence-producing properties (Bardo et 
al., 1999) 
 Less potent than nicotine against thermal antinociception in mice (Bardo et al., 
1999) 
Nornicotine exists in two enantiomeric forms as S-(-) and R-(+)-nornicotine. Holtman 
et al. (2010) performed a recent study to determine: (i) if either or both of the 
enantiomers of nornicotine have analgesic activity in well-established rodent models of 
acute and chronic pain; (ii) if the analgesic activities of S-(-) and/or R-(+)-nornicotine are 
separated from adverse side-effects; and (iii) if an enhanced analgesia and reduced side 
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effect profile can be achieved when either of the enantiomer of nornicotine is combined 
with morphine. 
Several interesting facts evolved from the study. A summary of the results is provided 
below. 
 Antihyperalgesic and antiallodynic effects of S-(-) and R-(+)-nornicotine were 
observed in a CCI model of neuropathic pain. 
 The antihyperalgesic effect of the S-(-) enantiomer was approximately three-fold 
greater than the R-(+) enantiomer. 
 The S-(-) enantiomer was more effective than the R-(+) enantiomer at comparable 
doses. 
 R-(+)-nornicotine caused a significant decrease in locomotor activity compared to 
the control (saline). No statistically significant side-effects were observed in case 
of S-(-)-nornicotine. Thus, the undesirable side-effects were more pronounced 
with the R-(+) enantiomer. 
 A dose of S-(-)-nornicotine that caused an undesirable side-effect was higher than 
a dose that produced a desirable analgesic effect. 
 When given in combination, S-(-)-nornicotine at a dose that had no 
antinociceptive effect on its own, significantly enhanced morphine nociception in 
rats in the tail-flick test. 
 A similar combination of dose of morphine and R-(+)-nornicotine produced less 
pronounced antinociceptive effect. 
 A low dose of morphine enhanced the effectiveness of S-(-)-nornicotine at doses 
showing no antinociceptive effects on their own. 
 S-(-)-nornicotine at doses devoid of any significant analgesic activity of their own, 
produced dose-related antihyperalgesia in the presence of a low dose of morphine 
in the CCI pain model. 
 No motor effects were observed during combination therapy at the maximum 
antihyperalgesic doses of morphine and S-(-)-nornicotine. 
 Thus, the analgesic property resides predominantly in S-(-)-nornicotine while the 
side- effects were more pronounced with the R-(+) enantiomer. 
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 S-(-)-Nornicotine had an expanded therapeutic index compared to R-(+)-
nornicotine. 
 S-(-)-Nornicotine might be an analgesic agent of value, either alone or in 
combination with a mu-opioid agonist such as morphine as a novel analgesic 
therapy in managing a broader range of pain. 
 Enhanced analgesic activity and reduced toxicity, observed with higher doses of 
each drug, might be achieved by combining S-(-)-nornicotine with morphine. 
 
1.4.2 Opioid-NMDA Receptor Antagonist Combination 
There is evidence in the literature that pain associated with peripheral tissue or 
nerve injury involves activation of NMDA receptors (Petrenko et al., 2003; Parsons, 
2001). Thus, NMDA receptor antagonists were expected to have analgesic behavior. 
Many NMDA receptor antagonists have been shown to effectively relieve pain-related 
behavior in preclinical animal models, as well as in clinical settings (McCartney et al., 
2004). Also, attention has been focused on the concept of combining NMDA receptor 
antagonists with opioids in an effort to enhance analgesia, reduce side effects, and limit 
the development of tolerance and dependence potential. Recent research studies have 
shown the potential utility of combining NMDA receptor antagonists with opioids in 
rodents and humans (Mao, 1999). NMDA receptor antagonists are known to exhibit 
enhanced and prolonged opioid antinociception and reduced development of tolerance 
and physical dependence (Price et al., 2000). Thus, combination therapy with opioids 
may be useful in treating neuropathic pain, which is poorly managed by opioid alone 
therapy. Ketamine is a noncompetitive NMDA receptor antagonist and an intravenous 
anesthetic. Ketamine has been available in clinical practice for more than thirty years. 
Both preincisional and postincisional administration of ketamine was found to be useful 
as an adjuvant to opioids in several clinical trials (Hocking and Cousins, 2003). Ketamine 
is also considered as an additive in surgical situations with large opioid requirements 
(Subramaniam et al., 2004). In addition to its usefulness in surgical pain management, 
ketamine is also considered as a useful adjuvant for the management of pain in cancer 
patients (Subramaniam et al., 2004).  
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A recent study in rodent models of pain showed that combination of ketamine 
with two different opioids (morphine and methadone) resulted in a synergistic 
antinociceptive action in the neuropathic paw and additive antinociceptive effects in the 
normal paw (Pelissier et al., 2003). All the above findings support the combination of 
ketamine with opioids for a well-balanced pain treatment. 
Ketamine is associated with side effects such as sedation, dysphoria and 
hallucinations. In the body, ketamine is extensively metabolized to norketamine, the N-
desmethyl derivative of ketamine. Norketamine is also an NMDA receptor antagonist and 
is expected to have analgesic activity. A recent study done by Holtman et al. (Holtman et 
al., 2008 [1]; Holtman et al., 2008 [2]) revealed some interesting facts regarding the 
analgesic effects norketamine and norketamine-morphine combinations. A summary of 
these findings is provided below: 
 Norketamine showed efficacy in two well established rodent models of persistent 
pain; the chronic constriction nerve injury rodent model of peripheral neuropathy 
(CCI) and the formalin model of tonic inflammatory pain. 
 The antinociceptive effect of norketamine could be separated from significant side 
effects. 
 Norketamine might be an effective agent for treatment of chronic pain. 
 Norketamine has lower potency than ketamine in attenuation of nociception in the 
nerve injury assay (CCI model) or injury to peripheral tissue assay (formalin test). 
 The time courses for both antihyperalgesia and motor dysfunction were of shorter 
duration for norketamine than for ketamine. 
 Norketamine might be likely to have a better side-effect profile than ketamine. 
 Norketamine, in a dose range having no antinociceptive activity, significantly 
increased the antinociceptive effect of low doses of morphine in the tail-flick test. 
 Norketamine, at doses which are not antihyperalgesic or antiallodynic alone, 
enhanced the effects of morphine against mechanical hyperalgesia and tactile 
allodynia in rats in the CCI pain model. 
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 A norketamine and morphine drug combination did not produce motor 
dysfunction at doses that achieved maximum efficacy against thermal 
nociception, mechanical hyperalgesia and formalin induced flinches. 
 No over toxicity was observed with a norketamine-morphine combination, as 
shown by a lack of sedation in rats. 
 A norketamine and morphine combination had no significant effect on locomotor 
activity. 
 A norketamine and morphine combination therapy might be useful for the 
treatment of a broader range of pain, including acute nociceptive, neuropathic and 
persistent inflammatory pain. 
 
1.4.3 Opioid-Gabapentin Combination 
Gabapentin is an anti-epileptic agent which was initially developed as a gamma-
aminobutyric acid mimetic compound for the treatment of spasticity (Mao and Chen, 
2000). Later, gabapentin was shown to have clinically useful anticonvulsant effects (Rose 
and Kam, 2002). Initially approved to treat partial seizures, gabapentin showed promise 
as an analgesic agent for the treatment of chronic pain syndromes, especially neuropathic 
pain (Mao and Chen, 2000). Both clinical and experimental studies suggest that 
gabapentin has analgesic effects in neuropathic pain (Gupta et al., 2004). Preclinical 
studies also suggested that gabapentin has antinociceptive properties in animal models of 
both nociceptive pain and neuropathic pain (Bennett and Simpson, 2004). Many animal 
experiments have also revealed that gabapentin increased the antinociceptive effects of 
opioids in a variety of animal pain models when given in combination with opioids 
(Nicholson, 2000). The following is the summary of the results obtained from several 
animal experiments carried out with gabapentin alone and in combination with an opioid. 
 A recent study conducted by Meymandi et al. showed that a high dose of 
gabapentin increased the latency time significantly when compared to a control 
group in rat tail-flick experiments. It was also found that co-administration of 
gabapentin with morphine increased both tail-flick latency time and duration of 
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action compared to rats treated with morphine alone. Thus it can be concluded 
that gabapentin enhances morphine antinociception in acute models of pain 
(Meymandi et al., 2006).  
 Another study performed by O-Arciniega et al. involving neuropathic pain 
induced by chronic constriction nerve injury showed synergistic antinociceptive 
interaction of morphine and gabapentin. Combination of a low dose of morphine 
with gabapentin demonstrated supra-additive effect on mechanical hyperalgesia 
and cold allodynia (O-Arciniega et al., 2009).  
 The antinociceptive effect of a morphine and gabapentin combination was 
evaluated in a study by Shimoyama et al. after spinal administration of the 
morphine-gabapentin combination. The authors found that when sub-
antinociceptive doses of morphine and gabapentin were co-administered, there 
was a significant antinociceptive effect in the rat tail-flick test. Furthermore, the 
sub-antinociceptive dose of gabapentin shifted the dose-response curve for 
morphine to the left, demonstrating a potentiation of the antinociceptive effects of 
morphine. Enhancement of antinociception resulting from the combination of 
spinal morphine and gabapentin suggests that the drug combination might be 
effective for the treatment of persistent pain syndromes in patients (Shimoyama et 
al., 1997).  
 Gilron et al. investigated the effect of gabapentin to prevent and reverse chronic 
opioid tolerance. These studies demonstrated that the combination of morphine 
and gabapentin resulted in a maximal and supra-additive antinociceptive effect in 
the paw pressure and tail-flick tests. Also, visual inspection of the treated animals 
did not show any sign of motor impairment. It was also observed that gabapentin 
inhibited the development of antinociceptive tolerance to morphine. Gabapentin 
was also able to partially restore opioid potency in tolerant rats in the paw 
pressure test (Gilron et al., 2003).  
In addition to the above series of animal experiments, gabapentin also showed 
enhancement of the analgesic effect of opioids in clinical studies. In a recent study 
performed by Eckhardt et al. on healthy volunteers, where analgesic effects were assessed 
by using the cold pressor test, the investigators showed that gabapentin significantly 
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enhanced the analgesic effect of morphine (Eckhardt et al., 2000). A single oral dose of 
600 mg of gabapentin did not show any effect on its own in comparison to placebo. 
However, both pain tolerance and pain threshold were increased after the administration 
of morphine plus gabapentin in comparison to morphine plus placebo. 
 
1.4.4 Opioid-Cannabinoid Combination 
A body of evidence suggests the existence of independent but interacting 
mechanisms of modulation of antinociception by cannabinoid and opioid systems 
(Hohman et al., 1999). It has been shown previously that ∆
9
-THC and morphine exhibit 
synergistic effects in the production of antinociception (Williams et al., 2006). 
Importantly, cannabinoids have been shown to produce analgesia through interaction 
with kappa opioid receptors in the spinal cord by releasing endogenous opioids (Hohman 
et al., 1999). 
A synergism between morphine and ∆
9
-THC has also been observed in the spinal 
cord of mice. Inactive doses of both morphine and ∆
9
-THC showed a greater than 
additive effect when given by i.v. administration (Bidaut-Russell and Howlett, 1988; 
Reche et al., 1996). A mixture of these two drugs produced an analgesic effect through 
mu opioid receptor-mediated as well as CB1 cannabinoid receptor-mediated pathways. 
 
The following section of Chapter 1 is taken from the published chapter 
“Improving the use of Drug Combinations through the Codrug Approach” (Part Three: 
Codrugs and Soft Drugs, Chapter 13, Page Number 347-383) coauthored by Peter A. 
Crooks, Harpreet K. Dhooper, and Ujjwal Chakraborty and published in the book 
„Prodrugs and Targeted Delivery: Towards Better ADME Properties‟, edited by Jarkko 
Rautio. Copyright © 2010 WILEY-VCH, ISBN: 978-527-32603-7. Published in the year 
of 2010. 
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1.5 Codrug 
There are advantages of delivering a single chemical entity than a physical 
mixture of two drugs. There are instances in prodrug design where the prodrug molecule 
incorporates two identical or non-identical drugs into a single chemical entity. This is 
often desirable when two synergistic drugs have different physicochemical and 
pharmacokinetic properties, and it is desirous to have the parent drugs released 
concomitantly at the site of action to obtain a synergistic pharmacodynamic effect that is 
not attainable by delivering a physical mixture of the two drugs. Also, one of the drugs in 
the codrug structure may be incorporated to counterbalance the known side-effects 
associated with the other parent drug, or may amplify the pharmacodynamic effect of the 
other parent drug through an action at another biological target. Thus, codrugs can be 
designed to overcome various barriers to drug formulation and delivery, such as poor 
aqueous solubility, chemical instability, insufficient oral absorption, rapid pre-systemic 
metabolism, inadequate brain penetration, toxicity and local irritation. Structurally, a 
codrug (also known as a mutual prodrug, or hybrid drug) comprises two or more different 
drugs within a single chemical entity where the drugs must each contain an appropriate 
chemical functionality to enable them to be connected together, either directly or by 
means of a cleavable, biolabile covalent linker (Hamad et al., 2006). Such codrugs can be 
either bipartate or tripartate in nature (Silverman, 2004) (Fig.1. 1) and the design of the 
linker moiety can be adopted from current linker design strategies and chemistry already 
established in the broad area of prodrug design. 
Thus, a codrug strategy can be useful when: 
• Synergistic drugs need to be given concomitantly to act at the same time, either at 
the same or different biological targets. 
• The physicochemical properties of two synergistic drugs are not favorable for 
delivery of the two drugs as a physical mixture, but can be improved by chemical 
combination of the two drugs. 
• Improved pharmacokinetics results from a chemical combination of two 
synergistic drugs compared to those of a physical mixture of the two drugs. 
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Fig. 1.1:  Examples of bipartate and tripartate codrugs: A) conjugation of a carboxylic 
drug with an alcoholic drug to form a bipartate codrug where the two drugs are connected 
by an ester linkage which cleaves in vivo to release only the two parent drugs; B) 
conjugation of two alcoholic drug molecules via a carbonate ester linker to form a 
tripartate codrug which cleaves in vivo to form the two parent drugs and an equivalent of 
carbonic acid. 
 
As with prodrugs, the codrug structure can incorporate two drugs joined together 
by linker moieties such as ester, carbonate, amide, carbamate, etc., which are then 
cleaved enzymatically in vivo to release the active drugs at a required site in the body. By 
appropriate structural design of these linkers, it may be possible to control the release 
kinetics of one or both drugs. When the two drugs are chemically combined together, the 
resulting codrug will usually have different physicochemical properties to those of the 
individual parent drugs, which may provide superior properties for delivery of the two 
drugs when compared to delivery of a physical mixture of the drugs (Howard, 2007).
 
 
1.5.1 Ideal Codrug Characteristics 
An ideal codrug will generate the parent drugs with high recovery rates, and will 
incorporate linkers that give rise to non-toxic linker residues upon in vivo cleavage. There 
may be other advantages in delivering of two drugs as a single chemical entity versus a 
physical mixture. These include, for example, improved chemical stability of the 
formulation (i.e. no chemical interaction of the two parent drugs within the formulation), 
improved metabolic stability (especially with regard to possible protection of either drug 
from high first pass metabolism), as well as improved targeting of drugs to the site of 
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action (e.g., the central nervous system), and more desirable pharmacokinetic properties, 
in particular for drugs with different physicochemical properties (e.g., differences in lipid 
solubility or polarity). 
There are also certain disadvantages that are associated with a codrug strategy. 
One disadvantage is that codrugs are usually large molecules with molecular weights that 
are often greater than 500. Thus, codrugs with large molecular weights may well violate 
Lipinsky‟s rule of five (Lipinski et al., 2001) as unfavorable molecules for oral or topical 
dosage form development, or for CNS delivery.  In addition, by the very nature of their 
structural design, these cleavable molecules may possess poor stability profiles for 
formulation development. Thus, it must be initially established that the codrug is resilient 
enough to withstand the rigors of formulation development, but must not be too stable 
that it will not efficiently cleave to the parent drugs in vivo. 
Another important aspect of codrug design is the toxicological significance of 
delivering a codrug to an individual. Since codrugs are novel chemical entities (although 
the parent drugs they generate may or may not be novel), they will have to be treated as 
new xenobiotics by the FDA, as are all new drugs entities that have never been 
previously administered to humans. Thus, there are important toxicological and safety 
issues associated with the development of codrugs, as they move toward clinical status. 
Several important criteria are required for codrugs to be effective. The codrug 
must be well absorbed and distribution, metabolism and elimination of the codrug should 
be superior to the physical mixture of the parent drugs. Both parent drugs should be 
released concomitantly and quantitatively after absorption, and the maximal effect of the 
drug combination should occur when a simple molar ratio, i.e. 1:1, 2:1, or 3:1, is utilized. 
Before designing the codrug, one needs to know the route of administration. 
Routes of administration can be broadly divided into topical, enteral and parenteral 
routes. The topical route involves a local drug effect. The drug is directly applied where 
the action is desired, e.g. asthma medications, eye or eardrops, and decongestant nasal 
sprays. In the enteral route, drug administration involves any part of the gastrointestinal 
tract. The effect is non-local. Sublingual, oral and rectal are all enteral routes. In 
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sublingual administration, the drug is placed under the tongue, is rapidly absorbed and 
avoids first-pass metabolism. The first-pass effect term refers to the hepatic metabolism 
of a drug when it is absorbed from the gastrointestinal tract and delivered to the liver via 
the hepatic portal circulation. The greater the first-pass effect, the lower the concentration 
of drug that reaches the systemic circulation. In the oral route, the drug is swallowed. It 
passes through the whole gastrointestinal tract. Drugs taken orally are usually less 
expensive to manufacture than ones administered by any other route, and can easily be 
self-administered (minimal invasiveness) by the patient. The disadvantage of oral 
delivery is that the drug has to be absorbed from the gastrointestinal tract and experience 
the first pass effect. Sometimes this route of administration is inefficient because only 
part of the drug may be absorbed; also a significant first-pass effect may occur. In 
addition, some orally administered drugs can cause irritation of the gastric mucosa, and 
cause nausea and vomiting. 
Note: drugs given orally take more time than any other route to show a 
pharmacological response, but the oral route is considered to be the safest, pain-free and 
cheapest method of drug administration. Other routes are used if there is an emergency 
situation where the effect of the drug is needed immediately (Silverman, 2004). 
 
1.5.2 Examples of Marketed Codrugs 
A good example of an effective and marketed codrug is the antibiotic sultamicillin 
(Unasyn Oral), a tripartate codrug of ampicillin and penicillanic acid sulfone (Fig. 1.2) 
(Baltzer et al., 1980; Hartley and Wise, 1982). Ampicillin is a well-known β-lactam 
antibiotic, but suffers from ineffectiveness against resistant bacteria that excrete high 
concentrations of the bacterial enzyme, β-lactamase. β-Lactamase degrades penicillins 
such as ampicillin by hydrolysis of the β-lactam ring with consequent loss of antibacterial 
activity. Subsequent co-administration of a β-lactam antibiotic with a β-lactamase 
inhibitor was utilized as a strategy for treating resistant strains of bacteria. For example, 
the antibiotic Augmentin is a mixture of the β-lactam penicillin, amoxicillin and the β-
lactamase inhibitor, potassium clavulanate (Fig. 1.2). One of the problems of 
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administering the two synergistic drugs together (as a physical mixture) is that they may 
not have similar pharmacokinetic profiles, and thus may not arrive at the target site at the 
same time or at the same concentration. The codrug sultamicillin incorporates a labile 
linker, which on hydrolysis by a plasma esterase affords the two synergistic parent drugs 
in equimolar amounts together with a molar equivalent of formaldehyde. 
 
 
Fig.1.2: Sultamicillin codrug and the in vivo hydrolysis products generated from the 
codrug. 
 Another example of a marketed codrug is sulfasalazine (Svartz, 1942), which is 
prescribed for the treatment of ulcerative colitis. Ulcerative colitis is a chronic 
inflammatory disease characterized by a diffuse inflammation the mucosa which is 
mainly restricted to the colon. Aminosalicylates are the mainstay of treatment in case of 
active ulcerative colitis. Sulfasalazine is the prototype of this drug class and releases 5-
aminosalicylic acid and antibacterial sulfonamide, sulfapyridine in the colon. After oral 
administration, 80-90% of the drug is delivered to the colon intact. 10-20% of the drug is 
absorbed from small intestine and undergoes enterohapatic circulation without 
biotransformation and is excreted in the bile (Das et al., 1973). In the colon, the azo bond 
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in sulfasalazine is cleaved by colonic bacterial azoreductases liberating sulfapyridine and 
5-aminosalicylic acid (Peppercorn and Goldman, 1972; Khan et al., 1983) (Fig. 1.3).  
 
 
Fig.1.3: Generation of 5-aminosalicylic acid and sulfapyridine from sulfasalazine codrug. 
 
 Benorylate is another good example of a marketed codrug used in the treatment of 
rheumatoid arthritis. Benorylate is an ester of acetylsalicylic acid and paracetamol and is 
an effective analgesic and anti-inflammatory drug with less potential for gastric irritation. 
The antipyretic activity of benorylate is similar to that of acetylsalicylic acid (aspirin) and 
paracetamol (Beales et al., 1972). The pharmacological actions of benorylate are due to 
the effects of both aspirin and paracetamol released by hydrolytic cleavage. Benorylate is 
actively hydrolyzed by liver cytosol and plasma to generate the two parent drugs (Fig. 
1.4). Only paracetamol and salicylate can be detected in plasma after oral administration 
of benorylate (Robertson et al., 1972).  
 
 
Fig.1.4: Generation of paracetamol and aspirin from hydrolysis of benorylate. 
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1.5.3 Topical Codrug Therapy for the Treatment of Ophthalmic Diseases 
 Codrugs for the treatment of diabetic retinopathy  
The codrug strategy has previously been utilized when the physicochemical 
and/or pharmacokinetic properties of two synergistic drugs are not favorable for delivery 
of the two drugs as a physical mixture, but can be improved by chemical combination of 
the two drugs. For example, 5-fluorouracil (5-FU) is a polar, water-soluble antiviral and 
cytotoxic drug that is rapidly cleared from the vitreous when delivered topically to the 
eye. In a topical drug combination treatment consisting of 5-FU and the lipophilic, water-
insoluble, anti-inflammatory drug, trihydroxy steroid (THS), a codrug strategy was 
utilized which provided a superior sustained release delivery of these two synergistic 
parent drugs for the treatment of diabetic retinopathy (Howard-Sparks et al., 2005; 
Howard et al., 2007). The individual physicochemical properties of 5-FU and THS are 
not favorable for sustained release of a physical mixture of the two drugs. However, 
utilizing a codrug approach, the chemical combination of 5-FU and THS in a 2:1 molar 
ratio, respectively (for optimal synergistic activity) afforded a molecule with greatly 
improved physicochemical characteristics for sustained delivery compared to 
formulations of the two drugs as a physical mixture (Howard-Sparks et al., 2005). Fig. 
1.5 shows the structure of THS, 5-FU and the THS-BIS-5-FU codrug.  
 
 
Fig. 1.5: Structures of THS, 5-FU and the THS-BIS-5-FU codrug. 
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Fig. 1.6: Cumulative release of THS and 5-FU from neat pellets containing 2 mg of the 
THS-BIS- 5-FU codrug in bovine vitreous humor (Reprinted from Journal of Enzyme 
Inhibition and Medicinal Chemistry, Howard et al., 2005, copyrighted by Informa 
Healthcare, used by permission). 
 
The 5-FU-THS codrug was designed as a “chemical delivery” system (Howard-
Sparks et al., 2005) which joined together the two drugs via a labile linker moiety. The 
physicochemical properties of the codrug were favorable for formulation as a sutured 
ophthalmic pellet, and for slow dissolution of the codrug pellet in the vitreous humor. 
The labile linker was specifically designed to undergo rapid hydrolysis once the codrug 
pellet had dissolved, providing sustained release of the parent drugs, which was 
dependent on the rate of dissolution of the codrug pellet. This concept of a chemical 
delivery system, where the target tissue is never exposed to dissolved codrug, has been 
patented (Ashton et al., 2000), and represents a unique form of a codrug formulation, 
which may be considered as just another formulation for delivery of the parent drugs; the 
important concept is that the body is never exposed to the new codrug entity, and thus, 
issues of codrug toxicity would not be relevant.  One molar equivalent of the codrug 
produces one molar equivalent of THS, two molar equivalents of 5-FU, and two molar 
equivalents of both formaldehyde and carbon dioxide after hydrolysis. Another important 
consideration in the design of the 5-FU-THS codrug was the structure of the labile linker. 
28 
 
The two drugs were linked together via a linker that afforded hydrolysis products that 
were considered to be non-toxic. The pellets containing the THS-BIS-5-FU codrug 
simultaneously released THS and 5-FU in 0.1 M phosphate buffer, (pH=7.4), in human 
serum, and in bovine vitreous humor. Fig. 1.6 shows the release of THS and 5-FU from 
the codrug in bovine vitreous humor. The results demonstrate that a neat pelleted THS-5-
FU codrug can be utilized as a sustained release ocular delivery form of the parent 
compounds, and that the unique physicochemical properties of the codrug allow both 
slow dissolution and rapid release of the two parent drugs (Fig. 1.6). 
 
 Codrugs containing corticosteroids for proliferative vitreoretinopathy  
Proliferative vitreoretinopathy (PVR) refers to migration and proliferation of cells 
into the subretinal space, vitreous cavity and onto the retinal surface and undersurface. 
Subsequent collagen production and cell-mediated contraction of the resulting 
collagenous scar leads to retinal detachment and loss of vision (Machemer, 1988). 
Different pharmacological adjuncts have been examined in animal models and human 
trials to reduce the formation of fibrocellular membranes in PVR, but due to the short half 
lives of these drugs when delivered by intravitreal injection, repeated post-operative 
intraocular injections are necessary. When administered systemically, toxic effects are 
observed as a consequence of the high doses needed to achieve therapeutic intraocular 
drug levels. This also limits the clinical usefulness of these therapeutic agents. An 
intraocular device providing therapeutic intraocular drug levels for several months via 
sustained delivery of the drugs is needed for the treatment of PVR, since re-proliferation 
and recurrent retinal detachment can occur in the first few months after initial retinal 
reattachment surgery. An implantable, non-erodible intraocular device has been 
developed, and has shown potential in the treatment of experimental uveitis (Cheng et al., 
1995). Both 5-FU (a cytotoxic agent) and corticosteroids such as dexamethasone (DX) 
and triamcinolone (TA) are known to be effective in the treatment of experimental PVR. 
The following are some pros and cons associated with 5-FU and corticosteroids as 
therapeutic agents for the treatment of PVR.  
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 Both DX and TA are known to reduce incidents of retinal detachment in a rabbit 
model of PVR (Tano et al., 1980 [1]; Tano et al., 1980 [2])
 
 
 Although corticosteroids are advantageous in suppressing the inflammatory arm 
of the wound healing response, their weak anti-proliferative properties reduce 
their clinical potential 
 5-FU is known to be a potent inhibitor of rabbit dermal fibroblast proliferation in 
cell culture (Blumenkranz et al., 1981)  
 5-FU is also well tolerated in the rabbit when administered intra-vitreally at high 
doses 
 Due to a very short half-life and rapid clearance of 5-FU from the eye, repeated 
injections of 5-FU are required to achieve a clinically significant effect of the 
drug when given alone 
 Repeated injections of ophthalmic drugs can cause endophthalmitis and retinal 
detachment, and is also inconvenient and uncomfortable for the patient 
 5-FU is toxic to the cornea and retina when given in high doses (Stern et al., 1983) 
 
In a recent study, codrugs of 5-FU covalently linked to either DX or TA have been 
prepared and evaluated in a rabbit model of PVR (Berger et al., 1996). The 
corticosteroid-5-FU codrugs retain the anti-inflammatory properties of the corticosteroids 
and incorporate the anti-proliferative properties of 5-FU. 
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Fig. 1.7: Codrugs of corticosteroids and 5-fluorouracil. 
 
The codrugs of 5-FU and corticosteroids were designed to take advantage of the 
best characteristics of the individual drugs, and to reduce their individual disadvantages 
(Fig. 1.7). The parent drugs possessed unfavorable physicochemical properties for 
sustained delivery; however, when converted the codrug form the molecules were found 
to possess good characteristics for sustained delivery of the parent drugs.  An implantable 
sustained-release formulation containing the DX-5-FU codrug was developed and 
surgically implanted into the right eyes of New Zealand white rabbits. In separate 
experiments, as an alternate to DX-5-FU pellets, a suspension of the more insoluble TA-
5-FU codrug was injected into the vitreous of the right eye of the rabbits. TA is less 
soluble than DX and as a result TA-5-FU codrug is less soluble and therefore longer 
lasting than DX-5-FU codrug. It was observed that the DX-5-FU device fully released the 
parent drugs after approximately one week, whereas the TA-5-FU suspension took an 
extended period of time (1 month) to release the parent drugs. In vitro pharmacokinetic 
data showed that the DX-5-FU pellet was effective but allowed the disease to progress at 
the later time points, due to insufficient amount of the drug left in the pellet as a 
consequence of high solubility of DX-5-FU pellet. However, the TA-5-FU codrug was 
much more effective in causing regression of PVR severity especially at the later time 
points. Thus, intravitreal sustained release of the DX-5-FU device and the TA-5-FU 
suspension were both effective against progression of PVR in the rabbit model. 
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Codrugs containing non-steroidal anti-inflammatory agents for treatment of 
proliferative vitreoretinopathy 
Although corticosteroids have been used to prevent and treat intraocular 
inflammation, these therapeutic agents might interfere more severely with wound healing, 
exacerbate infection, or cause an increase in intraocular pressure. The development of 
non-steroidal anti-inflammatory drugs (NSAIDs) provides the ocular surgeon with an 
alternative way to control inflammation and to avoid the problems associated with 
corticosteroid therapy. Also, a sustained release of the drug with prolonged effects is 
expected to be more effective in the treatment of experimental post-traumatic PVR than 
the transient nature of the free drug form, and it is also known that single intra-vitreal 
injections of either 5-FU or the NSAID naproxen have too short a half life to provide an 
adequate therapeutic effect (Algyere and Bill, 1981). Based on these observations and on 
the encouraging data from the 5-FU-corticosteroid codrugs, a naproxen-5-FU codrug 
(Fig. 1.8) was synthesized for the treatment of experimental post-traumatic PVR. It was 
also hypothesized that treatment with a NSAID and 5-FU together might be more 
effective than either of the drugs alone, and that such a drug combination could 
simultaneously down-regulate the inflammatory and proliferative components of the 
wound healing response. Bio-erodible implantable sustained release pellets containing a 
naproxen-5-FU codrug were developed and tested in a rabbit trauma model of PVR. The 
naproxen-5-FU pellets were found to release 5-FU and naproxen linearly over a 30-day 
time course in in vitro release experiments. Rabbits, after administering codrug as sutured 
corneal pellet implants, showed a significant decrease in retinal detachment rate 
compared with the control group (untreated eye) at almost all time points. The codrug 
pellet did not exhibit any toxic effects on the retina when examined electro-
physiologically or histologically. The overall results of the study showed that the 
napreoxen-5-FU codrug device effectively inhibited the frequency and severity of PVR in 
a rabbit trauma model without any observable toxic effects of the codrug on the retina. 
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Fig. 1.8: Naproxen-5-fluorouracil codrug. 
 
Codrugs containing ethacrynic acid for treatment of elevated intraocular pressure 
Elevated intraocular pressure (IOP) is one of the major risk factors leading to 
glaucomatous damage of the optic nerve and a consequent cause of blindness. It is known 
that ethacrynic acid (ECA), a diuretic drug, can reduce IOP in rabbit and monkey eyes 
(Tingey et al., 1992, Epstein et al., 1997). Intracameral injection of ECA into the eye can 
also reduce IOP in humans (Melamed et al., 1992). These observations suggest ECA as a 
potential glaucoma drug. However, topical administration of ECA shows many adverse 
effects, and limitations.  For example: 
 Eyelid edema, conjunctival hyperaemia, and moderate diffuse superficial corneal 
erosion are some of the side effects of long term topical administration of ECA. 
 Due to the low pKa (2.8) of ECA, the molecule exists exclusively in the anionic 
form at physiological pH (pH=7.4), and the very low lipophilicity of the anionic 
form of ECA limits its ability to effectively penetrate cornea to provide a 
therapeutic dose at the site of action. 
 Oral administration of ECA does not produce any significant effect on IOP 
(Peczon and Grant, 1968). 
  
On the other hand, β-adrenergic receptor antagonists such as atenolol (ATL) and 
timolol (TML) are effective against a variety of hypertensive disorders, ischemic heart 
disease, some arrhythmias and ocular hypertensive effects (Shargel et al., 1997). 
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Diuretics produce additive antihypertensive effects when co-administered with β-
adrenergic receptor antagonists (Safran et al., 1993). Thus, ECA delivered together with a 
β-adrenergic receptor antagonists, can act synergistically to lower elevated IOP, since 
these two classes of drug work via different physiological mechanisms. To overcome the 
unsuitable physicochemical properties of ECA for ocular delivery and to utilize the 
synergistic interaction between ECA and β-adrenergic receptor antagonists, codrugs of 
ECA with ATL and TML have been synthesized and evaluated (Fig. 1.9).  
 
 
Fig. 1.9: Ethacrynic acid-β-adrenergic receptor antagonist codrugs. 
  
ECA was coupled with ATL and TML through an ester linkage using 1,1-
carbonyldiimidazole (CDI) as the coupling reagent. The stability of the ECA-ATL codrug 
was studied in non-enzymatic aqueous buffer at pH 7.4 and enzymatic hydrolysis was 
studied using human serum. The codrug was hydrolyzed in both buffer (half life =14 h) 
and human serum (half life = 30 min) to produce the parent drugs. The stability study 
confirmed that biotransformation of the codrug would occur after penetration into the 
vitreous. The main target behind the codrug approach was to overcome the solubility and 
clearance problems associated with the parent drugs, and thus improve the delivery of the 
parent drugs through topical membranes.  
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1.5.4 Codrugs for Transdermal Delivery 
Many currently available drugs do not have suitable physicochemical properties 
for transdermal delivery. For a drug to permeate across the skin, it must be able to 
partition into and diffuse across the lipophilic region of stratum corneum, and also the 
more hydrophilic underlying epidermis. Many different strategies have been utilized to 
enhance topical drug delivery. One of these startegies is to chemically modify the 
structure of the penetrant. Prodrug and codrug approaches to drug delivery come under 
this category.  
 
Codrugs for the treatment of alcohol abuse and tobacco dependence 
Naltrexone (NTX) is an opioid antagonist and useful drug for the treatment of 
alcohol dependence (Volpicelli et al., 1992) and cigarette smoking is known to be a social 
cue for alcoholics. Many alcoholics are also chronic smokers. Naltrexol (NTXOL) is the 
active metabolite of NTX (Rukstalis et al, 2000; Wang et al., 2001). Currently NTX is 
used in the form of an oral tablet for the treatment of the above-mentioned morbidities. It 
has been shown that alcohol dependence can be reduced by 50% in adult alcoholics after 
administering NTX orally (Volpicelli et al., 1997). However, there are adverse g.i. side 
effects associated with NTX oral therapy, such as abdominal pain, constipation, nausea 
and vomiting. NTX is also a hepatotoxin, having the ability to cause dose-related 
hepatocellular injury. Due to this hepatotoxicity, dosage cannot be increased above 50 
mg/day, and patients who need a dosage regimen of more than 50 mg/day cannot benefit 
from oral NTX therapy. In addition to these adverse effects, in humans, NTX undergoes 
extensive first pass metabolism, which reduces the oral bioavailability of NTX to about 
5-40% (PDR Generics, 1996). Thus, these adverse effects, along with the low 
bioavailability limit the clinical utility of oral NTX therapy and poor patient compliance 
is observed. Neither NTX nor NTXOL is deliverable in therapeutic concentrations via the 
transdermal route (Kiptoo et al., 2006). A codrug approach was applied to attempt to 
solve these problems. Hydroxybupropion (BUPOH) is the active metabolite of the orally 
active smoking cessation agent, bupropion (Zyban) (Cooper et al, 1994; Ascher er at., 
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1995; Sanchez and Hyttel, 1999; Slemmer et al., 2000). A transdermal NTX-BUPOH 
codrug should have improved transdermal delivery characteristics, lower toxicity, offer 
patients the freedom from intravenous injections and surgical implantations, and afford 
better patient compliance. This single codrug entity would have the potential to treat both 
alcohol and nicotine abusers when delivered transdermally. Fig. 1.10 shows the structure 
of NTX, NTXOL, BUP, BUPOH and two codrugs of BUPOH covalently linked to either 
NTX or NTXOL. 
 
 
Fig. 1.10: Structures of parent drugs NTX, NTXOL, BUP, BUPOH and codrugs NTX-
BUPOH and CB-NTXOL-BUPOH, which contain a cyclic carbamate prodrug moiety of 
BUPOH. 
 
            In order to determine the stability of the codrugs, hydrolytic studies were carried 
out in isotonic phosphate buffer at pH 7.4 (physiological pH). The results showed that the 
codrugs were susceptible to hydrolysis and produced the parent drugs at physiological 
pH. NTX, NTXOL and BUPOH were stable in the buffer solution and NTX-BUPOH and 
CB-NTXOL-BUPOH codrugs underwent slow hydrolysis in the buffer solution with 
half-lives of 36.68 and 28.88 h respectively. The proposed hydrolytic conversion of the 
NTX-BUPOH codrug to the parent drugs is shown in detail in Fig. 1.11. The NTX-
BUPOH codrug undergoes cleavage of the carbonate bond to generate NTX, and a 
relatively stable cyclic carbamate intermediate of BUPOH, which subsequently 
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undergoes hydrolysis to generate BUPOH. The chemical stability of the NTX-BUPOH 
codrug was studied in isotonic phosphate buffer at pH 7.4 over 4 days. The disappearance 
of the codrug and the appearance of the two parent drugs over time are shown in Fig. 
1.12. The rate of appearance of NTX was identical to the rate of disappearance of the 
codrug. However, the rate of formation of BUPOH was found to be slower than the rate 
of disappearance of the codrug, involving the formation of a relatively stable 
intermediate, which was identified as the 5-membered cyclic carbamate analogue of 
BUPOH (Hamad et al., 2006). 
The stability of the carbonate codrug of 6-β-naltrexol and hydroxybupropion (CB-
NTXOL-BUPOH) was also evaluated in Guinea pig plasma. Fig. 1.13 illustrates the 
hydrolytic profile of the carbonate codrug and the time course of formation of the two 
active parent drugs in the plasma. The release of 6-β-naltrexol from the codrug was a 
one-step process, as confirmed by the rate of appearance of 6-β-naltrexol correlating with 
the rate of disappearance of the carbonate codrug. The release of BUPOH involved the 
initial formation of the cyclic carbamate analogue of BUPOH, which was then converted 
subsequently to the parent drug, BUPOH. The rate of hydrolysis of the CB-NTXOL-
BUPOH codrug in plasma was 3 times faster compared to the rate of hydrolysis in 
isotonic phosphate buffer at pH 7.4 (Kiptoo et al., 2008). 
The CB-NTXOL-BUPOH codrug and 6-β-naltrexol were administered 
transdermally to hairless Guinea pigs. The plasma concentration profiles of the analytes 
following topical application of either CB-NTXOL-BUPOH or 6-β-naltrexol are shown 
in Fig. 1.14. The results showed a fivefold enhancement in the transdermal delivery of 6-
β-naltrexol when given in the form of the codrug. Also, the codrug delivered a significant 
amount of BUPOH to the plasma when administered transdermally. The cyclic carbamate 
intermediate of BUPOH was not detected in the plasma of codrug-treated Guinea pigs. 
The calculated pharmacokinetic parameters for the CB-NTXOL-BUPOH codrug and 6-β-
naltrexol are listed in Table 1.1 (Kiptoo et al., 2008). 
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Fig. 1.11: Hydrolytic behavior of the NTX-BUPOH codrug. 
 
 
Fig 1.12: Hydrolysis profile of the carbonate drug hybrid, NTX-BUPOH, in isotonic 
phosphate buffer at pH 7.4 (Reprinted from Journal of Bioorganic and Medicinal 
Chemistry Hamad et al., 2006, copyrighted by Elsevier, used by permission). 
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Table 1.1: Pharmacokinetic parameters of NTXOL in the Guinea pig after application of 
a gel formulation containing either CB-NTXOL-BUPOH or NTXOL base (Reprinted 
from European Journal of Pharmaceutical Sciences, Kiptoo et al., 2008, copyrighted by 
Elsevier, used by permission). 
 
 
 
 
Fig 1.13: Hydrolysis profile of the carbonate drug hybrid, CB-NTXOL-BUPOH, in 
Guinea Pig Plasma at 37 °C (Reprinted from European Journal of Pharmaceutical 
Sciences, Kiptoo et al., 2008, copyrighted by Elsevier, used by permission). 
Hydrolysis Profile of the Carbonate Drug Hybrid, CB-NTXOL-BUPOH, in 
Guinea Pig Plasma at 37oC.
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Fig 1.14: Mean (±S.D.) plasma concentration profiles in guinea pigs after topical 
application of a gel formulation containing either CB-NTXOL-BUPOH or 6-β-Naltrexol 
(control). The dotted line (----) indicates the plasma concentration after the removal of the 
formulation (Reprinted from European Journal of Pharmaceutical Sciences, Kiptoo et al., 
2008, copyrighted by Elsevier, used by permission). 
 
Duplex codrugs of naltrexone for transdermal delivery 
The problem of dealing with a released linker moiety was partially solved in the 
study of an NTX “Gemini”, or duplex codrug. Although the transdermal patch provides a 
sustained release of drug, NTX does not have the ideal physicochemical properties that 
allow delivery of therapeutic doses of the drug across the skin. Stinchcomb et al. 
addressed this problem in a recent study of transdermal delivery of NTX (Hammell et al., 
2004). A synthetic dimer of NTX termed a “duplex gemini prodrug” (NTX-NTX) (Fig. 
1.15) was synthesized, and then evaluated in in vitro diffusion studies utilizing human 
cadaver skin samples. 
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Fig. 1.15: Duplex gemini prodrug of NTX. 
 
It was observed that NTX-NTX was hydrolyzed in the skin to afford two 
equivalents of NTX and one equivalent of harmless carbon dioxide (half-life = 31 min), 
and appeared primarily as NTX in the receiver solution of an in vitro Franz cell. It was 
also observed that the maximum flux from the duplex drug, in terms of NTX equivalents, 
was twice as high as that from NTX alone (6.2 and 3.0 nmol/cm
2
/hr from the duplex 
codrug and NTX, respectively). According to the authors, the main reason for the 
increased flux from the NTX-NTX duplex was due to rapid bioconversion causing a 
difference in the concentration gradient profile for the NTX-NTX codrug. 
 
Codrugs containing α-tocopherol for skin hydration 
Proper hydration conditions of human skin are maintained by natural moisturizing 
factors, which contain different amino acids, pyroglutamic acid and some other water-
soluble molecules (Morganti, 1999). Water retention inside the stratum corneum is 
maintained by fatty acids and cholesterol present on the skin surface. α-Tocopherol (VE) 
is one of the lipophilic antioxidants and carries out several important functions in the 
skin. Some of the important properties of VE are listed below. 
 VE along, with ascorbic acid, form an antioxidant network in the skin to protect 
the skin from oxidative damage
 
(Thiele et al., 2000) 
 VE also protects polyunsaturated fatty acids (PUFA) and biological membranes 
against attack by free radicals that initiate lipid peroxidation 
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 Biological membranes containing high levels of PUFA are protected against 
oxidizing radicals by VE as it penetrates into the lipid bi-layers and acts as a 
radical scavenger 
 VE functions as a moisturizer by reducing trans-epidermal water loss 
Although possessing many useful properties, the VE molecule has some 
disadvantages. It is very readily degraded by oxidants, moisture, and UV irradiation. The 
stability of VE towards oxidation is generally increased by converting it to either an 
acetate or succinate ester (Henegouwen et al., 1995; Lampen et al, 2003; Gensler et al., 
1996). However, during this process the bioavailability of VE becomes dependent on the 
enzyme-catalyzed hydrolysis of the ester linkage. Bearing in mind that amino acids are 
components of natural moisturizing factors, Santi et al. synthesized ester codrugs of VE 
with amino acids such as alanine and glycine (Fig. 1.16) (Ostacolo et al., 2004).  
 
 
Fig. 1.16: Structures of α-tocopherol and α-tocopherol-amino acid codrugs. 
 
As VE is the main active moiety in the codrug, the ester linkage should be 
cleavable by hydrolytic enzymes to produce the parent compounds. Porcine liver esterase 
was used to examine the stability of the ester bond between VE and various amino acids; 
these molecules can also be regarded as prodrugs. Under the experimental conditions 
utilized, the codrug concentration decayed exponentially, and the concentration of the 
parent compound (VE) increased exponentially. The experimentally determined half-
lives of the glycine and alanine codrugs of VE were 49.5 and 142 hours, respectively. 
Skin accumulation and metabolism experiments were performed on freshly excised rabbit 
ear skin that is considered to be similar to human skin in terms of drug permeability. The 
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extent of metabolism for the glycine codrug was higher than that of the alanine codrug, a 
trend that was followed in the in vitro stability of the two codrugs. Experiments also 
showed that the alanine and glycine codrugs accumulated in skin in significant 
concentrations. The amount of VE found in the dermis after 6 hours was almost double 
compared to the amount in dermis when VE was administered alone. 
 
1.5.5 Codrugs of L-DOPA for the Treatment of Parkinson’s Disease 
L-DOPA Codrugs that incorporate inhibitors of L-DOPA metabolism  
Dopamine is deficient in the brains of patients suffering from Parkinson‟s disease. 
Unfortunately, dopamine cannot be given as a drug for this disease because it cannot 
cross the blood-brain barrier. L-3,4-Dihydroxyphenylalanine (L-DOPA) is a precursor of 
dopamine, and is used in the treatment of Parkinson‟s disease. L-DOPA crosses the 
blood-brain barrier via facilitated transport, and is then converted to dopamine in the 
brain by the enzyme DOPA decarboxylase. For the treatment of Parkinson‟s disease, L-
DOPA is given in combination with a peripheral DOPA decarboxylase inhibitor such as 
carbidopa, to prevent degradation of L-DOPA in the systemic circulation. Entacapone is a 
catechol-O-methyltransferase (COMT) inhibitor, which is also currently used with L-
DOPA to treat Parkinson patients; entacapone inhibits the metabolism of L-DOPA by 
COMT to afford the inactive O-methylated metabolite. Since oral L-DOPA 
bioavailability is low, a codrug approach was utilized, by combining L-DOPA and 
entacapone via an ester linkage to improve L-DOPA brain delivery (Fig. 1.17). The 
codrug showed stability in aqueous media at different pHs and was hydrolysed to the 
parent drugs in liver homogenate, fulfilling the codrug criteria (Leppanen et al., 2002). 
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Fig.1.17: L-DOPA-entacapone codrug. 
 
Similar to carbidopa, benserazide is a DOPA-decarboxylase inhibitor. An L-
DOPA codrug that incorporates benserazide was demonstrated to have good lipophilicity 
as compared to either L-DOPA or benserazide (Fig. 1.18). The codrug was also stable in 
aqueous buffer solutions. In plasma, the catechol esters and amide bonds in the codrug 
structure were efficiently cleaved, releasing the parent drugs in one step (Stefano et al., 
2006 [1]). 
 
 
Fig. 1.18: Codrugs of L-DOPA with benserazide. 
 
L-DOPA-antioxidant codrugs  
A series of codrugs have also been designed by linking L-DOPA and dopamine 
with antioxidant compounds such as α-lipoic acid, glutathione, caffeic acid, carnosine, 
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benserazide and N-acetylcysteine (Stefano et al., 2006 [2]; Stefano et al., 2007; Piera et 
al., 2008; Stefano et al.; 2006 [3], Pinnen et al., 2009). 
 
                       
     (a)                       (b) 
Fig. 1.19: (a) L-DOPA and α-lipoic acid codrugs; and (b) dopamine and α-lipoic acid 
codrugs. 
 
As shown in Fig.1.19, L-DOPA and dopamine can be conjugated directly to α-
lipoic acid via an amide linkage (Stefano et al., 2006 [2]). α-Lipoic acid is an effective 
antioxidant. It exists as dihydrolipoate in vivo, which can regenerate (reduce) antioxidants 
such as glutathione, vitamin C and vitamin E (Biewenga et al., 1997; Packer at al., 1995). 
The strained 5-membered ring conformation of lipoic acid contributes to its good 
scavenging activity (Haenen and Bast, 1991). All the four codrugs in Fig. 1.19 showed 
good stability in the gastrointestinal tract and are cleaved enzymatically in rat and human 
plasma to release the parent drugs. The prolonged release of L-DOPA showed the 
effectiveness of the L-DOPA codrugs. Codrugs 1 and 2 were used to test antioxidant 
efficacy using superoxide dismutase (SOD) and glutathione peroxidase (GPx) markers. 
These enzymes have a central role in the control of reactive oxygen species (ROS). SOD 
dismutates highly reactive superoxide into oxygen and hydrogen peroxide, and GPx 
reduces hydrogen peroxide to water by oxidizing GSH. The oxidized form of GSH 
(GSSG) is reduced back to GSH by glutathione reductase, as shown in the equations 
below: 
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Codrugs 1 and 2 afforded an increase in GPx activity as compared to L-DOPA 
alone, which indicating a decreased production of free radicals. Also, these codrugs 
induced a decrease in the activity of SOD as compared to L-DOPA alone, indicating a 
reduced production of superoxide anions.  
  Similar results were obtained when codrugs of L-DOPA and glutathione were 
constructed with amide linkages joining the two drug entities (Fig. 1.20) (Stefano et al., 
2007). Glutathione is involved in the decomposition of toxic peroxide molecules, and 
protects enzymes by maintaining their SH groups in a reduced state; it is also involved in 
the repair of oxidized iron-sulfur centers of the mitochondrial complex. No hydrolysis of 
the glutathione-L-DOPA codrugs was observed in gastrointestinal fluids and L-DOPA 
was shown to be released in plasma via enzymatic hydrolysis. The codrugs also exhibited 
an antioxidant effect as indicated using SOD and GPx markers. 
 
 
       (a)        (b) 
Fig. 1.20: (a) L-DOPA and glutathione codrugs; and (b) dopamine and glutathione 
codrugs. 
 
Like glutathione and α-lipoic acid, two other antioxidants, caffeic acid and 
carnosine, have also been conjugated with L-DOPA (Fig. 1.21), and the resulting codrugs 
assessed by evaluating plasma activities utilizing SOD and GPx markers in rats (Piera et 
al., 2008). These codrugs were devoid of significant antioxidant activity, although the 
literature lists many reports that caffeic acid and carnosine act as natural antioxidants 
with hydroxyl radical-scavenging and lipid-peroxidase activities. 
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To overcome the pro-oxidant effects of L-DOPA, other antioxidants utilized in L-
DOPA codrug design were sulfur containing compounds, such as N-acetyl cysteine 
(NAC), methionine and bucillamine (Fig. 1.22).  N-Acetylation of cysteine speeds up 
cysteine absorption and distribution when given orally. NAC helps in increasing the 
intracellular concentration of glutathione by elevating intracellular cysteine levels. NAC 
is rapidly absorbed, enters cells, and is rapidly hydrolyzed to cysteine. Methionine is also 
an intermediate in the synthesis of cysteine, and helps PC 12 cells against DA–induced 
nigral cell loss in Parkinson‟s disease by binding to oxidative metabolites of dopamine 
(Grinberg et al., 2005; Offen et al., 1996; Martinez et al., 1999). Bucillamine is a 
synthetic cysteine derivative used for the treatment of rheumatoid arthritis (Horwitz, 
2003). It contains two thiol groups, which makes it a more powerful antioxidant as 
compared to NAC and methionine. It can be easily transported into cells to restore 
glutathione under conditions of oxidative stress and glutathione depletion (Hammond et 
al., 2001). 
 
 
Fig. 1.21: Structures of (a) a 3, 4-diacetyloxy-L-DOPA methyl ester-caffeic acid codrug; 
and (b) a 3, 4-diacetyloxy-L-DOPA methyl ester–carnosine codrug. 
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Fig. 1.22: Codrugs of L-DOPA linked to cysteine, methionine and bucillamine. 
 
Six codrugs have constructed using L-DOPA as one of the parent drugs and 
NAC/methionine/bucillamine as the other parent drug (Pinnen et al., 2009). All the 
codrugs showed good lipophilicity and water solubility for optimal intestinal absorption. 
Stability studies at pH 1.3 and in SGF indicated that the codrugs would be stable enough 
to pass un-hydrolyzed through the stomach mucosa after oral administration. At pH 7.4, 
the codrugs were shown to be stable enough to be absorbed intact from the intestine. In 
rat and human plasma, the codrugs hydrolyzed to release the parent drugs, although the 
release of L-DOPA was very slow. The antioxidant efficacy of the codrugs was evaluated 
using a chemiluminescent assay, and compared with NAC; all the codrugs showed a 
superior antioxidant effect as compared to NAC. The physicochemical and 
pharmacokinetic data showed high levels of L-DOPA in the plasma and brain, even 12 h 
after administration. Ac-Met-LD-OMe and Ac-LD-Met-OMe Codrugs were able to 
induce a sustained release of L-DOPA and dopamine in rat striatum with respect to an 
equimolar dose of L-DOPA. When Ac-LD-Met-OMe codrug was injected 
intracerebroventricularly, it afforded levels of dopamine in the striatum that were higher 
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than those in L-DOPA-treated rats, and indicated that the codrug had a longer half-life in 
brain than L-DOPA (Pinnen et al., 2009). 
1.5.6 Analgesic Codrugs Containing Non-steroidal Anti-inflammatory Agents 
The clinical usefulness of non-steroidal anti-inflammatory drugs (NSAIDs) has 
been documented for decades, and these drugs constitute a mainstay in the treatment of 
rheumatic disorders and other degenerative and inflammatory joint diseases, in sports 
medicine, and as a multipurpose pain killer. However, NSAIDs containing carboxylic 
acids are known to have g.i. toxicity, causing upper g.i. irritation, bleeding, ulceration, 
and perforation, due to the presence of a free carboxylic acid group, and due to local 
inhibition of the cytoprotective actions of prostaglandins on gastric mucosa. In addition, 
NSAIDs may have an indirect effect attributed to their ion-trapping properties. One 
common way to solve the g.i toxicity problem is to design ester prodrugs of NSAIDs by 
masking the carboxylic acid group in the molecule. A recent and more effective approach 
is the design of codrugs of NSAIDs with another drug molecule by forming an ester 
linkage with the carboxylic acid group of the NSAID. 
 
Flurbiprofen-histamine-H2 antagonist codrugs 
The first codrug of this category was synthesized and examined by Otagiri et al. 
(Otagiri and Fukuhara, 1999). Flurbiprofen (FP) was chosen as a model NSAID and 
linked to an anti-ulcer histamine H2-antagonist agent to reduce the gastric mucosal 
damage caused by the NSAID. N-[3-{3-(1-Piperidinylmethyl)phenoxy}propyl]-2-(2-
hydroxyethylthio)acetamide (PPA) was chosen as the histamine-H2 antagonist (Fig. 
1.23). The FP-PPA codrug showed high hydrophilicity and lipophilicity, suggesting that 
the codrug would not have an adverse effect on FP absorption. The codrug was also 
stable in the aqueous buffers over the pH range 1-7.4, and was also stable in the presence 
of the enzymes pepsin and trypsin. The codrug rapidly hydrolyzed in 10% plasma (half-
life = 35 s). The pharmacokinetic results showed that the codrug was nearly completely 
absorbed into systemic circulation after oral delivery, and was sufficiently hydrolyzed to 
produce both the parent drugs. The acute anti-inflammatory effects of both the FP-PPA 
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codrug and parent drug (FP) were analyzed by measurement of the inhibition of 
carrageenan-induced edema. No difference was observed when the inhibitory effects of 
FP and the FP-PPA codrugs were compared, demonstrating that the codrug had the same 
anti-inflammatory effect as FP.  Pharmacokinetic data in rats also supported this result. 
However, experimental data showed the occurrence of gastric damage after FP 
administration; and when PPA was co-administered with FP as a physical mixture the 
gastric damage by FP was not reduced. On the other hand, while the FP-PPA codrug 
inhibited ulcer formation induced by FP, the codrug was effective in reducing the gastric 
damage caused by FP alone, and this was attributed to the masking of the carboxylic acid 
group of FP by linking it to the histamine-H2 antagonist, PPA. 
  
Fig. 1.23: Codrug of Flurbiprofen and PPA. 
 
NSAID-acetaminophen codrugs 
In another approach, Omar et al. utilized a well-known analgesic, acetaminophen, 
to mask the carboxylic acid group of NSAIDs (Fig. 1.24) (Fadl and Omar, 1998). 
Although, acetaminophen is relatively safe at therapeutic doses, large overdoses can 
produce the toxic metabolite, N-acetyl-p-benzoquinoneimine (NAPQI). Codrugs of 
acetaminophen with NSAIDs would reduce the g.i. adverse effects of NSAIDs and could 
also reduce formation of the toxic metabolite NAPQI from acetaminophen. A series of 
ester-linked codrugs of acetaminophen with NSAIDs were synthesized and evaluated, 
and the stability of these codrugs was examined at pH 1.3 and 7.4 in non-enzymatic 
aqueous buffers, and 80% human plasma. Result showed appreciable stability of the 
codrugs in both non-enzymatic simulated gastric fluid (pH 1.3) (half-life = 6.7-43 h) and 
50 
 
in non-enzymatic simulated intestinal fluid (pH 7.4) (half-life = 1.5-25 h). The codrugs 
exhibited much shorter half-lives in human plasma (half-life = 13.9-38.4 min) and in rat 
liver homogenate (half-life = 12.6-42.9 min). From the hydrolytic study it was found that 
the susceptibility of the codrugs to enzymatic hydrolysis was dependent upon the type of 
NSAID covalently linked to the acetaminophen molecule. The aspirin-acetaminophen 
codrug having the smallest acyl moiety, was found to be the most susceptible to 
enzymatic degradation. Codrugs with bulkier acyl moieties were found to be least 
susceptible to enzymatic hydrolysis. Based on in vitro data, the codrug of ibuprofen and 
acetaminophen was selected for bioavailability studies. No appreciable concentration of 
the codrug was detected in plasma after oral administration of the codrug, confirming 
very fast hydrolysis of the ester linkage in vivo compared to in vitro hydrolysis. Over a 
24 time course, the ibuprofen-acetaminophen codrug produced higher concentration of 
ibuprofen in the plasma compared to a physical mixture of the two parent drugs, 
indicating a higher bioavailability of the codrug due to improved lipophilicity. 
 
 
Fig. 1.24: A series of codrugs of acetaminophen and NSAIDs. 
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A codrug of diclofenac and acetaminophen was chosen for an ulcerogenicity 
study, and was compared with an equivalent physical mixture of the two parent drugs. 
Mice treated with a physical mixture of the two drugs showed significant damage of the 
mucous layer and ulceration of submucosal cells. However, mice treated chronically with 
the corresponding codrug did not show any significant gastric mucosal injury. The 
analgesic activities of the codrugs and the corresponding physical mixtures were 
analyzed using the mouse hot-plate assay. The results showed a significant increase in the 
analgesic activity of the codrug over time, compared to the physical mixture of the parent 
drugs. All the synthesized codrugs showed significantly higher analgesic activity than the 
control groups (equivalent physical mixture of parent drugs). 
 
Naproxen-propyphenazone codrugs 
In another study aimed at suppressing the g.i. toxicity of NSAIDs without 
affecting their anti-inflammatory activity, codrugs of naproxen (NAP) and 
propyphenazone were synthesized and evaluated (Fig. 1.25) (Shehaa et al., 2002). NAP is 
a potent carboxylic acid-containing NSAID, and has moderate analgesic activity 
associated with g.i. irritation (Shanbhag et al., 1992).  Previously reported alkyl ester and 
thioester prodrugs of NAP showed reduced g.i. erosive properties and similar anti-
inflammatory activity but significantly reduced analgesic potency (Venuti et al., 1989). 
On the other hand, propyphenazone is a non-acidic pyrazole drug with good analgesic 
and antipyretic activity and no anti-inflammatory activity (Burne, 1986). The metabolism 
of propyphenazone is known to proceed via the formation of its active metabolite, 3-
hydroxymethylpropyphenazone (HMP), which has similar activity as the parent drug 
(Goromaru et al., 1984; Neugebauer et al., 1997). A NAP-propyphenazone codrug 
strategy was considered a rational approach to achieving an anti-inflammatory and 
synergistic analgesic effect with a reduction in g.i. irritation associated with the NSAID. 
Propyphenazone was first converted to HMP or 3-aminomethylpropyphenazone (AMP). 
In one of the codrug molecules HMP was directly linked to NAP to afford the NAP-HMP 
codrug. In the second codrug design, HMP was linked to the endogenous amino acid 
glycine through an ester linkage, and the free amino group of glycine was then covalently 
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linked to NAP via an amide bond. In the third codrug molecule, a different linker, 
glycolic acid, was utilized to link AMP and NAP. Since the carboxylic acid group of 
NAP is essential for its analgesic activity, the release of NAP from the various codrugs 
was studied initially in non-enzymatic aqueous buffer solutions at pH 1.2 and 7.4, and in 
liver homogenates having activated esterase enzymes. Stability studies of the codrugs in 
aqueous buffers showed significant stability (half-life = 60-91 h at pH 1.2, and 10-19 h at 
pH 7.4). The codrugs showed a high susceptibility towards hydrolysis in rat liver 
homogenate (half-life 54-85 min). The analgesic activity of the codrugs compared to 
equimolar doses of the two parent drugs were tested in the mouse hot-plate assay. As a 
general trend, the codrugs showed improved analgesic activity over time compared to the 
parent drugs, reaching a maximum effective dose after about 4-6 hours due to improved 
codrug bioavailability and efficient hydrolysis to the parent drugs. Comparative anti-
inflammatory activity of the codrugs and NAP was determined by measuring the swelling 
of the paw after intraplantar injection of carrageenan in the rat. The codrug of NAP and 
HMP linked through glycolic acid also reduced inflammation in a pattern similar to an 
equimolar dose of NAP. This codrug was analyzed for its ulcerogenic activity and 
compared to those of the parent drugs, NAP and HMP. The NAP-treated mice, and to 
some extent the HMP-treated mice, showed complete damage of the mucous layer in 
addition to ulceration of the sub-mucosal cells of the g.i. tract, while the codrug-treated 
group and the control group (treated with vehicle only) did not show any ulcerogenic 
activity. 
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Fig. 1.25: A series of naproxen-propyphenazone codrugs. 
 
Flurbiprofen-amino acid codrugs 
In another approach, the adverse G.I. effects of the NSAID, flurbiprofen, were 
reduced by masking the carboxylic acid group through the formation of an amide bond 
with a series of amino acids. The anti-inflammatory activity of amino acids against 
gelatin induced hind paw edema in rats and their healing effects on gastric lesions 
produced by NSAIDs have been reported in literature (Meyers et al., 1979). Thus, 
conjugates of flurbiprofen with anti-inflammatory amino acids can clearly be considered 
as codrugs, since they would produce amino acids as hydrolytic products having 
synergistic anti-inflammatory effects with NSAIDs, and would also afford g.i. protective 
effect against NSAIDs. By covalently linking appropriate amino acids to NSAIDs, 
codrugs with optimal polarity, solubility profile and acid-base properties can be designed. 
Thus, a series of amide codrugs of flurbiprofen with methyl esters of L-tryptophan, L-
histidine, L-phenylalanine, and DL-alanine (Fig. 1.26) were synthesized and evaluated 
(Gairola et al., 2005). The stability of the codrugs was studied in hydrochloric acid buffer 
(pH=1.2), phosphate buffer (pH=7.4) and 80% human plasma. The codrugs were found 
to be stable in hydrochloric acid buffer but underwent hydrolysis in phosphate buffer 
with half-life values ranging from 30.19 min to 70.09 min. This result suggested that the 
codrugs were likely to be stable enough to be absorbed intact from the intestine. The 
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comparatively shorter half-lives of the codrugs in plasma (ranging from 16.2 min to 29.3 
min) indicated that rapid production of the parent drugs in the systemic circulation was 
likely. Results from the evaluation of the anti-inflammatory properties of the codrugs 
revealed that flurbiprofen-phenylalanine and flurbiprofen-alanine codrugs were superior 
to flurbiprofen alone; the flurbiprofen-tryptophan and flurbiprofen-histidine codrugs were 
comparable to flurbiprofen in terms of anti-inflammatory activity. 
  
 
Fig. 1.26: Amino acid codrugs of flurbiprofen. 
 
NSAID-chlorzoxazone codrugs 
In a recent study, an active muscle relaxant drug was used to mask the carboxylic 
acid group of NSAIDs via the formation of a codrug (Abdel-Azeem et al., 2009).
 
Chlorzoxazone is an active muscle relaxant, and is marketed as a single component drug 
or in combination with NSAIDs. On the basis of these observations, codrugs of 
chlorzoxazone with three different NSAIDs were synthesized in an attempt to minimize 
the adverse gastrointestinal effects of NSAIDs, and to improve the pharmacokinetic 
properties of the parent drugs while retaining anti-inflammatory and skeletal muscle 
relaxant activities (Fig. 1.27). Chlorzoxazone was first converted to the key intermediate, 
hydroxymethylchlorzoxazone and then coupled with the carboxylic acid group of the 
appropriate NSAID to form ester-linked codrugs. Hydrolysis of these codrugs was 
studied in non-enzymatic aqueous buffers at pH 1.2 and 7.4 and in 80% human plasma. 
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The hydrolysis data showed that the codrugs were sufficiently stable at pH 1.2 and 7.4 to 
be absorbed almost unchanged from the g.i. tract. The codrugs showed susceptibility 
towards hydrolysis in 80% human plasma (half-life = 34-37 min). In the carrageenan-
induced paw edema bioassay ibuprofen and the ibuprofen-chlorzoxazone codrug showed 
the greatest inhibition of inflammation followed by the naproxen-chlorzoxazone and 
mefenamic acid-chlorzoxazone codrugs. The overall data showed that the codrugs 
exhibited comparable anti-inflammatory activity to their parent NSAIDs. The muscle 
relaxant activity of the codrugs in comparison with that of the muscle relaxant 
chlorzoxazone was examined using rat sciatic nerve tibialis muscle preparation. Muscle 
relaxant activity was exhibited by all the codrugs, while that of the ibuprofen-
chlorzoxazone codrug was comparable with chlorzoxazone. Importantly, the ibuprofen-
chlorzoxazone codrug treated animals showed far less damage to the mucous layer of the 
gastrointestinal tract compared to that produced by ibuprofen alone.  
 
 
Fig. 1.27: A series of codrugs of chlorozoxazone with NSAIDs. 
 
Acetaminaphen-chlorzoxazone codrug 
In a related study, a codrug molecule incorporating chlorzoxazone and 
acetaminophen has been reported (Fig. 1.28) (Vigroux and Bergon, 1995). The main 
reason for the synthesis of this codrug was the observed synergistic effects of these two 
drugs when administered together. The rate of liberation of the parent drugs from this 
codrug was studied at pH 7.4 in phosphate buffer, and in human and rat plasma. The 
codrug regenerated chlorzoxazone and acetaminophen simultaneously and quantitatively 
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under the experimental conditions. The codrug showed a higher susceptibility to 
formation of parent drugs in phosphate buffer than in either human or rat plasma, 
indicating that the release of chlorzoxazone from the codrug did not need to be enzyme-
mediated. 
 
 
Fig. 1.28: Codrug of chlorozoxazone and acetaminophen. 
 
1.5.7 Analgesic Codrugs of Opioids and Cannabinoids  
There is a continuing need for analgesic medications that are able to provide high 
efficacy pain relief while providing more favorable pharmacokinetics and reducing the 
possibility of undesirable side effects. Enhancement of the analgesic effect of opioids 
with cannabinoids has been previously described (Cichewicz et al., 1999). These two 
classes of drug work via opioid and cannabinoid receptors, which are found throughout 
the central and peripheral nervous system. Synergy between ∆
9
-THC and opioids is well 
documented in the literature (Bloom and Dewey, 1978; Cichewicz and McCarthy, 2002). 
In addition, these two classes of drug produce similar effects on calcium levels and cyclic 
AMP accumulation through G protein-mediated pathways. However, appropriate dosing 
of these active agents to their site of action, e.g., the brain or spinal column, can be 
difficult because of their differential pharmacokinetics. A codrug approach can be useful 
in overcoming the differential physicochemical and pharmacokinetic properties of opioid 
and cannabinoid drugs. In addition, opioids exert their analgesic effect on nociceptive 
pain while cannabinoids are effective in modulating neuropathic pain. Thus, an opioid-
cannabinoid codrug might be able to cover a broader range of pain. Keeping these points 
in mind, a series of opioid-cannabinoid codrugs were designed and synthesized and a 
codrug of codeine and ∆
9
-THC (Cod-THC) was fully evaluated in pain models, stability 
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indicating assays and in vivo pharmacokinetic studies (Holtman et al., 2006; Dhooper et 
al., 2008).  
 
 
Fig. 1.29: Structures of delta-9-THC, codeine and Cod-THC codrug. 
 
The effect of the Cod-THC codrug after oral administration in nociceptive and 
neuropathic pain models utilizing tail-flick and chronic constriction injury pain models in 
the rat was evaluated. The oral efficacies of each of the parent drugs, codeine and Δ
9
-
THC, were also compared with the Cod-THC codrug as pain modulators in the above 
pain models to determine their relative effectiveness. In both pain models, the codrug 
showed improved effectiveness, as well as more prolonged pain management properties, 
when compared to the parent drugs (Fig. 1.30).  
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Fig. 1.30: (a) Dose-Response Curves for the Antinociceptive Effects of the Codeine-THC 
Codrug and Codeine Alone in the Tail-Flick Test. (b) Antihyperalgesic Effect of 
Codeine, THC and the Cod-THC Codrug in the Chronic Constriction Nerve Injury (CCI) 
Model. 
 
The Cod-THC codrug was initially evaluated for its stability in buffers ranging 
from pH 1 to pH 9, as well as in simulated gastric and intestinal fluids (SGF and SIF, 
respectively), and in rat plasma and brain homogenate. The codrug was found to have a 
favorable drug stability profile for oral administration, being stable in aqueous solutions 
over a wide range of physiologically relevant pHs from 1 to 7.4, and was also stable in 
simulated gastric fluid, simulated intestinal fluid and rat brain homogenate. In rat plasma, 
the codrug was hydrolyzed to the two parent drugs, codeine and Δ
9
-THC with a rate 
constant of 0.282 hr
-1 
(Fig. 1.31). 
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Fig. 1.31: Hydrolysis of the Cod-THC codrug under different enzymatic conditions. 
 
The pharmacokinetic profile of the Cod-THC codrug was evaluated in the rat after 
oral administration and compared with the pharmacokinetic profile of an equimolar 
physical mixture of the parent drugs. Several groups have reported low bioavailability of 
THC (2 to 6%) and codeine (4 to 8%) after oral administration in rats, due to poor 
absorption from the gastrointestinal tract (Chiang and Barnett, 1984; Shah and Mason, 
1990). Rat plasma concentrations of the Cod-THC codrug were determined after oral and 
i.v. administration. These resulting data were compared with those obtained after oral 
administration of an equimolar physical mixture of the two parent drugs, codeine and Δ
9
-
THC. The plasma concentrations of codeine and Δ
9
-THC were found to be much higher 
after oral administration of the codrug in the rat, compared to plasma concentrations of 
these drugs after oral administration of the equimolar physical mixture of the two parent 
drugs. The parent drugs were clearly released from the codrug molecule in 1:1 ratio in 
plasma, while administration of the physical mixture did not afford equimolar 
concentrations of codeine and Δ
9
-THC in the plasma (Fig. 1.32). This is likely due to the 
different pharmacokinetic profiles of the two parent drugs, and to the different 
pharmacokinetic profile of the Cod-THC codrug. Also, the parent drugs were present in 
plasma for a longer period of time after oral administration of codrug, likely due to the 
sustained release of the parent drugs from the codrug in the plasma. 
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Fig. 1.32: Plasma concentrations of codeine, Δ
9
-THC  and Cod-THC codrug after 
administration of physical mixture of codeine, 4.9 mg/kg, and Δ
9
-THC, 5.1 mg/kg, (a); 
and Cod-THC codrug, 10 mg/kg (b). 
 
1.5.8 Codrugs containing Anti-HIV Drugs 
The rapid spread of the human immunodeficiency virus (HIV), the etiological agent 
of acquired immunodeficiency syndrome (AIDS), has stimulated intensive efforts 
worldwide to develop chemotherapeutic agents effective against HIV. 2‟,3‟-
Dideoxynucleosides (ddNs) are one of the most potent series of compounds active against 
HIV (Mitsuya and Broder, 1986; De Clercq, 1997). The expression of activity of these 
drugs requires bioconversion into their corresponding 5‟-O-triphosphate analogs (Furman 
et al., 1986, Hao et al., 1988; Balzarini and De Clercq, 1999). The resulting triphosphate 
analogs may inhibit the replication of the virus by competitive inhibition of viral reverse 
transcriptase (RT) and/or by incorporation into, and subsequent chain termination of the 
growing viral DNA strand (Cheng et al., 1987). Six drugs from the ddN family have been 
marketed: zidovudine (AZT, Retrovir), stavudine (d4T, Zerit), zalcitabine (ddC, Hivid), 
didanosine (ddI, Videx), lamivudine (3TC, Epivir) and abacavir (1592U89, Ziagen). AZT 
was the first drug to be approved by FDA (Mitsuya et al., 1985). Some other families of 
compounds have also been approved by FDA and are now commercially available as 
anti-HIV therapeutic agents, for example: nucleoside analogs (adefovir, dipivoxil), non-
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nucleoside reverse transcriptase inhibitors, also known as NNRTIs (nevirapine), and 
protease inhibitors (indinavir). AZT is still one of the most effective anti-HIV agents 
used, although it is the oldest compound approved by FDA. Although AZT therapy has 
reduced the mortality rate and frequency of opportunistic infections in AIDS patients, it is 
associated with some adverse effects and unsuitable pharmacokinetic properties. These 
adverse effects are provided below: 
 AZT administration is associated with significant dose-related toxicity leading to 
anemia and leucopenia (Fischl et al., 1987; Richman et al., 1987)  
 Pharmacokinetic studies in phase I trials revealed that the plasma half-life of AZT 
was only 1 hour (Klecker et al., 1987), requiring frequent administration of AZT 
to maintain therapeutic plasma concentration of the drug 
 Bone marrow toxicity was caused by the high doses of AZT needed to achieve 
adequate concentrations in cerebrospinal fluid (CSF) 
 AZT does not penetrate into brain tissue from the CSF (Terasaki and Pardridge, 
1988), and thus causes no suppression of viral replication in the brain 
 
Designing lipophilic prodrugs of AZT is one approach to increase its permeability 
through plasma membranes and to improve blood-brain barrier permeability. 
Combination therapy of AZT with other nucleoside derivatives, or certain NNRTIs, or 
different protease inhibitors, has been found to be more effective than AZT therapy alone 
(De Clercq, 1995). Based on these observations and the need for improvements in 
chemotherapeutic agents to treat AIDS, a series of codrugs of AZT has been synthesized 
and evaluated. 
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 Fig. 1.33: Anti-HIV codrug of AZT. 
 
AZT-retinoic acid codrug 
Agrawal et al. synthesized a series of mutual prodrugs of AZT with improved 
permeability properties to achieve higher concentrations of AZT in the both the central 
nervous system (CNS) and in targeted HIV-infected cells. Among these was a codrug of 
retinoic acid and AZT linked through an ester moiety (Fig. 1.33) (Aggarwal et al., 1990).  
Retinoic acid has previously been shown to inhibit HIV replication. The synthesized 
AZT-retinoic acid codrug and the parent drug AZT were partitioned between n-octanol 
and phosphate buffer (0.2 M, pH 7.4) to determine their partition coefficients (PC), and 
the codrug (PC = 17.9) was found to be more lipophilic than AZT (PC = 1.2). The 
hydrolysis of the codrug to the parent compounds was examined in phosphate buffer 
(pH=7.4) and in human plasma. The codrug was found to be stable in phosphate buffer, 
and the half-life of the codrug was found to be 120 minutes in human plasma. The 
stability of the codrug was also studied upon incubation with hepatic microsomes isolated 
from rat. The half-life of the codrug was found to be 60 minutes, indicating relatively 
rapid and complete microsomal enzymatic hydrolysis to the two parent drugs. The extent 
of cell membrane permeability of AZT and the retinoic acid-AZT codrug was measured 
by comparing the uptake of the radiolabeled drugs into H9 cells. The data showed that the 
uptake of the retinoic acid-AZT codrug in H9 cells was highest among all the synthesized 
AZT derivatives, and that the uptake the retinoic acid-AZT codrug was 4 times greater 
than the parent compound, AZT. The anti-viral activity of the retinoic acid-AZT codrug 
and AZT against HIV-1 was determined in vitro in peripheral blood lymphocytes (PBL) 
obtained from HIV-seronegative donors. The codrug was found to have similar anti-viral 
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activity to AZT, although cellular uptake of the codrug was much higher than that of 
AZT, and this may indicate incomplete cellular hydrolysis of the codrug under in vitro 
conditions. Although retinoic acid is known to inhibit HIV replication, the codrug did not 
exhibit synergistic effects, most likely due to only partial release of retinoic acid. 
 
1.5.9 Overall Aim of the Study 
 The object of the study is to first design and synthesize a series of codrugs 
combining an opioid drug with either a nicotinic receptor agonist or an NMDA receptor 
antagonist or an anticonvulsant or a cannabinoid drug, then to study the stabilities of the 
codrugs in different enzymatic and nonenzymatic conditions and finally to determine the 
pharmacological and pharmacokinetic profiles of some of the synthesized codrugs. 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Ujjwal Chakraborty 2012 
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Chapter 2 
Synthesis of Parent Drugs and Codrugs 
 
2.1 Enantioselective Syntheses of S-(-)-Nornicotine  
For the syntheses of the first series of codrugs containing S-(-)-nornicotine and 
opioids, S-(-)-nornicotine was required to be prepared. There are few enantioselective 
syntheses of S-(-)-nornicotine reported in literature. Schemes 2.1 and 2.2 summarize 
previously reported enantioselective synthetic strategies. As both the synthetic strategies 
involve several steps and afford only moderate yields, it would be beneficial if the 
naturally occurring, chirally pure, and inexpensive tobacco alkaloid S-(-)-nicotine could 
be N-demethylated without compromising the chirality of the pyrrolidine 2‟-carbon, to 
afford S-(-)-nornicotine.  
 
 
Scheme 2.1: Enantioselective synthesis of S-(-)-nornicotine by Loh et al., 1999. The key 
step in the synthesis involved reductive aminocyclization of a 1,4-ketoaldehyde with 
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2,3,4,6-tetra-O-pivaloyl-β-D-galactosylamine in presence of sodium cyanoborohydride. 
This step diastereoselectively afforded the desired stereoisomer. 
 
 
Scheme 2.2: Enantioselective synthesis of S-(-)-nornicotine by Swango et al., 1999. The 
key step in the synthesis involved alkylation of a chiral ketimine with 3-bromopropan-1-
ol. In later steps, the ketimine was cleaved followed by base catalyzed intramolecular 
ring closure. 
 
2.2 N-Demethylation of S-(-)-Nicotine 
A new method was developed for the N-demethylation of S-(-)-nicotine to afford 
S-(-)-nornicotine. Several oxidative conditions with or without high oxidation state metal 
oxides are reported in literature for dealkylation purpose (Nehru et al., 2007; McCamley 
et al., 2003; Rosenau et al., 2004). Based on the literature evidence that metal oxides can 
be used for N-dealkylation reactions, MnO2 was selected for N-demethylation of S-(-)-
nicotine. S-(-)-Nicotine was refluxed in 0.3 N H2SO4 in the presence of MnO2. After 
work up, S-(-)-nornicotine was obtained as an oil in 35% yield (Scheme 2.3). 
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Scheme 2.3: Synthesis of S-(-)-nornicotine. 
 
 
Fig. 2.1: GC-MS of synthesized S-(-)-nornicotine. 
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Chiral analysis of the S-(-)-nornicotine product was performed via derivatization 
with (-)-menthyl chloroformate, followed by chiral GC/MS analysis. The GC/MS 
retention time for the derivatized S-(-)-nornicotine (Fig. 2.2) was 9.12 minutes (NOTE: 
the (-)-menthyl R-(+)-nornicotine derivative has a retention time of 9.37 minutes). The 
compound showed a parent molecular ion (m/z = 329) using electron impact mass 
spectrometry (Fig. 2.3). The S-(-)-nornicotine product was found to have an enantiomeric 
excess (ee) of greater than 99 percent. 
 
 
Fig. 2.2: Total ion chromatogram of derivatized S-(-)-nornicotine. 
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Fig. 2.3: Mass spectrum of derivatized S-(-)-nornicotine. 
 
Chiral purity of the synthesized S-(-)-nornicotine was also determined by utilizing 
a chiral complexing agent, 1,1‟-binaphthyl-2,2‟-diylphosphoric acid (BNPPA) (Ravard 
and Crooks, 1996). Enantiopure (-)-R-BNPPA was used as the chiral complexing agent. 
When racemic nornicotine was treated with (-)-R-BNPPA a mixture of diastereomeric 
salts was formed; the 2-H and 6-H pyridinyl signals of racemic nornicotine could be seen 
as separate signals and were integratable. These two proton signals could be used for 
chiral purity analysis without any interference from the aromatic signals from the chiral 
complexing agent. If the sample of nornicotine contains two enantiomers then both of the 
enantiomers will form complex with (-)-R-BNPPA and produce a mixture of two 
diastereomeric salts. 2-H and 6-H pyridinyl hydrogens from the two diastereomeric salts 
have different chemical shifts and show up as separate peaks in the spectrum and thus can 
be used to determine chiral purity of a nornicotine sample. Along with the pyridinyl 
protons, the 5‟-H protons of the pyrrolidine ring were also found to be useful for chiral 
analysis. In presence of the chiral complexing agent, the 5‟-H protons of (+)-R-
nornicotine were observed as a single broad multiplet. In the case of (-)-S-nornicotine, the 
5‟-H protons were split into two broad multiplets. Synthesized S-(-)-nornicotine was 
treated with 1.6 equivalents of (-)-R-BNPPA and the resulting salt was analyzed by 
1
H 
NMR spectroscopy. The spectrum showed only two signals above 8 ppm, corresponding 
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to the 2-H and 6-H pyridinyl protons of the (-)-S-nornicotine enantiomer complex. No 
signals were observed for the 2-H and 6-H pyridinyl protons that corresponded to the (+)-
R-nornicotine enantiomer complex. Similarly, analysis of the 2.6-4.2 ppm region of the 
spectrum revealed two broad multiplets centered around 3.1 and 2.8 ppm. These two 
multiplets correspond to the 5‟ protons of the (-)-S-nornicotine enantiomer complex. A 
broad multiplet centered at 2.95 ppm corresponding to the 5‟-H protons of the (+)-R-
nornicotine enantiomer complex was barely negligible (noise level), and below levels of 
integration. Thus, the analysis of the proton NMR spectrum of synthesized nornicotine in 
presence of the chiral complexing agent demonstrated that (-)-S-nornicotine was 
exclusively obtained by the oxidative N-demethylation of (-)-S-nicotine. 
 
 
Fig. 2.4: Important protons for chiral analysis of the nornicotine molecule with compound 
numbering scheme. 
 
 
Fig. 2.5: Proton NMR spectrum of racemic nornicotine in the presence of the chiral 
complexing agent R-(-)-1,1‟-binaphthyl-2,2‟-diylphosphoric acid (BNPPA) in the region 
8.0-8.8 ppm. (Reprinted from Chirality, Ravard and Crooks, 1996, with permission)  
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Fig. 2.6: Proton NMR spectrum of synthesized (-)-S-nornicotine in presence of the chiral 
complexing agent R-(-)-BNPPA in the region 8.0-8.8 ppm. 
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Fig. 2.7: Proton NMR spectrum of racemic nornicotine (I), R-(+)-nornicotine (II) and S-(-
)-nornicotine (III) in the presence of the chiral complexing agent R-(-)-BNPPA in the 
region 2.6-4.4 ppm. (Reprinted from Chirality, Ravard and Crooks, 1996, with 
permission) 
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Fig. 2.8: Proton NMR spectrum of synthesized nornicotine in the presence of chiral 
complexing agent in the region 2.5-4.4 ppm. 
 
To determine if this N-demethylation procedure could be utilized as a general 
procedure for the N-demethylation of tertiary amino compounds bearing an N-methyl 
group. Several other N-methyl compounds were treated with MnO2 and 0.3 N H2SO4 
under reflux conditions and the products were analyzed by GC-MS. The following 
scheme (Scheme 2.4) summarizes the outcomes of these oxidative N-demethylation 
reactions. It can be concluded from the obtained results, that MnO2 can be used for 
oxidative N-demethylation reactions without compromising the chirality of any adjacent 
stereocenters present in such molecules. It is observed that the presence of a double bond 
is not compatible with the above methodology, affording extensive oxidation at the C=C 
moiety.  
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Scheme 2.4: N-Demethylation of several N-methyl compounds. 
 
2.3 Synthesis of Codrugs and Analogs 
2.3.1 Opioid-S-(-)-Nornicotine Codrugs Syntheses 
A series of codrugs were designed combining an opioid or a prodrug of an opioid 
with S-(-)-nornicotine. Codeine, morphine and 3-O-acetylmorphine (a prodrug of 
morphine) were chosen as the opioid molecules. Codeine, morphine and 3-O-
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acetylmorphine contain either an alcoholic OH group or a phenolic OH group. On the 
other hand, S-(-)-nornicotine contains a secondary amino group. The most logical way to 
join these molecules is through a carbamate bond between OH groups of opioids and the 
amino group of S-(-)-nornicotine. The first codrug in this series that was aimed for 
synthesis was a carbamate codrug combining codeine and S-(-)-nornicotine through a 
carbamate bond. 
 
 
Fig. 2.9: Design of codeine-S-(-)-nornicotine carbamate codrug. 
 
Since the essential conjugation chemistry in the synthesis of the codeine-S-(-)-
nornicotine codrug is the formation of a carbamate linkage, reactions were initiated to 
generate carbamate linkages between an amine and a phenol. Before commencing the 
synthetic work with expensive controlled substances such as codeine and S-(-)-
nornicotine, coupling reactions were initially carried out with model compounds or 
chemical-mimics of the drug molecules to optimize the desired chemistry. 3-Ethylphenol 
was chosen as the model compound for codeine and morphine, and pyrrolidine was 
selected as a chemical mimic for the S-(-)-nornicotine molecule. Initially, three 
retrosynthetic schemes were devised for the synthesis of a carbamate conjugate of the 
two desired molecules (Scheme 2.5). The first approach (route A) involves the 
intermediacy of the N-carbamoyl chloride analogue of pyrrolidine, followed by its 
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reaction with a phenol to generate the desired carbamate conjugate. The second approach 
(route B) involves conversion of the phenol to a symmetrical carbonate ester, followed by 
nucleophilic substitution of one of the carbonate moieties with the desired amine. The last 
approach (route C) involves the formation of a chloroformate derivative of the phenol 
followed by reaction with pyrrolidine, to generate the desired carbamate conjugate. 
 
 
Scheme 2.5: Different synthetic strategies to afford carbamate conjugates of a phenol and 
a secondary amine.  
 
In the first synthetic approach (route A), to generate the carbamate linkage, 
pyrrolidine was allowed to react with triphosgene to form the desired N-carbamoyl 
chloride derivative of pyrrolidine (Gulin et al., 2006). The reaction was followed by GC-
MS monitoring. The reaction yielded the desired intermediate, along with a urea side 
product (Scheme 2.6 and Fig. 2.10). This side reaction not only decreased the yield of the 
desired product, but also caused complications in the purification of the carbamoyl 
chloride intermediate. Urea formation would significantly increase the cost of the final 
process, as it would consume the expensive parent drugs during the actual synthesis of 
the codeine-S-(-)-nornicotine codrug. The mass spectra of the N-carbamoyl chloride and 
the urea side product are shown in Fig. 2.11 and 2.12. 
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Scheme 2.6: Reaction of pyrrolidine with triphosgene. 
 
 
Fig. 2.10: Total ion chromatogram of synthetic pyrrolidine N-carbamoyl chloride 
(retention time: 3.81 min) and the pyrrolidine urea side product (retention time: 8.41 
min). 
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Fig. 2.11: Mass spectrum of pyrrolidine N-carbamoyl chloride. 
 
 
Fig. 2.12: Mass spectrum of pyrrolidine urea. 
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In the second synthetic approach (route B), the symmetrical carbonate of the 
phenolic compound was formed by reacting the phenol with triphosgene (Burk and Roof, 
1993). The carbonate intermediate was then allowed to react with pyrrolidine to form the 
desired carbamate conjugate (Scheme 2.7). Both reactions were monitored by GC-MS. 
The reactions were comparatively cleaner than the reaction in the previous synthetic 
approach, but suffered from the loss of half equivalent of the phenolic compound as a 
byproduct. This would cause an increase in cost when the final opioid (codeine and 
morphine)-nornicotine codrug molecule was synthesized. The mass spectra of the 
symmetrical carbonate of 3-ethylphenol and the 3-ethylphenol-pyrrolidine carbamate 
conjugate are shown in Fig. 2.13 and 2.14. 
 
 
Scheme 2.7: Synthesis of carbamate conjugate via the intermediacy of a symmetrical 
carbonate ester. 
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Fig. 2.13: Mass spectrum of 3-ethylphenol carbonate ester. 
 
 
Fig. 2.14: Mass spectrum of the 3-ethylphenol-pyrrolidine carbamate conjugate. 
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A third synthetic approach (route C) was explored in an attempt to solve the 
problems faced in the first two approaches. Following this retrosynthetic route, a 
chloroformate derivative of the phenolic starting material was synthesized by reacting the 
phenol with triphosgene reagent in the presence of a base (pyridine) (Martin et al., 2006). 
The chloroformate derivative was then allowed to react with pyrrolidine to yield the 
carbamate conjugate (Scheme 2.8). This route was found to be the best choice among the 
three approaches investigated. Nevertheless, some minor problems were observed. 
Formation of a symmetrical carbonate side product during the synthesis of chloroformate 
derivative was one of the minor problems in this approach. The mass spectrum of the 
chloroformate intermediate of 3-ethylphenol is shown in Fig. 2.15.  
 
 
Scheme 2.8: Synthesis of a carbamate conjugate via the intermediacy of a chloroformate. 
Table 2.1: Comparison of three synthetic routes. 
Route GC yield of the intermediate GC yield of the product Problem 
A 50% 88% 50% of the starting material 
amine wasted as urea 
intermediate 
B 82% 79% 50% of the starting material 
phenol wasted at the last step 
C 62% 87% Minor problem of symmetrical 
carbonate formation 
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Fig. 2.15: Mass spectrum of 3-ethylphenol chloroformate.  
 
In the next series of reactions, one of the chemical mimics was replaced by the 
actual drug molecule. Pyrrolidine was replaced with the S-(-)-nornicotine molecule. The 
chloroformate derivative of the model phenolic compound was synthesized utilizing the 
same methodology as previously described, and then it was allowed to react with S-(-)-
nornicotine in presence of triethylamine (TEA). The reaction was monitored by GC-MS, 
which confirmed the formation of the carbamate conjugate of 3-ethylphenol and S-(-)-
nornicotine. 
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Scheme 2.9: Synthesis of 3-ethylphenol-S-(-)-nornicotine carbamate conjugate. 
 
 
Fig. 2.16: Mass spectrum of 3-ethylphenol-S-(-)-nornicotine carbamate conjugate. 
 
After the successful formation of the carbamate conjugate of S-(-)-nornicotine and 
3-ethylphenol, the carbamate conjugates of morphine and S-(-)-nornicotine and codeine 
and S-(-)-nornicotine were undertaken. Morphine or codeine was added to dry THF along 
with pyridine or triethylamine and the reaction temperature was maintained at 0 °C. 
Triphosgene solution was then added drop-wise to the reaction mixture. An immediate 
white precipitation was observed after the addition of triphosgene to the morphine or 
codeine solution. GC-MS analysis of the each of the precipitates from these two reactions 
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showed a product with the molecular mass of morphine and codeine, respectively. 
13
C 
NMR spectra of the two precipitates did not show any carbonyl peak in the region where 
a chloroformate carbon would show up. The precipitates were identified to be protonated 
morphine and codeine. A series of different solvents and bases were utilized in these 
reactions, but in all the different situations, precipitation of the starting materials always 
occurred. Due to this problem a new synthetic method was sought for the formation of 
the carbamate codrugs.  
In attempting to solve the above problem it was found that p-
nitrophenylchloroformate analogues have been utilized in the literature for the formation 
of unsymmetrical carbonates and carbamates (Anderson and McGregor, 1957). Initially, 
an alcohol is reacted with p-nitrophenylchloroformate (pNPCF) to form the carbonate 
conjugate of the alcohol and p-nitrophenol. This intermediate is then reacted with an 
amine to form the carbamate conjugate of an alcohol and an amine. In the second step, 
the good leaving group property of the p-nitrophenol moiety is advantageous in the 
selective formation of the desired carbamate conjugate. 
Utilizing this approach, codeine was first allowed to react with pNPCF in the 
presence of N,N-dimethylamino pyridine (DMAP) in anhydrous dichloromethane (DCM) 
to yield the p-nitrophenyl carbonate analog of codeine (i.e. cod-pnp). The structure of this 
compound was confirmed by 
1
H- and 
13
C-NMR spectroscopy and mass spectrometry. p-
Nitrophenol was generated as a side-product of the reaction, and was difficult to remove 
from the desired product. Washing the DCM solution of the cod-pnp carbonate with 
saturated aqueous NaHCO3 solution reduced the p-nitrophenol contamination, but could 
not remove it completely. An attempt to purify the carbonate intermediate of codeine and 
p-nitrophenol using column chromatography with DCM-MeOH as eluent yielded the 
methanolic carbonate analog of codeine; the structure of this product was determined by 
mass spectrometry and 
1
H- and 
13
C-NMR spectroscopy. This carbonate conjugate 
between methanol and codeine may be utilizable as a novel prodrug of codeine. 
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Scheme 2.10: Synthesis of the p-nitrophenoxy carbonate of codeine. 
 
 
Scheme 2.11: Reaction of the p-nitrophenoxy carbonate of codeine with methanol in the 
presence of silica. 
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Fig. 2.17: MALDI-TOFMS of codeine-p-nitrophenol carbonate. 
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Fig. 2.18: GC-MS of the methanolic carbonate derivative of codeine. 
 
Codeine-p-nitrophenyl carbonate was then allowed to react with the model 
compound pyrrolidine under reflux conditions in the presence of TEA. The progress of 
the reaction was followed by TLC, and after the completion of the reaction, the desired 
carbamate conjugate of codeine and pyrrolidine was obtained as a solid product. The 
structure of the conjugate was confirmed by 
1
H- and 
13
C-NMR spectroscopy and mass 
spectrometry. 
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Scheme 2.12: Synthesis of the codeine pyrrolidine carbamate conjugate. 
 
 
Fig. 2.19: Mass spectrum of the codeine-pyrrolidine carbamate conjugate. 
 
After the success of generating the carbamate conjugate between codeine and 
pyrrolidine, synthesis of the codrug containing codeine and S-(-)-nornicotine was 
attempted using the same synthetic methodology. Cod-pnp carbonate was allowed to 
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react with S-(-)-nornicotine under reflux conditions yielding the desired codrug. The 
structure of the codeine-S-(-)-nornicotine carbamate codrug was confirmed by 
1
H- and 
13
C-NMR spectroscopy and mass spectrometry and the purity of the codrug was 
determined using HPLC-diode array assay.  
 
 
Scheme 2.13: Synthesis of the carbamate codrug of S-(-)-nornicotine and codeine. 
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Fig. 2.20: Mass spectrum of the carbamate codrug of codeine and S-(-)-nornicotine. 
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Fig. 2.21: HPLC chromatogram of codeine-S-(-)-nornicotine carbamate (retention time: 
14.485 min). 
 
The synthesis of a second series of codrugs were then pursued that incorporated 
the opioid alkaloid morphine and S-(-)-nornicotine. The first codrug prepared in this 
series was the carbamate codrug of S-(-)-nornicotine and morphine; carbamate 
conjugation was through the 6-hydroxy group of the morphine molecule. Morphine was 
first converted into 3-O-acetylmorphine by acetylation with acetic anhydride/NaHCO3. 
 
 
Scheme 2.14: Synthesis of 3-O-acetylmorphine. 
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Fig. 2.22: GC-MS spectrum of 3-O-acetylmorphine. 
 
  3-O-Acetylmorphine was converted into its para-nitrophenoxycarbonate ester. 
The structure of the intermediate was confirmed by 
1
H- and 
13
C-NMR spectroscopy and 
mass spectrometry. 
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Scheme 2.15: Synthesis of the p-nitrophenoxy carbonate derivative of 3-O-
acetylmorphine. 
 
 
Fig. 2.23: Mass spectrum 3-O-acetylmorphine-p-nitrophenol carbonate. 
 
  The reactive carbonate intermediate was then allowed to react with S-(-)-
nornicotine to afford the 3-O-acetylmorphine-S-(-)-nornicotine codrug. The acetyl 
protected codrug was subsequently O-deacetylated in the presence of LiOH to provide 
the desired carbamate codrug of morphine and S-(-)-nornicotine. The 3-O-acetyl 
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protected codrug was considered to be a useful structural modifaction of the target 
morphine-S-(-)-nornicotine codrug, since it represents a derivative that may have 
improved  bioavailability over the codrug, due to increased lipophilicity and reduced 
number of sites for metabolism. 
 
Scheme 2.16: Synthesis of 3-O-acetylmorphine-S-(-)-nornicotine carbamate codrug. 
 
 
Scheme 2.17: Synthesis of morphine-S-(-)-nornicotine carbamate (6-oxy) codrug. 
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Fig. 2.24: LC-MS chromatogram of 3-O-acetylmorphine-S-(-)-nornicotine carbamate 
codrug. 
 
A second codrug was synthesized in this series which incorporated two molecules 
of S-(-)-nornicotine with one molecule of morphine. In the preparation of this novel 
codrug, morphine was allowed to react with excess of p-nitrophenyl chloroformate to 
afford a dicarbonate ester derivative of morphine with two equivalents of p-nitrophenol 
(Scheme 2.18). The structure of the intermediate in this synthesis was confirmed by mass 
spectrometry and 
1
H- and 
13
C-NMR spectroscopy. 
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Scheme 2.18: Synthesis of the dicarbonate ester derivative of morphine and p-
nitrophenol. 
 
 
Fig. 2.25: LC-MS analysis of the dicarbonate ester derivative of morphine and p-
nitrophenol. 
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The p-nitrophenol dicarbonate ester of morphine was then allowed to react with S-
(-)-nornicotine to yield morphine-bis-S-(-)-nornicotine codrug. The structure of the 
codrug was confirmed by LC-MS. 
 
Scheme 2.19: Synthesis of the morphine-S-(-)-nornicotine dicarbamate codrug. 
 
 
Fig. 2.26: LC-MS analysis of morphine-S-(-)-nornicotine dicarbamate codrug. 
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The last codrug to be synthesized in this series was the S-(-)-nornicotine-
morphine carbamate codrug in which the S-(-)-nornicotine moiety was connected to the 
3-hydroxy group of morphine (instead of the 6-hydroxy group). Initially, conjugation 
reactions were carried out utilizing different bases and conditions to selectively form the 
3-oxy carbonate (avoiding formation of 6-oxy carbonate product). In the first attempt, 
morphine was allowed to react with 1 equivalent of p-nitrophenyl chloroformate in 
presence of 1 equivalent of DMAP at 0 °C. This reaction turned out to be non-selective, 
producing a mixture of three different carbonate conjugates of morphine, as shown in 
Scheme 2.20. 
 
 
Scheme 2.20: Reaction of morphine with 1 equivalent of p-nitrophenyl chloroformate in 
presence of DMAP at 0 °C. 
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 In another attempt, 1 equivalent of a strong alkali base (NaH) was utilized along 
with 1 equivalent of p-nitrophenyl chloroformate to form the desired 3-oxy carbonate of 
morphine and p-nitrophenol. This reaction showed better regioselectivity although 
formation of 6-oxy carbonate could not be completely avoided. The purification of the 3-
oxy carbonate from the mixture of 3-oxy and 6-oxy carbonates was nearly impossible, 
due to their very similar Rf values, and also due to the reactivity of the p-nitrophenoxy 
carbonate conjugates with methanol in presence of silica; thus, a different synthetic 
scheme was sought.  
 
 
Scheme 2.21: Reaction of morphine with 1 equivalent of p-nitrophenyl chloroformate in 
the presence of NaH. 
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In a different synthetic strategy S-(-)-nornicotine was converted into its p-
nitrophenoxy carbamate derivative using p-nitrophenyl chloroformate (Scheme 2.22). 
The structure of the carbamate conjugate was confirmed by GC-MS analysis and 
1
H- and 
13
C-NMR spectroscopy. 
 
Scheme 2.22: Synthesis of the p-nitrophenoxy carbamate derivative of S-(-)-nornicotine. 
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Fig. 2.27: GC-MS analysis of the p-nitrophenoxy carbamate of S-(-)-nornicotine. 
  The p-nitrophenoxy carbamate of S-(-)-nornicotine was then allowed to react with 
morphine in the presence of 1 equivalent of NaH. This reaction yielded the 3-
oxycarbamate conjugate of morphine linked with S-(-)-nornicotine. 
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Scheme 2.23: Synthesis of morphine-S-(-)-nornicotine carbamate (3-oxy) codrug. 
 
 
Fig. 2.28: Mass spectrum of morphine-S-(-)-nornicotine carbamate (3-oxy) codrug. 
 
102 
 
2.3.2 Opioid-Ketamine/Norketamine Codrugs Syntheses 
After completing the syntheses of the opioid-S-(-)-nornicotine codrug series, the 
next series of codrugs to be synthesized were opioid - NMDA receptor antagonist 
conjugates. Racemic ketamine and racemic norketamine were chosen as NMDA receptor 
antagonist molecules. As racemic ketamine and racemic norketamine were used for the 
synthesis of opioid-ketamine and opioid-norketamine codrugs, a mixture of 
diastereomeric codrugs were obtained in each case. The first synthetic target was a 
codrug containing ketamine and codeine. Since codeine contains an allylic alcohol and 
ketamine is a secondary amine, a carbamate linkage was utilized to conjugate these two 
molecules. The previously developed synthetic strategies to form carbamate linkages in 
the previous examples were utilized for synthesis of the desired opioid-ketamine codrugs. 
The p-nitrophenoxy carbonate ester of codeine was allowed to react with ketamine in the 
presence of DMAP. The progress of the reaction was monitored by TLC. Reflux 
conditions utilizing several different solvents were attempted but none afforded product. 
ESI-MS analysis of the reaction mixture did not afford any proof of product formation. 
Failure of the carbamoylation reaction could be due to steric hindrance around the 
secondary amino group of the ketamine molecule.  
 
 
Scheme 2.24: Reaction between the p-nitrophenoxy carbonate ester of codeine and 
ketamine. 
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Fig. 2.29: ESI-MS analysis of the mixture from the reaction of ketamine with the p-
nitrophenoxy carbonate ester of codeine. 
 
In a second attempt to form the ketamine-codeine carbamate conjugate, an initial 
reaction was carried out to synthesize the p-nitrophenoxy carbamate of ketamine 
followed by subsequent reaction with codeine. Thus, a mixture of ketamine and p-
nitrophenyl chloroformate was refluxed in presence of Na2CO3. This reaction yielded the 
desired carbamate product (Crooks and Rivera, 2004). 
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Scheme 2.25: Synthesis of the p-nitrophenoxy carbamate derivative of ketamine. 
 
 
Fig. 2.30: ESI-MS analysis of the p-nitrophenoxy carbamate of ketamine. 
 
The p-nitrophenoxy carbamate conjugate of ketamine was then allowed to react 
with codeine in presence of NaH. Since the ketamine utilized was racemic ketamine, the 
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reaction yielded a diastereomeric mixture of two codeine-ketamine codrugs. The two 
diastereomers of the desired codrug could not be separated by column chromatography. 
 
Scheme 2.26: Synthesis of codeine-ketamine codrug (diastereomeric mixture). 
 
 
Fig. 2.31: ESI-MS of ketamine-codeine carbamate codrug. 
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A codeine-norketamine codrug was synthesized by first converting racemic 
norketamine into the p-nitrophenoxy carbamate conjugate followed by reaction with 
codeine in the presence of NaH. The reaction produced a diastereomeric mixture of two 
codeine-norketamine codrugs. The two diastereomers could not be separated by column 
chromatography, but under HPLC analysis the diastereomeric mixture exhibited two 
separate peaks. 
 
Scheme 2.27: Synthesis of codeine-norketamine codrug (diastereomeric mixture). 
107 
 
 
Fig. 2.32: LC-MS chromatogram of codeine-norketamine codrug. 
 
Using a similar synthetic strategy, a codrug containing morphine and racemic 
norketamine was synthesized. The p-nitrophenoxy carbamate conjugate of norketamine 
was allowed to react with morphine in the presence of 1 equivalent of NaH. This yielded 
a diastereomeric mixture of the carbamate codrug of morphine and racemic norketamine. 
One equivalent of NaH allowed the selective deprotonation of the 3-hydroxy group of 
morphine followed by its nucleophlic attack on the carbamate linkage of the 
norketamine-p-nitrophenol conjugate. Formation of the desired carbamate codrug was 
confirmed by 
1
H- and 
13
C-NMR spectroscopy and mass spectrometry. Column 
chromatographic separation of the two diastereomers could not be achieved due to the 
very similar Rf values of both diastereomers. Peaks corresponding to the two 
diastereomeric codrugs could be observed in the HPLC-diode array assay.  
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Scheme 2.28: Synthesis of morphine-norketamine codrug (diastereomeric mixture). 
 
 
Fig. 2.33: LC-MS chromatogram of morphine-norketamine codrug. 
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2.3.3 Opioid-Gabapentin Codrugs Syntheses 
The next series of codrugs that were synthesized were codrugs combining an 
opioid molecule with gabapentin (an anticonvulsant). The presence of a primary amino 
group and a carboxylic acid group in the gabapentin molecule makes this molecule more 
versatile in terms of its conjugation chemistry. Opioids can be joined to gabapentin 
through its amino group yielding a carbamate codrug, or can be connected to gabapentin 
via its carboxylic acid group yielding an ester codrug. Since an ester linkage is more 
susceptible to hydrolysis than a carbamate linkage, the first drug to be considered in this 
series was an ester codrug containing codeine as the opioid molecule. To prevent the 
likely internal cyclization of this codrug molecule, gabapentin has to be kept in the 
diprotonated amine form. The structure of the proposed ester codrug is shown in Fig. 
2.34. 
 
                                                       
Fig. 2.34: Proposed structure of codeine-gabapentin ester codrug with protonated amines 
and chloride counterions.  
 
Since all the codrugs thus far were targeted for oral delivery, the proposed codrug 
of codeine and gabapentin (Fig. 2.34) will likely be relatively stable in the acid pH of the 
stomach, but will be deprotonated in the alkaline pH of the intestine, which will generate 
a free primary amino group that will attack the adjacent ester moiety, leading to rapid 
ester cleavage of the codrug in the g.i. tract. Cleavage of the ester linkage will afford a 5-
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membered lactam derivative of gabapentin as well as free codeine. This reaction would 
produce a very stable cyclic lactam of gabapentin, which might not be easily cleaved in 
vivo to produce gabapentin. Also, due to this intramolecular nucleophilic substitution, the 
codrug would likely cleave completely in the intestine before entering the systemic 
circulation. . To examine this hypothesis, the designed ester codrug was synthesized and 
its stability was determined in pH 7.4 buffer (the pH of the small intestine). Results of the 
stability studies will be discussed in the in vitro stability studies section of chapter 4.  
 
 
Scheme 2.29: Synthesis of the di-HCl salt of the codeine-gabapentin ester codrug. 
 
In the preparation of the ester codrug, the primary amino group of gabapentin was 
protected initially with a BOC protecting group (Green and Wuts, 1999). The free 
carboxylic acid group of BOC-protected gabapentin was coupled with the alcoholic 
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group of codeine in the presence of DCC to generate an ester conjugate. The BOC-
protected amino group of the ester conjugate was then deprotected to form the 
dihydrochloride salt of the ester codrug of codeine and gabapentin (Green and Wuts, 
1999). 
 
Scheme 2.30: Proposed in vivo hydrolytic behavior of the di-HCl salt of the codeine-
gabapentin ester codrug. 
 
Since the above ester codrug of codeine and gabapentin may suffer from 
instability in intestine, a carbamate codrug of gabapentin and codeine was designed by 
directly conjugating the amino group of gabapentin with the hydroxyl group of codeine. 
The p-nitrophenoxy carbonate ester of codeine was allowed to react with gabapentin to 
afford the desired carbamate codrug (Scheme 2.31) (Bolla et al., 2005). The structure of 
the desired codrug was confirmed by mass spectrometry and 
1
H- and 
13
C-NMR 
spectroscopy. The purity of the codrug was also determined by HPLC-diode array assay. 
 
112 
 
Scheme 2.31: Synthesis of the codeine-gabapentin carbamate codrug. 
 
 
Fig. 2.35: LC-MS chromatogram of the gabapentin-codeine carbamate codrug. 
 
 Several other codrugs were designed by protecting the free amino group of 
gabapentin as a labile amide or carbamate and conjugating the carboxylic acid group of 
gabapentin with the 6-hydroxyl group of codeine through an ester linkage. In the first 
attempt, the amino group of gabapentin was protected as a simple amide which was then 
conjugated with codeine in the presence of DCC to form an ester linkage. The structure 
of the resulting codrug and the intermediate were confirmed by mass spectrometry and 
1
H- and 
13
C-NMR spectroscopy. 
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Scheme 2.32: Synthesis of the amide-protected ester codrug of codeine and gabapentin. 
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Fig. 2.36: LC-MS chromatogram of N-acetylgabapentin. 
 
 
Fig. 2.37: Single crystal X-ray structure of N-acetylgabapentin. 
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Fig. 2.38: LC-MS chromatogram of N-acetylgabapentin-codeine ester codrug. 
 
In another attempt, the free amino group of gabapentin was protected as an 
ethanolic carbamate (Cundy et al., 2004) and then coupled with codeine following the 
same chemistry as previously described, to obtain a different ester linked codrug of 
gabapentin and codeine (Scheme 2.33). 
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Scheme 2.33: Synthesis of an N-carbamate protected ester codrug of codeine and 
gabapentin. 
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Fig. 2.39: GC-MS analysis of the N-ethyl carbamate of gabapentin (molecular mass 
corresponds to dehydration product). 
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Fig. 2.40: ESI-MS analysis of carbamate N-protected ester codrug of codeine and 
gabapentin. 
 
2.3.4 Attempt to Synthesis of Opioid-∆
9
-Tetrahydrocannbinol Codrug 
The next series of codrugs to be synthesized were opioid-∆
9
-tetrahydrocannbinol 
(∆
9
-THC) codrugs. Morphine-∆
9
-THC and codeine-∆
9
-THC codrugs were synthesized 
and studied by Dhooper et al. (2006). Thus a different opioid (oxycodone) was chosen for 
this project.  The proposed structure oxycodone-∆
9
-THC codrug contains a carbonate 
linkage between hydroxyl group of oxycodone and phenolic group of ∆
9
-THC.  
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Fig. 2.41: Proposed structure of the oxycodone-∆
9
-THC codrug. 
 
Several synthetic strategies can be planned to synthesize the desired codrug. The 
first synthetic route was based on conversion of oxycodone to its p-nitrophenoxy 
carbonate ester and then reaction between ∆
9
-THC and p-nitrophenoxy carbonate ester of 
oxycodone to afford the carbonate codrug. In contrast to codeine and morphine, 
oxycodone does not contain a phenolic or allylic hydroxyl group; instead it has a very 
sterically hindered tertiary alcoholic group (the 14-hydroxy group). There are very few 
literature references that report any chemical modification of the 14-hydroxy group of 
oxycodone. Only two esters of oxycodone have previously been synthesized (Cami-
Kobeci et al., 2009; Moynihan et al., 2009). It was initially planned to convert oxycodone 
to its p-nitrophenoxy carbonate analog to afford one component for the subsequent 
conjugation reaction with a second drug. A solution containing oxycodone, p-nitrophenyl 
chloroformate and DMAP was refluxed in anhydrous THF. After two days of continuous 
reflux, one new faint spot was observed by TLC analysis. GC-MS analysis of the reaction 
mixture showed a new peak of molecular mass 377 bearing the signature of the presence 
of one chlorine atom in the molecule. To enhance the rate of the reaction microwave 
irradiation was investigated.  
Microwave heating has become a widely accepted, non-conventional heating 
source for improving the yields of organic reactions. The major advantage of using 
microwave irradiation as a source of heating is the spectacular acceleration of the 
reaction kinetics as compared to conventional heating. In addition to shorter reaction 
times, higher yields are generally achieved in microwave assisted organic synthesis 
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(Gabriel et al., 1998). Some reactions which cannot be performed by conventional 
heating can be done using microwave irradiation (Gabriel et al., 1998). Greatly 
accelerated reaction rates under microwave heating are generally explained in terms of a 
combination of thermal and non-thermal effects. Thermal effects may include 
overheating, hotspots and selective heating, and non-thermal effects incorporate changes 
in mobility and diffusion increasing the probabilities of effective contacts and the effects 
of a highly polarizing field (Roberts and Straus, 2005).  
Thermal Effects 
The microwave heating technique utilizes the ability of some compounds to 
transform electromagnetic irradiation into heat. Conventional heating, in contrast, relies 
on convection and conduction of heat. Microwave heating is rapid and volumetric, 
meaning the whole material is heated up simultaneously and very rapidly. On the other 
hand, conventional heating is superficial and relatively slow. The magnitude of heating in 
the case of microwave irradiation depends on the dielectric properties of the solvent or 
the reactants, thus making it a selective heating procedure (Lew et al., 2002).  
Overheating of polar liquids through microwave irradiation is also instrumental in 
rate enhancement in microwave assisted organic synthesis. Generally overheating in the 
range of 13-26 °C above the normal boiling point is observed in polar liquids when 
heated under microwave conditions (Hoz et al., 2004). The major reason behind the 
overheating is inverted heat transfer, i.e. heating occurs from the irradiated mass towards 
the exterior. Overheating under microwave condition is helpful in improving the yields 
and efficiency of many chemical reactions. “Hot spots” in microwave irradiated samples 
are also considered as one of the thermal effects. Hot spots are defined as certain zones 
within the sample being irradiated with microwaves whose temperature is much greater 
than the macroscopic temperature of the sample. This effect is caused by the 
inhomogeneity of the applied field. In addition to these thermal effects, another 
advantage of microwave heating is its selective nature. Microwaves cause rapid heating 
of polar substances while nonpolar substances are not able to absorb microwave 
radiation, and as a consequence are not heated (Jacob et al., 1995).  
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Non-thermal effects 
The presence of non-thermal effects in addition to thermal effects is still being 
debated. In an experiment carried out by Berlan et al.,(1999) cycloaddition reactions were 
carried out under reflux conditions in nonpolar solvents under conventional heating and 
under microwave conditions at the same temperature. Reaction rates were observed to be 
faster under microwave irradiation, even though the temperature was maintained the 
same and poorly microwave absorbing nonpolar solvents were used. The authors 
proposed a decreased free energy of activation through a change in the entropy of the 
system as an explanation of the observed phenomenon. It is also believed that microwave 
causes rapid rotation of the polarized dipoles in the molecules generating heat due to 
friction, and also increases the probability of contact between molecules and atoms. 
Increased probability of contact will increase the rate of the reaction and also will 
decrease the activation energy (Hoz et al., 2004).  
Since the microwave approach is proven to be more efficient than conventional 
heating, microwave irradiation was utilized in an attempt to increase the rate of reaction 
between oxycodone and p-nitrophenyl chloroformate. Oxycodone, p-nitrophenyl 
chloroformate and DMAP were dissolved in anhydrous THF and the reaction mixture 
was irradiated in a microwave unit to achieve a reaction temperature of 170 °C. The 
reaction temperature was maintained at 170 °C for 4 minutes. GC-MS analysis of the 
reaction mixture showed an intense peak of molecular mass 377. This mass does not 
correspond to the molecular mass of the desired p-nitrophenoxy carbonate ester of 
oxycodone and the pattern of isotopic peaks in the mass spectrum of the compound 
indicated the presence of chlorine in the synthesized compound.  
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Scheme 2.34: Reaction between oxycodone and p-nitrophenyl chloroformate under 
microwave heating conditions. 
 
 
Fig. 2.42: GC-MS analysis of the product of the reaction between oxycodone and p-
nitrophenyl chloroformate. 
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To determine the structure of the newly generated oxycodone analog, the 
compound was purified followed by 
1
H and 
13
C NMR spectral analysis. The 
13
C NMR 
spectrum of the compound showed one new peak at 156.33 ppm which was absent in the 
13
C NMR spectrum of oxycodone. A literature search showed that the carbonyl carbon of 
a chloroformate group shows up at around 156 ppm in 
13
C NMR spectra (Mizuno et al., 
2002; Olofson et al., 1978).  
 
 
Fig. 2.43: 
13
C NMR spectrum of the product from the reaction between oxycodone and p-
nitrophenyl chloroformate. 
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Fig. 2.44: Proposed structure of the product from the microwave reaction between 
oxycodone and p-nitrophenyl chloroformate. 
 
The 377 m/z molecular mass of the product was also a match with the molecular 
mass of the expected chloroformate derivative of oxycodone. To analyze the chemical 
behavior of the compound several reactions were attempted with different phenolic and 
alcoholic nucleophiles in presence of different bases. The outcomes of those chemical 
reactions are summarized in the Scheme 2.35. The behavior of the molecule in the above 
mentioned reactions indicated that the molecule is likely not a chloroformate, unless it is 
a highly sterically hindered one (which could not be ruled out). X-ray crystallography 
was used to determine the crystal structure of the molecule.  
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Scheme 2.35: Reactions of synthesized oxycodone intermediate with different 
phenoxides and alkoxides. 
 
Crystals of the product from the above microwave reaction were formed from 
ethyl acetate solution, and analyzed by X-ray crystallography. X-ray crystallographic 
analysis of the compound indicated that the molecule was not the desired chloroformate 
derivative of oxycodone, but was a cyclic carbamate with incorporation of a chlorine 
atom (Fig. 2.45). The 14-hydroxy group and the amine group of oxycodone formed a 
carbamate ring. Also, one of the six membered rings (containing N) opened up with 
incorporation of a chlorine atom. Formation of the 5-membered cyclic carbamate can be 
explained as a result of initial formation of p-nitrophenoxy intermediate followed by 
simultaneous ring closure and ring opening. 
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Fig. 2.45: Single crystal X-ray structure of the oxycodone analog from the microwave 
reaction of oxycodone with p-nitrophenyl chloroformate. 
 
Since the oxycodone skeletal rearrangement chemistry was interesting, similar 
reactions were carried out with other opioids containing a 14-hydroxy functionality. Two 
other opioids containing a 14-hydroxy group are naltrexone and naloxone. Along with 
14-hydroxy group, both the opioids have phenolic hydroxyl groups. The phenolic 
hydroxyl group of naltrexone was protected as an allyl ether (Scheme 2.36) (Green and 
Wuts, 1999) and then the compound was allowed to react with p-nitrophenyl 
chloroformate under the same microwave irradiation conditions as previously described. 
The reaction was monitored by TLC and LC-MS. No new spots in TLC analysis or new 
peaks in LC-MS were observed, even after 10 minutes of microwave heating at 170 °C.  
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Scheme 2.36: Reaction of allyl-protected naltrexone with p-nitrophenyl chloroformate 
under microwave irradiation conditions. 
 
Similar non-reactivity was observed in case of naloxone. Naloxone was first 
converted into 3-oxyallyl ether derivative (Green and Wuts, 1999) and then allowed to 
react with p-nitrophenyl chloroformate in the presence of DMAP under microwave 
heating at 170 °C. No new product formation was observed. The presence of an N-
cyclopropylmethyl group in the case of naltrexone, and an N-allyl group in the case of 
naloxone, on the tertiary N-atom rather than presence of a N-methyl group (in the case of 
oxycodone) may be the reason behind naltrexone and naloxone not exhibiting similar 
skeletal rearrangement chemistry that was observed with oxycodone.  
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Scheme 2.37: Reaction of allyl protected naloxone with p-nitrophenyl chloroformate 
under microwave irradiation. 
 
Since the p-nitrophenoxy carbonate ester of oxycodone could not be formed, a 
new synthetic approach was investigated, involving the coupling of ∆
9
-
tetrahydrocannbinol (∆
9
-THC) with oxycodone via a carbonate linkage. Thus, ∆
9
-THC 
would be converted into its p-nitrophenoxy carbonate ester and then reacted with 
oxycodone. To determine the feasibility of the chemistry, reactions were initially carried 
out with model compounds. Tetrahydro-2-naphthol was used as a model compound for 
∆
9
-THC. The phenolic compound was converted into its p-nitrophenoxy carbonate ester 
by reaction with p-nitrophenyl chloroformate and then the resulting carbonate derivative 
was allowed to react with oxycodone in the presence of DMAP under microwave 
conditions. The progress of the reaction was followed by monitoring of the reaction 
mixture by LC-MS. LC-MS analysis of the reaction mixture showed a peak 
corresponding to the mass of desired carbonate conjugate of tetrahydro-2-naphthol and 
oxycodone, but the yield of the product was low (14%, from analysis of the LC-MS 
chromatogram).  
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Scheme 2.38: Model reaction for the synthesis of the 14-hydroxy carbonate ester of 
oxycodone and tetrahydro-2-naphthol. 
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Fig. 2.46: LC-MS analysis of the mixture from the reaction of oxycodone and the p-
nitrophenoxy carbonate of tetrahydro-2-naphthol. 
 
As a consequence of the results from the above model reaction, ∆
9
-THC was 
converted into its p-nitrophenoxy carbonate ester by reaction with p-nitrophenyl 
chloroformate and the resulting intermediate was allowed to react with oxycodone in 
presence of DMAP under microwave heating at 170 °C. The progress of the reaction was 
followed by TLC and LC-MS monitoring of the reaction mixture. Several new spots were 
observed in the TLC but LC-MS analysis did not show any peak corresponding to the 
molecular mass of the ∆
9
-THC-oxycodone carbonate codrug. The two most intense spots 
observed by TLC were isolated by silica column chromatography, and the compounds 
were analyzed by GC-MS and NMR spectroscopy. The two isolated compounds were 
identified as ∆
9
-THC and ∆
8
-THC. The observed result can be explained as a thermal 
breakdown of the p-nitrophenoxy carbonate ester of ∆
9
-THC into ∆
9
-THC followed by 
subsequent conversion of ∆
9
-THC into the more stable ∆
8
-THC isomer. Conversion of 
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∆
9
-THC into ∆
8
-THC is already reported in the literature (Neumeyer and Shagoury, 
2006).  
 
Scheme 2.39: Reaction between p-nitrophenoxy carbonate of ∆
9
-THC and oxycodone 
under microwave irradiation conditions. 
 
Since the coupling chemistry between ∆
9
-THC and oxycodone was not successful 
utilizing p-nitrophenyl chloroformate, new coupling chemistry was tried. Two commonly 
used coupling reagents are 1,1‟-carbonyldiimidazole (CDI) and N,N‟-disuccinimidyl 
carbonate (DSC).  
In intial attempts, oxycodone was allowed to react with CDI under microwave 
conditions and the reaction was monitored by TLC and LC-MS analysis. Heating the 
reaction mixture at 180 °C did not produce any of the desired products, as confirmed by 
TLC and LC-MS chromatograms. 
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Scheme 2.40: Reaction between oxycodone and CDI under microwave irradiation 
conditions. 
 
In the next attempt, oxycodone was mixed with DSC in the presence of DMAP in 
anhydrous THF and the mixture was heated at 180 °C under microwave irradiation 
conditions. TLC of the reaction mixture did not show any new spots. LC-MS analysis of 
the reaction mixture showed a very small peak corresponding to the molecular mass of 
the DSC-oxycodone carbonate. Prolonged heating under microwave condition did not 
result in isolable yields of the DSC-oxycodone carbonate.  
 
 
Scheme 2.41: Reaction between oxycodone and DSC under microwave irradiation 
conditions. 
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Fig. 2.47:  ESI-MS analysis of the carbonate ester of oxycodone and DSC. 
 
Several coupling reagents and strategies were used (as discussed above) in the 
synthesis of ∆
9
-THC-oxycodone carbonate; however, none were successful in yielding 
the desired product. The reason for this failure was attributed to the sterically hindered 
nature of the 14-hydroxy group of oxycodone and to the thermal instability of the ∆
9
-
THC molecule. More synthetic endeavor is required for the synthesis of this desirable 
codrug.  
 
2.4 Experimental Section 
General Procedures. All experimental procedures were carried out under nitrogen and in 
oven-dried glassware unless otherwise mentioned. Solvents and reagents were obtained 
from commercial vendors. All solvents were removed by evaporation using a rotary 
evaporator unless indicated otherwise. 
1
H and 
13
C NMR spectra were recorded on Varian 300 MHz, 400 MHz and 500 
MHz spectrometers. HPLC analyses were carried on an Agilent 1100 series Quatpump, 
equipped with a photodiode array detector and a computer integrating apparatus. GC-MS 
analyses were carried out on an Agilent 6890 GC instrument attached to a 593 mass-
selective detector. Microwave reactions were carried out on a Biotage 355422-AD 
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microwave synthesizer. ESI and MALDI mass spectrometry was performed by the 
University of Kentucky Mass Spectrometry facility. X-ray crystallography was 
performed by the University of Kentucky Crystallographic facility. 
 
 
S-(-)-Nornicotine 
S-(-)-Nicotine free base (6 g, 37 mmol), with a specific rotation of [α]D
 25
 = -
169.9° (neat), was added with stirring to a mixture of 0.3 N aqueous sulfuric acid (120 
ml) and manganese dioxide (36 g).  The mixture was stirred and heated to reflux under a 
condenser for 10-12 hours. After cooling to room temperature, the resulting mixture was 
filtered through a Kimax Büchner Funnels with Fritted Disc and solid was washed with 
0.3 N sulfuric acid (10 ml x 2 times) and water (100 ml). The filtrate was washed with 
chloroform or methylene chloride (50 ml x 5 times, total volume 250 ml), and the 
resulting aqueous solution was basified with 2.5N NaOH to pH 10-11. The resulting 
basic mixture was first filtered and then extracted with chloroform (100 ml x 4 times, 
total volume 400 ml), and the chloroform layer was decolorized with charcoal, filtered 
through celite and then concentrated under reduced pressure to afford S-(-)-nornicotine 
(1.92 g, 35% yield), recovered as an oil.  The product showed over 99% purity by 
GC/MS analysis and HPLC analysis. 
1
H NMR (300 MHz, CDCl3): δ 8.533 (1H, d), 8. 
415 (1H, dd), 7.657 (1H, dt), 7.183 (1H, dd), 4.101 (1H, t), 3.060 (2H, m), 2.310 (1H, 
broad), 1.940-1.563 (4H, m) ppm; 
13
C NMR (300 MHz, CDCl3): δ 148.8, 148.4, 140.6, 
134.2, 123.5, 60.2, 47.1, 34.5, 25.6 ppm; GC-MS M
+
 148 m/z. 
 
Same synthetic procedure was used for all other N-demethylation reactions.  
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Codeine-p-nitrophenol carbonate  
All glasswares were oven-dried and cooled under a nitrogen atmosphere. Codeine 
(0.6 g, 2.01 mmol) was placed in a round bottom flask under a nitrogen atmosphere and 
was dissolved in 6 mL of dry chloroform. The solution was cooled to 0 °C. DMAP (0.295 
g, 2.41 mmol) was then added to the solution and the mixture stirred for 5 min. para-
Nitrophenylchloroformate (0.486 g, 2.41 mmol) was dissolved in 5 mL of dry chloroform 
and the solution was added to the reaction mixture drop-wise, the mixture was allowed to 
warm to the ambient temperature. The progress of the reaction was monitored by TLC. 
After completion of the reaction, the mixture was diluted with chloroform (50 mL). The 
chloroform layer was washed 5 times with 30 mL 50% NaHCO3 solution and with brine 
(30 mL), dried over anhydrous sodium sulfate and concentrated to afford a solid yellow 
colored product (0.532 g, 57% yield). 
1
H NMR (300 MHz, CDCl3): δ 8.27 (2H, dd), 7.45 
(2H, dd), 6.66 (1H, d), 6.56 (1H, d), 5.70 (1H, dd), 5.52 (1H, dd), 5.16 (2H, m), 3.82 (3H, 
s), 3.36 (1H, m), 3.04 (1H, d), 2.75 (1H, m), 2.58 (1H, dd), 2.43 (3H, s), 2.36 (1H, dt), 
2.29 (1H, dd), 2.03 (1H, dt), 1.88 (1H, d) ppm; 
13
C NMR (300 MHz, CDCl3): δ 156.1, 
152.2, 146.7, 145.3, 142.7, 130.4, 127.4, 126.7, 126.6, 125.6, 122.2, 121.9, 119.9, 115.0, 
114.5, 87.4, 72.4, 59.5, 56.9, 46.9, 43.1, 42.6, 40.5, 35.3, 20.6 ppm; MS (ESI): (M+1) 
465 m/z. 
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Codiene-S-(-)-nornicotine carbamate 
Codeine-p-nitrophenol carbonate (0.5 g, 1.08 mmol) was dissolved in dry 
chloroform (8 mL) and then DMAP (0.158 g, 1.3 mmol) and S-(-)-nornicotine (0.192 g, 
1.3 mmol) was added to the solution. The reaction mixture was refluxed and progress of 
the reaction was monitored by running TLC samples. After completion, the reaction 
mixture was diluted with 25 mL of chloroform and washed three times (15 mL each time) 
with 50% aqueous solution of NaHCO3. Organic layer was dried with anhydrous sodium 
sulfate and concentrated to afford a solid product. The crude product was purified using 
silica gel column chromatography and a methylene chloride-methanol mixture as eluent, 
to afford the pure product (0.28 g, 54% yield). 
1
H NMR (500 MHz, CDCl3): δ 8.519 (1H, 
s), 8.465 (1H, d), 7.539 (1H, d), 7.225 (1H, dd), 6.671 (1H, d), 6.552 (1H, d), 5.696 (1H, 
d), 5.413(1H, d), 5.082 (1H, s), 5.25 (1H, dd), 3.852 (3H, s), 3.772 (1H, t), 3.733-3.572 
(2H, m), 3.37 (1H, m), 3.032 (1H, d), 2.758 (1H, s), 2.599 (1H, dd), 2.445 (3H, s), 2.421-
2.378 (2H, m), 2.349 (1H, dt), 2.304 (1H, d), 2.066-1.944 (2H, m), 1.906 (1H, m), 1.88 
(1H, d) ppm; 
13
C NMR (500 MHz, CDCl3): δ 154.5, 148.4, 147.9, 146.9, 142.2, 139.0, 
133.6, 130.9, 129.2, 129.0, 127.0, 123.4, 119.2, 113.8, 88.5, 68.7, 59.6, 59.3, 56.7, 47.4, 
46.8, 43.1, 42.6, 40.5, 35.3, 34.8, 24.1, 20.6; MS (ESI): (M+1) 474 m/z. 
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3-O-Acetylmorphine 
Morphine free base (1.102 g, 3.87 mmol) was suspended in saturated sodium 
bicarbonate solution (55 mL). To the stirred suspension, 1.1 mL (11.68 mmol) of acetic 
anhydride was added drop-wise. Reaction mixture was stirred at ambient temperature and 
the progress of the reaction was monitored by running TLC. After completion of the 
reaction, aqueous phase was extracted with chloroform (5 x 20 mL), dried over sodium 
sulfate and concentrated under reduced pressure to afford a white solid product (1.21 g, 
96%). 
1
H NMR (300 MHz, CDCl3): δ 6.73 (1H, d), 6.60 (1H, d), 5.74 (1H, dd), 5.27 (1H, 
dd), 4.92 (1H, m), 4.16 (1H, m), 3.38 (1H, m), 3.06 (1H, d), 2.60 (1H, m), 2.54 (1H, dd), 
2.43 (3H, s), 2.37 (1H, dt), 2.32 (3H, s), 2.29 (1H, dd), 2.05 (1H, dt), 1.88 (1H, d) ppm; 
13
C NMR (300 MHz, CDCl3): δ 168.6, 148.7, 134.2, 132.7, 132.3, 131.7, 127.8, 121.1, 
119.8, 92.5, 66.0, 59.1, 46.0, 43.3, 42.3, 41.6, 35.4, 21.4, 20.9 ppm; MS (ESI): (M+1) 
328 m/z. 
 
 
3-O-Acetylmorphine-p-nitrophenol carbonate 
3-O-Acetylmorphine (2.0 g, 6.12 mmol) was placed in a round bottom flask under 
a nitrogen atmosphere and was dissolved in dry chloroform (10 mL). The solution was 
cooled to 0 °C. DMAP (0.9 g, 7.34 mmol) was added to the solution and allowed to stir 
for 5 min. p-Nitrophenylchloroformate (1.48 g, 7.34 mmol) dissolved in dry chloroform 
(8 mL) was added to the reaction mixture drop-wise and the mixture was allowed to 
come to room temperature. Progress of the reaction was monitored by running TLC. 
After completion of the reaction, the mixture was diluted with chloroform (20 mL). The 
chloroform layer was washed 5 times with 25 mL 50% NaHCO3 solution and with brine 
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(20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure 
to afford a solid product (1.69 g, 56%). 
1
H NMR (300 MHz, CDCl3): δ 8.30 (2H, dd), 
7.51 (2H, dd), 6.82 (1H, d), 6.64 (1H, d), 5.71 (1H, dd), 5.58 (1H, dd), 5.24 (1H, m), 5.19 
(1H, m), 3.42 (1H, m), 3.09 (1H, d), 2.80 (1H, m), 2.62 (1H, dd), 2.45 (3H, s), 2.41 (1H, 
dt), 2.19 (3H, s), 2.09 (1H, dt), 1.92 (1H, d) ppm; 
13
C NMR (300 MHz, CDCl3): δ 168.5, 
155.9, 151.8, 149.2, 145.6, 132.2, 131.9, 130.4, 127.8, 126.4, 125.5, 122.3, 122.2, 121.8, 
119.9, 113.8, 88.2, 72.6, 59.1, 46.7, 43.8, 42.9, 40.7, 35.3, 21.0, 20.8 ppm; MS (ESI): 
(M+1) 493 m/z. 
 
 
3-O-Acetylmorphine-S-(-)-nornicotine carbamate 
3-O-acetylmorphine-p-nitrophenol carbonate (1.2 g, 2.44 mmol) was dissolved in 
dry chloroform (18 mL) and then DMAP (0.358 g, 2.93 mmol) and S-(-)-nornicotine 
(0.433 g, 2.93 mmol) was added to the solution. The reaction mixture was refluxed and 
progress of the reaction was monitored by running TLC samples. After completion, the 
reaction mixture was diluted with 30 mL of chloroform and washed three times with 50% 
aqueous solution of NaHCO3. Organic layer was dried over anhydrous sodium sulfate 
and concentrated to afford a solid product. The crude product was purified using silica 
gel column chromatography and a methylene chloride-methanol mixture as eluent, to 
afford the pure product (0.623 g, 51% yield). 
1
H NMR (300 MHz, CDCl3): δ 8.492 (1H, 
s), 8.440 (1H, d), 7.515 (1H, d), 7.204 (1H, dd), 6.739 (1H, d), 6.560 (1H, d), 5.646 (1H, 
d), 5.370 (1H, d), 5.074 (2H, m), 4.990 (1H, dd), 3.726 (2H, m), 3.639 (2H, m), 3.330 
(1H, m), 3.026 (1H, d), 2.686 (1H, broad), 2.569 (1H, dd), 2.433 (3H, s), 2.406- 2.295 
(2H, m), 2.275 (3H, s), 2.100-1.852 (4H, m); 
13
C NMR (300 MHz, CDCl3): δ 168.2, 
154.2, 149.5, 148.2, 147.6, 138.7, 133.4, 132.4, 131.7, 131.6, 129.1, 128.9, 123.3, 121.8, 
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119.2, 89.5, 68.9, 59.4, 58.9, 47.3, 46.5, 43.1, 43.0, 42.9, 40.7, 35.3, 34.9, 24.2, 20.9; MS 
(ESI): (M+1) 502 m/z. 
 
 
Morphine-S-(-)-nornicotine carbamate (6-oxy) 
3-O-acetylmorphine-S-(-)-nornicotine carbamate (0.9 g, 1.8 mmol) was dissolved 
in 10 mL 1:1 mixture of water and THF and then LiOH (0.095 g, 3.96 mmol) was added 
to the solution. Reaction mixture was stirred at room temperature and progress of the 
reaction was followed by running TLC. After completion, reaction mixture was diluted 
with chloroform and washed two times with water. Organic layer was then dried over 
anhydrous sodium sulfate and then concentrated to afford a solid product (0.727 g, 88%). 
1
H NMR (300 MHz, CDCl3): δ 8.825 (1H, d), 8.473 (1H, dd), 7.642 (1H, dt), 7.318 (1H, 
dd), 6.710 (1H, d), 6.470 (1H, d), 5.532 (1H, d), 5.370 (1H, dt), 5.239 (1H, m), 4.890 
(1H, dd), 4.753 (1H, dd), 3.718 (2H, m), 3.339 (1H, dd), 3.026 (1H, d), 2.662 (1H, m), 
2.570-2.437 (4H, m), 2.426 (3H, s), 2.416-1.940 (5H, m), 1.554 (1H, dd); 
13
C NMR (300 
MHz, CDCl3): δ 154.2, 150.6, 147.3, 146.6, 138.7, 137.7, 134.0, 130.3, 130.0, 128.5, 
125.4, 123.6, 119.1, 118.6, 89.8, 70.8, 58.9, 58.5, 47.8, 46.6, 44.2, 43.3, 41.7, 36.1, 34.3, 
24.3, 20.9; MS (ESI): (M+1) 460 m/z. 
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Morphine-bis-p-nitrophenol carbonate 
All glasswares were oven-dried and cooled under a nitrogen atmosphere. 
Morphine (0.6 g, 2.11 mmol) was placed in a round bottom flask under a nitrogen 
atmosphere and was dissolved in 16 mL of dry THF. The solution was cooled to 0 °C. 
DMAP (0.566 g, 4.64 mmol) was then added to the solution and the mixture stirred for 5 
min. para-Nitrophenylchloroformate (1.28 g, 6.33 mmol) was dissolved in 4 mL of dry 
THF and the solution was added to the reaction mixture drop-wise, the mixture was 
allowed to warm to the ambient temperature. The progress of the reaction was monitored 
by TLC. After completion of the reaction, the mixture was diluted with chloroform (50 
mL). The chloroform layer was washed 5 times with 25 mL 50%  aqueous NaHCO3 
solution and with brine (25 mL), dried over anhydrous sodium sulfate and concentrated to 
afford a solid product (0.623 g, 48%). 
1
H NMR (500 MHz, CDCl3): δ 8.252 (2H, d), 
8.231 (2H, d), 7.432 (2H, d), 7.414 (2H, d), 6.987 (1H, d), 6.695 (1H, d), 5.745 (1H, d), 
5.554 (1H, dt), 5.306 (1H, m), 5.198 (1H, m), 3.456 (1H, dd), 3.132 (1H, d), 2.839 (1H, 
t), 2.671 (1H, dd), 2.480 (3H, s), 2.410 (1H, m), 2.130 (1H, td), 1.959 (1H, dd) ppm; 
13
C 
NMR (300 MHz, CDCl3): δ 155.5, 155.3, 151.9, 150.3, 148.8, 145.6, 132.4, 131.5, 129.7, 
127.5, 125.7, 125.4, 121.9, 121.6, 120.3, 88.5, 72.2, 59.4, 46.8, 42.9, 40.0, 34.7, 21.3; MS 
(ESI): (M+1) 616 m/z. 
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Morphine-bis-S-(-)-nornicotine carbamate 
Morphine-bis-p-nitrophenol (0.6 g, 0.98 mmol) carbonate was dissolved in dry 
chloroform (15 mL) and then DMAP (0.263 g, 2.16 mmol) and S-(-)-nornicotine (0.435 
g, 2.94 mmol) were added to the solution. The reaction mixture was refluxed and 
progress of the reaction was monitored by running TLC samples. After completion, the 
reaction mixture was diluted with 50 mL of chloroform and washed three times with 50% 
aqueous solution of NaHCO3 (25 mL each time) and with brine (25 mL), dried over 
anhydrous sodium sulfate and concentrated to afford a solid product (0.111 g, 18%). MS 
(ESI): (M+1) 634 m/z. 
 
 
S-(-)-Nornicotine-p-nitrophenol carbamate  
All glasswares were oven-dried and cooled under a nitrogen atmosphere. S-(-)-
nornicotine (0.3 g, 2.03 mmol) was placed in a round bottom flask under a nitrogen 
atmosphere and was dissolved in 5 mL of dry chloroform. The solution was cooled to 0 
°C. DMAP (0.3 g, 2.44 mmol) was then added to the solution and the mixture stirred for 
5 min. para-Nitrophenylchloroformate (0.492 g, 2.44 mmol) was dissolved in 5 mL of 
dry chloroform and the solution was added to the reaction mixture drop-wise, the mixture 
was allowed to warm to the ambient temperature. The progress of the reaction was 
monitored by TLC. After completion of the reaction, the mixture was diluted with 
chloroform (25 mL). The chloroform layer was washed 5 times with 50% aqueous 
NaHCO3 solution (15 mL each time) and with brine (15 mL), dried over anhydrous 
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sodium sulfate and concentrated to afford the product (0.426 g, 67%). The product was 
used in the next synthetic step without any further purification. GC-MS M
+
 313 m/z. 
 
 
Morphine-S-(-)-nornicotine carbamate (3-oxy) 
All glasswares were oven dried and cooled under a nitrogen atmosphere. 
Morphine (0.437 g, 1.53 mmol) was placed in a round bottom flask under a nitrogen 
atmosphere and was dissolved in 6 mL of dry THF. The solution was cooled down to 0 
°C. NaH (0.037 g, 1.53 mmol) was added to the solution and allowed to stir for 5 min. p-
Nitrophenol-S-(-)-nornicotine carbamate (0.4 g, 1.28 mmol), dissolved in 5 mL of dry 
THF was added to the reaction mixture drop-wise and the mixture was allowed to warm 
to the ambient temperature. The progress of the reaction was monitored by TLC. After 
the completion of the reaction, the mixture was filtered through a pad of celite and then 
the organic filtrate was concentrated under reduced pressure to afford yellow oil. The 
organic residue was dissolved in chloroform (50 mL), the organic layer was washed with 
50% aqueous sodium bicarbonate solution (5 x 20 mL) and brine (20 mL), dried over 
sodium sulfate and concentrated under reduced pressure to afford a solid. The crude 
product was purified using silica gel column chromatography and a methylene chloride-
methanol mixture as eluent, to afford the pure product (0.212 g, 36%). 
1
H NMR (500 
MHz, CDCl3): δ 8.828 (1H, s), 8.475 (1H, dd), 7.640 (1H, d), 7.316 (1H, dd), 6.708 (1H, 
d), 6.469 (1H, d), 5.540 (1H, d), 5.371(1H, dt), 5.258 (1H, dd), 4.892 (1H, dd), 4.751 
(1H, d), 3.740 (1H, m), 3.635 (1H, m), 3.339 (1H, dd), 3.029 (1H, d), 2.662 (1H, t), 2.542 
(1H, dd), 2.427 (3H, s), 2.386 (1H, dd), 2.271 (1H, dd), 2.161(1H, m), 2.076 (1H, m), 
2.043-1.953 (3H, m), 1.752 (1H, d), 1.88 (1H, d) ppm; 
13
C NMR (300 MHz, CDCl3): 
δ154.2, 150.6, 147.4, 146.6, 138.8, 137.7, 134.0, 130.4, 130.1, 128.5, 125.5, 123.6, 119.2, 
118.6, 89.8, 70.8, 59.0, 58.6, 47.9, 46.6, 44.3, 43.4, 41.8, 36.2, 34.3, 24.3, 20.9; MS 
(ESI): (M+1) 460 m/z. 
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Ketamine-p-nitrophenol carbamate 
All glasswares were oven dried and cooled under a nitrogen atmosphere. 
Ketamine (0.062 g, 0.26 mmol) was placed in a round bottom flask under a nitrogen 
atmosphere and was dissolved in 2 mL of dry toluene. Na2CO3 (0.1 g, 0.94 mmol) was 
added to the solution and allowed to stir for 5 min. para-Nitrophenylchloroformate 
(0.158 g, 0.78 mmol), dissolved in 3 mL of dry toluene was added to the reaction mixture 
drop-wise and the mixture was refluxed under nitrogen. The progress of the reaction was 
monitored by TLC. After the completion of the reaction, the mixture was filtered and 
then the organic filtrate was concentrated under reduced pressure to afford yellow oil. 
The organic residue was dissolved in chloroform (20 mL), the organic layer was washed 
with 50% sodium bicarbonate solution (3 x 10 mL), 1N HCl solution (2 X 10 mL) and 
brine (10 mL), dried over sodium sulfate and concentrated under reduced pressure to 
afford a brownish solid. The crude product was purified using silica gel column 
chromatography and a methylene chloride-methanol mixture as eluent, to afford the pure 
product (0.065 g, 62%). 
1
H NMR (300 MHz, CDCl3): δ 8.083 (2H, d), 7.347 (1H, dd), 
7.215-7.055 (5H), 3.385 (1H, m), 3.153 (3H, s), 2.734 (2H, m), 2.006-1.584 (5H, m); 
13
C 
NMR (300 MHz, CDCl3): δ 202.4, 155.6, 154.8, 154.1, 134.1, 132.8, 129.8, 129.2, 126.7, 
125.4, 124.9, 122.1, 121.7, 76.0, 41.2, 34.9, 36.6, 27.2, 22.4; MS (ESI): (M+1) 403 m/z. 
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Norketamine-p-nitrophenol carbamate 
Norketamine-p-nitrophenol carbamate was synthesized following the same 
methodology. Obtained yield: 69%. 
1
H NMR (500 MHz, CDCl3): δ 8.154 (2H, d), 7.868 
(1H, dd), 7.401-7.293 (3H, m), 7.216 (2H, d), 3.838 (1H, dd), 2.504 (1H, m), 2.404 (1H, 
m), 2.121 (1H, m), 1.878- 1.736 (5H, m); 
13
C NMR (300 MHz, CDCl3): δ 208.4, 155.7, 
150.5, 144.6, 133.8, 133.7, 131.7, 131.2, 130.0, 125.6, 126.1, 125.0, 122.0, 115.6, 67.5, 
39.3, 38.5, 30.9, 22.5; MS (ESI): (M+1) 389 m/z. 
 
 
Ketamine-codeine carbamate 
All glasswares were oven dried and cooled under a nitrogen atmosphere. Codeine 
(0.045 g, 0.15 mmol) was placed in a round bottom flask under a nitrogen atmosphere 
and was dissolved in 2 mL of dry THF. The solution was cooled down to 0 °C. NaH 
(0.05 g, 0.195 mmol) was added to the solution and allowed to stir for 5 min. Ketamine-
p-nitrophenol carbamate (0.050 g, 0.124 mmol), dissolved in 3 mL of dry THF was added 
to the reaction mixture drop-wise and the mixture was allowed to warm to the ambient 
temperature. The progress of the reaction was monitored by TLC. After the completion of 
the reaction, the mixture was filtered through a pad of celite and then the organic filtrate 
was concentrated under reduced pressure to afford yellow oil. The organic residue was 
dissolved in chloroform (20 mL), the organic layer was washed with 50% sodium 
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bicarbonate solution (3 x 10 mL) and brine (10 mL), dried over sodium sulfate and 
concentrated under reduced pressure to afford a brown solid. The crude product was 
purified using silica gel column chromatography and a methylene chloride-methanol 
mixture as eluent, to afford a diastereomeric mixture of the product (0.034 g, 48%). MS 
(ESI): (M+1) 563 m/z. 
 
 
 
Norketamine-codeine carbamate 
Norketamine codeine carbamate was synthesized following the procedure same as 
the synthetic method used for synthesizing ketamine-codeine carbamate. Obtained yield: 
42%. MS (ESI): (M+1) 549 m/z. 
 
Fig. 2.48: HPLC chromatogram of two diastereomers of norketamine-codeine carbamate 
codrug. 
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Norketamine-morphine carbamate 
  All glasswares were oven dried and cooled under a nitrogen atmosphere. 
Morphine (0.08 g, 0.28 mmol) was placed in a round bottom flask under a nitrogen 
atmosphere and was dissolved in 2 mL of dry THF. The solution was cooled down to 0 
°C. NaH (0.007 g, 0.3 mmol) was added to the solution and allowed to stir for 5 min. 
Norketamine-p-nitrophenol carbamate (0.084 g, 0.22 mmol), dissolved in 3 mL of dry 
THF was added to the reaction mixture drop-wise and the mixture was allowed to warm 
to the ambient temperature. The progress of the reaction was monitored by TLC. After 
the completion of the reaction, the mixture was filtered through a pad of celite and then 
the organic filtrate was concentrated under reduced pressure to afford yellow oil. The 
organic residue was dissolved in chloroform (20 mL), the organic layer was washed with 
50% sodium bicarbonate solution (3 x 10 mL) and brine (10 mL), dried over anhydrous 
sodium sulfate and concentrated under reduced pressure to afford a brown solid. The 
crude product was purified using silica gel column chromatography and a methylene 
chloride-methanol mixture as eluent, to afford a diastereomeric mixture of the product 
(0.047 g, 40%). MS (ESI): (M+1) 535 m/z. 
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Fig. 2.49: HPLC chromatogram of two diastereomers of norketamine-morphine 
carbamate codrug. 
 
 
Boc-protected gabapentin 
Gabapentin (0.3 g, 1.75 mmol) was placed in a round bottom flask and dissolved 
in 5 mL water. Sodium bicarbonate (0.368 g, 4.38 mmol) was added to the solution and 
stirred for 5 min. Boc anhydride (0.458 g, 2.1 mmol) was dissolved in THF (5 mL) and 
added to the reaction mixture. The reaction mixture was allowed to stir overnight at room 
temperature. The reaction mixture was then acidified with 1N HCl and the product was 
extracted into chloroform. Chloroform layer was dried over anhydrous sodium sulfate 
and concentrated under reduced pressure to produce a white colored solid product (0.413 
g, 87%). 
1
H NMR (500 MHz, CDCl3): δ 5.076 (1H, t), 3.156 (2H, d), 2.306 (2H, s), 
1.518-1.243 (19H, m); 
13
C NMR (300 MHz, CDCl3): δ 176.1, 157.4, 80.2, 47.5, 41.2, 
37.9, 34.2, 28.6, 26.1, 21.6. 
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Boc-protected gabapentin-codeine ester 
Boc-protected gabapentin (0.233 g, 0.86 mmol), codeine (0.257 g, 0.86 mmol), 
and DMAP (0.042 g, 0.34 mmol) were placed in a round bottom flask and dissolved in 12 
mL DCM. The mixture was cooled to 0 °C and then DCC (0.213 g, 1.03 mmol) was 
added to the stirred solution. The reaction mixture was allowed to come to room 
temperature and stirred at room temperature. Progress of the reaction was followed by 
running TLC. After the reaction was over, reaction mixture was diluted with 40 mL DCM 
and washed with 50% sodium bicarbonate solution (3 x 20 mL) and brine (20 mL), dried 
over sodium sulfate and concentrated under reduced pressure to afford a solid. The crude 
product was purified using silica gel column chromatography and a methylene chloride-
methanol mixture as eluent, to afford the pure product (0.328 g, 69%). 
1
H NMR (500 
MHz, CDCl3): δ 6.656 (1H, d), 6.538 (1H, d), 5.612 (1H, d), 5.160 (1H, dt), 5.200-5.120 
(2H, m), 5.096 (1H, dd), 3.819 (3H, s), 3.357 (1H, dd), 3.249 (2H, d), 3.038 (1H, d), 
2.733 (1H, m), 2.579 (1H, dd), 2.436 (3H, s), 2.412- 2.253 (4H, m), 2.045 (1H, td), 1.852 
(1H, d), 1.551-1.367 (19H, m);  
13
C NMR (300 MHz, CDCl3): δ 172.2, 156.7, 147.3, 
142.5, 130.9, 130.0, 128.6, 127.3, 119.4, 114.0, 88.4, 78.9, 68.9, 59.2, 56.8, 47.2, 46.7, 
43.2, 43.1, 41.2, 40.9, 38.2, 35.7, 34.2, 28.6, 26.1, 21.7, 20.5; MS (ESI): (M+1) 553 m/z. 
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Boc deprotection of Boc-protected gabapentin-codeine ester 
Boc protected gabapentin-codeine ester codrug (0.1 g, 0.18 mmol) was placed in 
an oven dried round bottom flask and kept under nitrogen. 4N HCl solution in anhydrous 
dioxane (5 mL) was added drop wise and the reaction mixture was stirred at room 
temperature under nitrogen atmosphere. Progress of the reaction was followed by running 
TLC. After completion, reaction mixture was diluted with 8 mL ether and stirred 
vigorously for 15 mins. The dihydrochloride salt separates out as brownish solid and was 
filtered out from the reaction mixture. The product (0.052 g, 52%) was dried under 
reduced pressure and stored under nitrogen atmosphere. 
1
H NMR (300 MHz, DMSO-D6): 
δ 11.01 (1H, broad), 7.864 (2H, broad), 6.790 (1H, d), 6.649 (1H, d), 5.685 (1H, d), 5.503 
(1H, d), 5.176 (2H, m), 3.748 (2H, s), 3.565 (3H, s), 3.416-3.205 (4H, m), 3.005 (2H, m), 
2.849 (2H, d), 2.512 (3H, s), 2.506 (1H, m), 2.349 (1H, m), 1.902 (1H, d), 1.508-1.290 
(10H, m); 
13
C NMR (300 MHz, CDCl3): δ 170.2, 146.0, 142.0, 129.5, 128.6, 126.8, 
123.7, 119.8, 114.1, 86.6, 67.7, 66.3, 59.3, 58.8, 58.0, 56.1, 46.3, 44.7, 41.8, 36.9, 34.9, 
32.5, 32.3, 31.9, 25.1, 20.7, 20.6. 
 
 
Gabapentin-codeine carbamate 
Codeine-p-nitrophenol Carbonate (0.262 g, 0.56 mmol) and gabapentin (0.106, 
0.62 mmol) were placed in a round bottom flask and dissolved in 8 mL 1:1 mixture of 
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water and THF. The reaction mixture was stirred at room temperature and progress of the 
reaction was followed by running TLC. After completion, reaction mixture was 
concentrated under reduced pressure and then diluted with 40 mL DCM. The organic 
layer was washed with 50% sodium bicarbonate solution (5 x 20 mL) and brine (20 mL), 
dried over sodium sulfate and concentrated under reduced pressure to afford a white 
solid. The crude product was purified using silica gel column chromatography and a 
methylene chloride-methanol mixture as eluent, to afford the pure product (0.164 g, 
59%). 
1
H NMR (500 MHz, CDCl3): δ 10.820 (1H, broad), 7.003 (1H, broad), 6.670 (1H, 
d), 6.542 (1H, d), 5.649 (1H, d), 5.508 (1H, broad), 5.322 (1H, d), 5.248 (1H, d), 3.852 
(3H, s), 3.704 (1H, broad), 3.318 (2H, m), 3.126 (1H, broad), 3.041 (2H, d), 2.636 (3H, 
s), 2.586 (2H, m), 2.385 (1H, m), 2.308 (2H, s), 1.913 (1H, d), 1.524-1.330 (10H, m); 
13
C 
NMR (300 MHz, CDCl3): δ 177.2, 156.2, 147.0, 142.5, 130.6, 129.8, 127.0, 124.5, 119.3, 
114.7, 88.8, 68.1, 58.9, 56.7, 48.6, 46.3, 43.2, 41.9, 41.4, 41.2, 38.2, 37.2, 33.9, 33.3, 
26.1, 21.6. 
 
 
N-Acetylgabapentin 
Gabapentin (0.2 g, 1.17 mmol) was placed in a round bottom flask and dissolved 
in 8 mL saturated aqueous sodium bicarbonate solution. Acetic anhydride (0.262 g, 2.57 
mmol) was added drop wise to the solution and the reaction mixture was stirred overnight 
at room temperature. The reaction mixture was then acidified with 1N HCl and the 
product was extracted into chloroform. Chloroform layer was dried over anhydrous 
sodium sulfate and concentrated under reduced pressure to produce a white colored solid 
product (0.234 g, 94%). 
1
H NMR (500 MHz, CDCl3): δ 6.939 (1H, broad), 3.262 (2H, d), 
2.304 (2H, s), 2.061 (3H, s), 1.513-1.308 (10H, m); 
13
C NMR (300 MHz, CDCl3): δ 
174.4, 172.7, 47.4, 41.7, 37.6, 34.5, 26.1, 23.4, 21.6; MS (ESI): (M+1) 214 m/z. 
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N-Acetylgabapentin-codeine ester codrug (CG-3) 
N-acetylgabapentin (0.149 g, 0.7 mmol), codeine (0.209 g, 0.7 mmol), and DMAP 
(0.34 g, 0.28 mmol) were placed in a round bottom flask and dissolved in 5 mL DCM. 
The mixture was cooled to 0 °C and then DCC (0.187 g, 0.91 mmol) was added to the 
stirred solution. The reaction mixture was allowed to come to room temperature and 
stirred at room temperature. Progress of the reaction was followed by running TLC. After 
the reaction was over, reaction mixture was diluted with 40 mL DCM and washed with 
50% sodium bicarbonate solution (3 x 20 mL) and brine (20 mL), dried over sodium 
sulfate and concentrated under reduced pressure to afford a white solid. The crude 
product was purified using silica gel column chromatography and a methylene chloride-
methanol mixture as eluent, to afford the pure product (0.229 g, 66%). 
1
H NMR (500 
MHz, CDCl3): δ 6.665 (1H, d), 6.566 (1H, d), 6.406 (1H, t), 5.615 (1H, d), 5.452 (1H, 
dt), 5.184 (1H, m), 5.076 (1H, dd), 3.719 (3H, s), 3.405-3.315 (2H, m), 3.055 (1H, d), 
2.772 (1H, t), 2.611 (1H, dd), 2.429 (1 H, m), 2.455 (3H, s), 2.413 (2H, s), 2.22 (1H, dd), 
2.077 (1H, td), 2.016 (3H, s), 1.874 (1H, d), 1.608-1.392 (10H, m); 
13
C NMR (300 MHz, 
CDCl3): δ 171.9, 170.7, 146.6, 142.2, 130.4, 129.9, 128.3, 126.8, 119.4, 113.1, 88.5, 68.8, 
59.1, 56.3, 46.7, 46.1, 43.2, 43.1, 41.7, 40.8, 38.2, 35.6, 34.8, 34.5, 26.2, 23.6, 21.7, 21.6, 
20.6; MS (ESI): (M+1) 495 m/z. 
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N-Ethoxycarbonylgabapentin 
Gabapentin (0.43 g, 2.51 mmol) was added to dry dichloromethane (12 mL) in a 
round bottom flask, followed by DMAP (0.92 g, 7.53 mmol). Chlorotrimethylsilane (0.64 
ml, 5.03 mmol) was added slowly while maintaining the reaction temperature below 15 
°C, and the resulting suspension was stirred for 30 min. Ethyl chloroformate (0.327 g, 
3.01 mmol) was added slowly while maintaining the temperature below 15 °C. DMAP 
(0.368 g, 3.01 mmol) was added, and the resulting suspension was stirred at room 
temperature for 30 min. The resulting silyl ester was converted to the corresponding acid 
by washing the reaction mixture with water (2 X 15 mL), followed by 1 N HCl (2 X 15 
mL) then brine (2 X 15 mL). After drying over anhydrous sodium sulfate and removal of 
the solvent in vacuo, the crude product (0.513 g, 84%) was obtained as colorless oil and 
used in the following step without further purification. 
1
H NMR (500 MHz, CDCl3): δ 
6.006 (1H, broad), 5.170 (1H, t), 4.136 (2H, q), 3.225 (2H, d), 2.333 (2H, s), 1.539-1.323 
(10H, m), 1.257 (3H, t); 
13
C NMR (300 MHz, CDCl3): δ 176.6, 157.8, 61.4, 47.8, 41.2, 
38.0, 34.2, 26.1, 21.6, 14.9; MS (ESI): (M+1) 244 m/z. 
 
 
N-Ethoxycarbonylgabapentin-codeine ester codrug (CG-4) 
N-ethoxycarbonylgabapentin (0.33 g, 1.36 mmol), codeine (0.487 g, 1.63 mmol), 
and DMAP (0.066 g, 0.54 mmol) were placed in a round bottom flask and dissolved in 15 
mL DCM. The mixture was cooled to 0 °C and then DCC (0.364 g, 1.76 mmol) was 
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added to the stirred solution. The reaction mixture was allowed to come to room 
temperature and stirred at room temperature. Progress of the reaction was followed by 
running TLC. After the reaction was over, reaction mixture was diluted with 50 mL DCM 
and washed with 50% sodium bicarbonate solution (3 x 20 mL) and brine (20 mL), dried 
over sodium sulfate and concentrated under reduced pressure to afford a white solid. The 
crude product was purified using silica gel column chromatography and a methylene 
chloride-methanol mixture as eluent, to afford the pure product (0.573 g, 67%). 
1
H NMR 
(500 MHz, CDCl3): δ 6.664 (1H, d), 6.558 (1H, d), 5.630 (1H, d), 5.450 (1H, dt), 5.311 
(1H, t), 5.172 (1H, m), 5.110 (1H, d), 4.106 (2H, q), 3.812 (3H, s), 3.374 (1H, m), 3.16 
(2H, d), 3.052 (1H, d), 2.736 (1H, m), 2.586 (1H, dd), 2.445 (3H, s), 2.410 (2H, d), 2.380 
(1H, d), 2.322 (1H, td), 2.053 (1H, td), 1.873 (1H, dd), 1.601-1.434 (10H, m), 1.239 (3H, 
t) ppm; 
13
C NMR (300 MHz, CDCl3): δ 171.9, 157.4, 146.9, 142.3, 130.6, 130.0, 128.4, 
127.1, 119.3, 113.5, 88.3, 69.0, 60.8, 59.2, 56.6, 49.4, 47.6, 46.8, 43.4, 43.2, 41.1, 38.4, 
34.4, 34.3, 31.9, 26.3, 25.2, 21.8, 20.6, 15.0; MS (ESI): (M+1) 525 m/z. 
 
 
Oxycodone derivative 
Oxycodone (0.25 g, 0.79 mmol) and DMAP (0.233 g, 1.91 mmol) were dissolved 
in 8 mL of anhydrous THF. para-Nitrophenylchloroformate (0.367 g, 1.82 mmol), 
dissolved in 2 mL of dry THF was added to the reaction mixture drop-wise and then the 
reaction mixture was heated to 170 °C for 4 minutes under microwave irradiation. THF 
was then evaporated under reduced pressure and the obtained solid was dissolved in 50 
mL DCM. The organic layer was washed with 50% sodium bicarbonate solution (5 x 20 
mL) and brine (20 mL), dried over sodium sulfate and concentrated under reduced 
pressure to afford a brown solid. The crude product was purified by recrystallization from 
ethyl acetate (0.25 g, 84%). 
1
H NMR (500 MHz, CDCl3): δ 6.786 (1H, d), 6.742 (1H, d), 
4.901 (1H, s), 3.07 (3H, s), 6.635 (1H, dd), 3.503 (1H, td), 3.236 (1H, dd), 2.995 (3H, s), 
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2.938 (2H, m), 2.757 (1H, dd), 2.513 (1H, m), 2.373 (1H, dt), 2.246 (1H, dt), 2.167 (1H, 
m), 1.611 (1H, td); 
13
C NMR (300 MHz, CDCl3): δ 204.0, 156.3, 145.8, 143.8, 125.8, 
121.5, 121.3, 115.1, 90.4, 90.3, 82.2, 64.4, 56.6, 39.4, 37.4, 36.8, 34.4, 30.9, 29.7; GC-
MS M
+
 377 m/z. 
 
 
3-O-Allylnaltrexone 
Naltrexone (0.052 g, 0.15 mmol) was placed in a round bottom flask and 
dissolved in 6 mL acetone. K2CO3 (0.084 g, 0.61 mmol) was added to the solution 
followed by drop wise addition of ally bromide (0.02 mL, 0.2 mmol). The reaction 
mixture was refluxed and progress of the reaction was monitored by running TLC. After 
completion, the reaction mixture was cooled to room temperature and filtered. The 
organic filtrate was evaporated under reduced pressure and obtained liquid was dissolved 
in ethyl acetate and washed with water and brine, dried over sodium sulfate and 
concentrated under reduced pressure to afford a colorless liquid (0.05 g, 87%). 
1
H NMR 
(300 MHz, CDCl3): δ 6.720 (1H, d), 6.569 (1H, d), 6.002 (1H, m), 5.350 (1H, d), 5.208 
(1H, d), 4.766-4.636 (3H, m), 3.185 (1H, d), 2.991 (2H, m), 2.974-2.560 (2H, m), 2.540-
2.225 (4H, m), 2.130 (1H, td), 1.892 (1H, m), 1.689-1.527 (3H, m), 0.869 (1H, m), 0.553 
(2H, q), 0.149 (2H, q). 
 
 
3-O-Allylnaloxone 
Allyl protection of naloxone was performed by following a procedure same as 
allyl protection of naltrexone. 90% yield; 
 1
H NMR (500 MHz, CDCl3): δ 6.730 (1H, d), 
6.612 (1H, d), 6.076 (1H, m), 5.827 (1H, m), 5.394 (1H, dq), 5.258-5.180 (3H, m), 4.76-
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4.662 (3H, m), 3.164 (2H, dd), 3.075-2.992 (3H, m), 2.583 (2H, m), 2.391(1H, td), 2.303 
(1H, dt), 2.146 (1H, td), 2.053 (1H, s), 1.872 (1H, ddd), 1.670-1.559 (2H, m); 
13
C NMR 
(300 MHz, CDCl3): δ 208.2, 145.2, 141.5, 135.0, 133.8, 129.6, 125.3, 119.4, 118.1, 
117.5, 117.5, 90.2, 70.9, 70.2, 62.2, 57.6, 50.7, 43.3, 36.2, 31.4, 30.6, 22.8; GC-MS M
+
 
367 m/z. 
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Chapter 3 
Analgesic Activities of Codrugs, Parent Drugs and Physical Mixtures of Parent 
Drugs 
 
3.1 Introduction 
Pain has been defined as “an unpleasant sensory and emotional experience 
associated with actual or potential damage or described in terms of such damage” 
(Merksey, 1979). Pain is always subjective and each individual learns the application of 
the word through experiences related to injury in early life. The sensation of pain is 
primarily a protective mechanism designed to avoid tissue damage (Joshi and Honore, 
2006). Unfortunately pain often outlives its usefulness as a warning system and instead 
becomes chronic and debilitating. Sherrington proposed the existence of the nociceptor, a 
primary sensory neuron that is activated by stimuli capable of causing tissue damage. 
According to this theory, nociceptors have characteristic thresholds or sensitivities that 
distinguish them from other sensory nerve fibers (Sherrington, 1908). 
Pain is broadly divided in two categories, nociceptive and neuropathic pain. 
Nociceptive pain is a normal response to noxious stimuli that elicits tissue injury. This 
type of pain serves as a warning to protect ourselves from real or impending injury. 
Nociceptive pain is illustrated by the type of response caused by briefly touching a hot 
surface or by a pin prick. Such mechanical or thermal stimuli result in the activation of C- 
and Aδ-fibers in primary afferent nociceptive pathways. Input from these pathways is 
then integrated in the dorsal horn of the spinal cord and relayed to the brain (Julius and 
Basbaum, 2001). On the other hand, neuropathic pain is elicited by injury to the 
peripheral or central nervous system. Injury to the nervous system can be caused by 
tissue trauma, surgery, limb crush or amputation, infection, autoimmune diseases such as 
diabetes and arthritis, radiation damage, and by various drug regimens (e.g. 
chemotherapeutic and anti-HIV agents) (Campbell and Meyer, 2006). The pain can occur 
even without any physical or chemical stimuli. Unlike nociceptive pain, neuropathic pain 
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can persist for a long time, even after the initiating injury has been completely healed. 
This leads to abnormal processing of sensory information by the nervous system. After 
the nerve injury, changes occurring in the central nervous system can persist indefinitely. 
The pain is felt in many different ways, such as burning, tingling, prickling, shooting, and 
spasm (Rotha et al., 1998).  Allodynia and hyperalgesia are two hallmarks of neuropathic 
pain. Allodynia refers to pain due to a stimulus, which does not normally provoke pain, 
e.g., touch, cold, light pressure can be felt as pain.  Hyperalgesia refers to an increased 
response to a stimulus which is normally painful (Riedel and Neeck, 2001). It has been 
anticipated that the prevalence of all sorts of neuropathic pain will exceed 75 million 
worldwide in the next decade (Cavenagh et al., 2006). Qualitatively, pain can further be 
defined in terms of its severity (mild, moderate and severe pain) and temporality (acute 
and chronic pain). Acute pain is commonly defined as the normal predicted physiological 
response to an adverse chemical, thermal or mechanical stimulus associated with surgery, 
trauma and acute illness (Carr and Goudas, 1999). On the other hand, chronic pain is 
defined as a pain of greater than six month duration and associated with cancer, AIDS, 
peripheral nerve disorders and diabetes (Ballantyne and Mao, 2003).  
 
3.2 Animal Models of Pain 
Research on the neurobiological bases of nociception and pain and related 
investigations of potential analgesic therapies require great reliance on animal models of 
pain. Assessment of clinical pain brings a unique problem compared to other major health 
conditions, such as heart disease or cancer. The attempts to assess pain in non-human 
species have involved observations of spontaneous behavioral or physiological reactions 
to presumed sources of pain. The use of comparable methods in preclinical studies in 
animals and clinical studies with humans is critical to successful translational research 
(Rice at al., 2009). Assessment of pain sensitivity should be approached similarly with 
behavioral observations of humans and laboratory animals. Stimulus response functions 
for escape from nociceptive stimulation can provide comparable information for 
laboratory animals (Joshi and Honore, 2006).  
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Fig. 3.1: The Tail-Flick test (Reprinted with permission from 
www.ottoenvironmental.com). 
 
Different animal pain models are used for different kinds of pain. For example 
models developed to measure responses to acute noxious thermal stimuli use a noxious 
heat or cold stimulus to the paw or tail of rodents (Mogil, 2009). These models are widely 
used for testing opioid analgesics. In these methods, latency to behavioral response is 
recorded and a cut-off time period is set to avoid any tissue damage to the animal. In the 
tail-flick test, an intense beam of light is applied to the tail of a rat and the latency period 
is measured until the tail is flicked out of the path of the light beam (Fig. 3.1). One other 
assay to determine sensitivity to heat in normal animals, as well as in animals under 
chronic pain conditions, has been described by Hargreaves et al. (Hargreaves et al., 1988) 
and uses a radiant heat source. In this method, the temperature of the heat source is 
applied to the hind paw and increases over time until it reaches a painful threshold. 
Latency of withdrawal of hind paw is recorded and analyzed. One widely used method to 
test for reactivity to cold is the application of a drop of cold acetone onto the skin of a rat. 
Acetone produces a distinct kind of sensation when it evaporates. Normal rats do not 
respond to this stimulus, while nerve-injured rats show an exaggerated response (Vissers 
and Meert, 2005). 
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Responses to acute noxious mechanical stimuli are measured by stimulating the 
paw or the tail of rodents. In the Randall Selitto test, increased pressure is applied to the 
dorsal surface of the hind paw/tail of a rat via a dome-shaped plastic tip. The threshold 
(in grams) for either paw or tail withdrawal is then recorded (Randall and Selitto, 1957).  
Similarly, responses to acute noxious chemical stimuli can be measured by injecting 
chemical irritants such as capsaicin, formalin or mustard oil. The animal responds by 
biting or licking the injected paw. These observations are recorded at various time points 
after administration of the drug to be tested (Rose and Woodbury, 2008).  
 
 
Fig. 3.2: The Paw-Pressure test (Reprinted with permission from 
www.ottoenvironmental.com). 
 
Different models are used for pain following injury to the nervous system. One 
example is the chronic constriction injury pain model (Bennett‟s model) (Bennett and 
Xie, 1988). This pain model involves the tying of four loose ligatures around the sciatic 
nerve of a rat, just tightly enough to touch the nerve.  Subsequent swelling of the nerve 
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constricts the nerve, which develops hyperalgesia and allodynia over 10 to 14 days 
(Hogan, 2002). 
One other most studied neuropathic pain model is L5-L6 spinal nerve ligation 
(SNL; Chung‟s model). In this ligation process, the L5 and L6 spinal nerves of the animal 
are isolated and tightly ligated with silk thread. This induces mechanical allodynia within 
7-10 days. Models have also been developed involving cold allodynia and thermal 
hyperalgesia. Animals exhibit a dynamic mechanical allodynia, which is assessed by 
gently brushing with a soft brush (Chung, et al., 2004).  
In the present chapter, the tail-flick test is used to assess the effect of the codrugs 
synthesized in Chapter 2 on nociceptive pain, and the chronic constriction injury pain 
model is used to assess the effect of codrugs on neuropathic pain. 
Advantages and disadvantages of animal pain models: 
 Animal studies allow controlled investigation of chronic pain conditions that are 
almost impossible to perform in humans. 
 Animal models of pain provide the means to explore basic physiological 
mechanisms of pain. 
 Prediction of analgesic efficacy leading to clinical drug development is 
moderately accurate based on results from animal studies. No analgesic agent has 
ever been found in humans that did not have a rodent counterpart.  
 One major criticism of animal pain testing is that too much emphasis has been 
placed on reflexive withdrawal from mechanical or thermal stimuli as a dependent 
measure. 
 In animal models emphasis has been placed on measuring pain itself and not 
giving importance to the states that accompany pain. Patients suffering from 
chronic pain experience disability, anxiety, depression, cognitive dysfunction, 
sleep loss, loss of libido, social withdrawal, and many other symptoms. Most of 
these symptoms are ignored in animal pain testing. 
 Preclinical animal models for chronic pain predominantly measure thermal and 
mechanical hypersensitivity, whereas symptoms of chronic pain in humans 
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mainly include spontaneous pain, numbness and dysethesia (unpleasant, abnormal 
sense of touch). 
 Chronic pain sufferers are overwhelmingly female in the case of humans and 
chronic pain is more prevalent in the middle aged and elderly population than in 
young adults. On the other hand, animals used in pain models are healthy, young, 
often genetically identical and overwhelmingly male rodents. 
 Some neuropathic pain models have been criticized because of the poor general 
health of the animals, which may interfere with the outcome of the study. (Mogil 
et al., 2010; Bennett, 1993; and Vierck et al., 2008) 
Codeine and morphine are well known opioid drugs commonly used to control pain, 
whether alone or in combination with an adjunct drug. Unfortunately, long term use of 
these opioids results in the development of tolerance and physical dependence 
(Ballantyne and Mao, 2003). This reduces the analgesic effects necessitating the 
administration of high and potentially harmful doses to achieve adequate pain control. 
The efficacies of physical mixtures of opioids and nornicotine enantiomers have 
previously been characterized in rodent models of nociceptive and neuropathic pain. 
These models included acute thermal nociception and peripheral neuropathy (chronic 
constriction nerve injury, CCI). In the present chapter, we have investigated codrug pain 
therapy where drugs from two different classes (opioids and a nicotinic receptor agonist) 
are administered as a single chemical entity, whereby the two molecules are covalently 
linked together via a carbamate linkage. The efficacies of each of the parent drugs as well 
as a 1:1 physical mixture of the parent drugs were compared with the respective codrug 
as pain modulators in the above pain models to determine their relative effectiveness.  
Analgesic activity study on the codrugs and parent drugs were carried out with the 
cooperation of Dr. Elzbieta Wala. 
3.3 Analgesic Activity of Opioid-S-(-)-Nornicotine Codrugs 
3.3.1 Animals 
 Male Sprague-Dawley rats (Harlan, Indianapolis) about 90 days old, weighing 
300-350 g were used for all experiments. Rats were housed separately in a transparent 
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cage; with free access to standard laboratory chow and tap water in a humidity and 
temperature-controlled facility with lights on between 0600 and 1800 h. Rats were 
trained in the test situation before initiation of the experimental procedures. Rats were 
fasted overnight before oral administration of drug. Body weights were determined on the 
day of experimentation. At the end of the experiment, rats were euthanized with 
pentobarbital sodium (150 mg/kg, intraperitoneal, IP). A crossover paradigm was used 
within an experiment (if possible) to minimize the number of rats. All testing was 
performed in accordance with the guidelines of the National Institute of Health Guide for 
Care and Use of Laboratory Animals (Publication No. 85-23, revised 1985). The protocol 
was approved by the University of Kentucky Animal Care and Use Committee.  
 
3.3.2 Drugs 
The codeine-S-(-)-nornicotine codrug was evaluated using the tail-flick and 
chronic constriction injury pain models. The individual parent drugs codeine and S-(-)-
nornicotine were also assessed using the same pain models. A 1:1 physical mixture of 
codeine and S-(-)-nornicotine was also analyzed in tail-flick assay. Similarly, the 3-O-
acetylmorphine-S-(-)-nornicotine codrug, and 3-O-acetylmorphine and S-(-)-nornicotine 
parent drugs were evaluated using the tail-flick pain assay. Drugs were dissolved in 15% 
PEG saline solution and administered by the oral route using a gavage feeding needle 
after overnight fasting of the animals. A 15% solution of PEG in saline (vehicle) served 
as the control. 
 
3.3.3 Tail Flick Test (Measure of Analgesia/Antinociception) 
  The tail-flick test primarily assesses the spinal antinociceptive (pain relief) 
response to noxious thermal stimuli (D‟Amour and Smith, 1941). An intense beam of 
light is applied to the tail of a Sprague-Dawley rat and the latency period is measured 
until the tail is flicked out of the path of the light beam (Fig. 3.1). Baseline tail-flick 
latencies were determined prior to drug administration using the tail-flick latency test. 
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Tail-flick latencies were also determined at several time points after administration of the 
analgesic drugs for each individual animal. Time response curve was generated by 
calculating the average TFL at each time point using 4-6 rats and was plotted as mean ± 
SEM versus time. SEM stands for Standard Error of the Mean and is calculated as 
[standard deviation / (N)
1/2
], where N is population size. During testing, a cutoff time of 
10 s was employed to prevent damage to the tail of the rat.  
Initially, rats (6/group) were treated with four different doses (10, 20, 30, and 40 
mg/kg) of codeine administered via the oral route. Responsiveness (TFL: Tail Flick 
Latency) was measured prior to (baseline) and after oral dosing. Time-response and dose-
response curves were drawn to calculate ED50
 
value for codeine (Fig. 3.3 and 3.7). 
 
Fig. 3.3: The Tail-Flick latencies of orally administered codeine. 
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Secondly, rats (6/group) were treated with three increasing doses (20, 40, and 80 
mg/kg) of S-(-)-nornicotine administered via the oral route. Responsiveness (TFL) was 
measured prior to (baseline) and after oral dosing. Time-response and dose-response 
curves were drawn to calculate ED50
 
value for S-(-)-nornicotine (Figs. 3.4 and 3.7).  
 
Fig. 3.4: The Tail-Flick latencies and dose response curve of orally administered S-(-)-
nornicotine. 
 
Thirdly, rats (6/group) were treated with three oral doses (5, 10 and 15 mg/kg) of 
the codeine-S-(-)-nornicotine codrug. In a separate experiment one dose (10 mg/kg 
codeine + 5 mg/kg S-(-)-nornicotine, total of 15 mg/kg, 1:1 molar ratio) of an equimolar 
physical mixture of the two parent drugs was administered. Drugs were administered via 
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the oral route. Animals were tested for tail-flick response using the tail-flick apparatus. 
Intensity of the heat source was adjusted to produce baseline tail-flick latencies of 2 to 3 
sec. These baseline tail-flick latencies of the rats were recorded three times (5, 10, 15, 30 
min apart). Responsiveness (TFL) was measured again after oral dosing (5, 10, 15, 30 
min apart) of the codrug doses and equimolar physical mixture dose of codeine and S-(-)-
nornicotine. Dose-response curves can be generated if a minimum of three doses of a 
drug are utilized in this assay. The time-response graphs obtained with the three different 
doses of codeine-S-(-)-nornicotine codrug are illustrated in Fig. 3.5 and are compared 
with that of an equimolar physical mixture of codeine and S-(-)-nornicotine (10 mg/kg 
codeine + 5 mg/kg S-(-)-nornicotine, total of 15 mg/kg of the physical mixture). In Figs. 
3.6 and 3.8, efficacy of the codrug is compared with the equivalent dose of physical 
mixture of the two parent drugs and comparable doses of the individual drugs alone. 
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Fig. 3.5: The Tail-Flick latencies of orally administered codeine-S-(-)-nornicotine codrug. 
 
In a similar manner, the 3-O-acetylmorphine-S-(-)-nornicotine codrug and its 
parent drugs 3-O-acetylmorphine and S-(-)-nornicotine were also assessed in the tail-flick 
test. Rats (6/group) were treated with 3-O-acetylmorphine alone (3 oral doses: 2.5, 5, and 
10 mg/kg), with S-(-)-nornicotine alone (3 oral doses: 5, 8, and 30 mg/kg) and with five 
doses (0.5, 1.25, 2.5, 4 and 8 mg/kg) of 3-O-acetylmorphine-S-(-)-nornicotine codrug.  
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3.4 Chronic Constriction Nerve Injury (CCI, Neuropathic Pain Model)  
3.4.1 Surgery 
 The rodent model of peripheral neuropathy (chronic constriction nerve injury, 
CCI) (Bennett and Xie, 1988) was used to characterize the antihyperalgesic effect of 
codeine, S-(-)-nornicotine and codeine-S-(-)-nornicotine codrug. This pain model 
involves the tying of four loose ligatures around the sciatic nerve, which results in the 
development of mechanical (tactile) allodynia in the ipsilateral hindpaw of the rat 
(Bennett and Xie, 1988).  
 
3.4.2 Mechanical Hyperalgesia 
Enhanced sensitivity to mechanical noxious stimuli (mechanical hyperalgesia) 
was evaluated using the paw pressure test (Randall and Selitto, 1957). This was done 
prior to surgery (pre-CCI baseline) and on the post-surgery day. The hind paw was placed 
between a blunt pointer and a flat surface and increasing pressure was applied to the 
dorsal side of the paw. Rats (6/group) were treated with codeine alone (4.9, 10, 20, 40 
mg/kg doses), S-(-)-nornicotine alone (5, 20, 40, and 60 mg/kg dose) and codeine-S-(-)-
nornicotine codrug (1, 5 and 10 mg/kg doses). Drugs were administered via the oral 
route.  
 
 
3.4.3 Statistical Analysis 
 Responses were normalized for baseline values. Percent maximum possible effect 
was calculated at the time of peak response: %MPE = [(TFL-baseline)/ (cut off-baseline)] 
x 100. ED50 values were computed for codeine-S-(-)-nornicotine codrug, codeine and S-(-
)-nornicotine. The overall effects (antihyperalgesia) were presented as areas-under-the-
time curves, calculated by the trapezoidal rule for baseline normalized responses. Data 
were analyzed using regression analysis, analysis of variance (ANOVA), post-hoc 
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Student Newman Keuls test (SNK) and t-test. Level of significance was P≤0.05. All data 
were mean ± SEM (n = number of rats).  
 
3.5 Results 
3.5.1 Codeine-S-(-)-Nornicotine Codrug Antinociception (Tail Flick Tests) 
 The antinociceptive effects of codeine alone, S-(-)-nornicotine alone, various 
doses of codeine-S-(-)-nornicotine codrug, and an equimolar physical mixture dose of the 
two parent drugs (codeine and S-(-)-nornicotine) were characterized after the oral 
administration in the tail-flick test. The present data provides evidence (Figs. 3.3, 3.4, 
3.5, 3.6, 3.7, and 3.8) that a codrug consisting of codeine (low dose) and S-(-)-nornicotine 
(non-effective dose) significantly enhances effectiveness of the analgesic agent against 
acute nociception. In preliminary experiments, one dose of codeine-S-(-)-nornicotine 
codrug and one dose of codeine were given to the rats to compare the analgesic effect of 
the codrug with codeine. A 15 mg/kg dose of codeine-S-(-)-nornicotine codrug and a 10 
mg/kg codeine dose were chosen for this purpose (Fig. 3.6) (15 mg/kg dose of codrug 
contains 10 mg/kg dose of codeine). Both codeine and codeine-S-(-)-nornicotine codrug 
tail-flick latency values were above baseline values, which indicates that both drugs 
exhibit analgesic effects. On comparing the effect of codeine with the codeine-S-(-)-
nornicotine codrug, it can be observed that the analgesic effect of the codrug is much 
greater than that of codeine, even though the dose of codeine utilized is one and a half 
times the weight of the codeine (on a molar equivalent basis) in the codrug molecule. 
Next, the time-response curve for the three doses of the codeine-S-(-)-nornicotine codrug 
(5, 10, and 15 mg/kg) was generated to obtain a dose-response curve. Figs. 3.5 and 3.7 
illustrate the time-response curve and dose response curve for the 5, 10, and 15 mg/kg 
doses of the codrug. To determine the efficacy of the analgesia produced by the codeine-
S-(-)-nornicotine codrug as compared to that of a physical mixture of the two parent 
drugs, an equimolar physical mixture dose (10 mg/kg codeine + 5 mg/kg S-(-)-
nornicotine, total of 15 mg/kg of the physical mixture) was administered orally and 
compared with the codrug in terms of dose-response curve.  
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Fig. 3.6: The Tail-Flick latencies codeine-S-(-)-nornicotine codrug and codeine.  
 
Fig. 3.7 illustrates the %MPE (Maximum Possible Effect) at the peak of the time 
response curve for codeine-S-(-)-nornicotine codrug, codeine, and S-(-)-nornicotine. % 
MPE can be related to the effectiveness of the drug. The greater the %MPE, the more 
effective the drug is. The highest %MPE achieved by codeine and the codeine-S-(-)-
nornicotine codrug is around 80%. Increasing the dose further for codeine does not result 
in a further increase in the %MPE. The 15 mg/kg dose of the codeine-S-(-)-nornicotine 
codrug produced the highest %MPE among the codrug doses. The equi-effective dose of 
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codeine was 30 mg/kg compared to a 15 mg/kg dose of the codeine-S-(-)-nornicotine 
codrug. The 15 mg/kg dose of the codeine-S-(-)-nornicotine codrug contains 10 mg/kg 
dose of codeine. Therefore, the analgesic effect shown by 10 mg/kg dose of codeine 
when given in the form of the codeine-S-(-)-nornicotine codrug is equivalent to a 30 
mg/kg dose of codeine alone. On the other hand, S-(-)-nornicotine does not possess very 
good analgesic activity on its own. To achieve %MPE similar to codeine or codrug, a 
very high oral dose of the drug molecule is required. A 60 mg/kg oral dose of S-(-)-
nornicotine produces %MPE approximately similar to a 15 mg/kg dose of codeine-S-(-)-
nornicotine codrug. The 15 mg/kg dose of codeine-S-(-)-nornicotine codrug contains only 
a 5 mg/kg dose of S-(-)-nornicotine. Fig 3.4 shows that 5 mg/kg dose of S-(-)-nornicotine 
is almost ineffective as an analgesic. It can further be noticed that the dose-response 
curve for the codrug is shifted to the left compared to the dose response curves of codeine 
and S-(-)-nornicotine. Shifting of the dose response curve to the left signifies that a lesser 
amount of codrug dose is required to produce analgesic effect similar to the parent drugs. 
 
 
Fig. 3.7: Dose-response curves for codeine, S-(-)-nornicotine, and codeine-S-(-)-
nornicotine codrug in tail-flick test. 
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Fig. 3.8 illustrates the %MPE (Maximum Possible Effect) at the peak of the time-
response curve for the codeine-S-(-)-nornicotine codrug (three doses: 5, 10, 15 mg/kg), 
codeine (one dose: 10 mg/kg), S-(-)-nornicotine (one dose: 5 mg/kg), equimolar physical 
mixture of the two parent drugs (10 mg/kg codeine + 5 mg/kg S-(-)-nornicotine, total of 
15 mg/kg of the physical mixture), and vehicle. It can be observed that the 15 mg/kg 
codrug dose is more effective than an equimolar physical mixture dose of codeine and S-
(-)-nornicotine weighing 15 mg/kg total. It can further be noticed that the 10 mg/kg 
codrug dose is also more effective than the 15 mg/kg physical mixture dose. The 10 
mg/kg codrug dose is also more effective compared to the 10 mg/kg dose of codeine. 
 
Fig. 3.8: Comparison of %MPE at peak time for codeine-S-(-)-nornicotine codrug, 
physical mixture, and the individual parent drugs in tail-flick test. 
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 In conclusion, the present data demonstrates that combining codeine with S-(-)-
nornicotine in the form of a codrug may enhance the effectiveness of both codeine and S-
(-)-nornicotine against acute nociception. Also side effects associated with higher doses 
of codeine and S-(-)-nornicotine can be avoided by the codrug approach, since lower 
doses of each parent drug can be utilized.  
 
3.5.2 Codeine-S-(-)-Nornicotine Codrug Antihyperalgesic Effect (CCI Model) 
Chronic constriction nerve injury (CCI) results in significantly decreased 
thresholds to mechanical noxious stimuli (hyperalgesia) compared to the pre-surgical 
threshold. The paw withdrawal threshold (PWT) (pre-CCI) was 225 ± 3.5 g versus a 
PWT (post-CCI) of 112 ± 4.3 g. The antihyperalgesic effect of codeine alone, S-(-)-
nornicotine alone and various doses of the codeine-S-(-)-nornicotine codrug were 
characterized after administration via the oral route. The data obtained provides evidence 
(Figs. 3.9, 3.10, 3.11, and 3.12) that the codeine-S-(-)-nornicotine codrug exhibits a 
synergistic antihyperalgesic effect. Fig. 3.9 demonstrates the time-response and dose-
response curves for various doses of codeine alone (4.9, 10, 20, and 40 mg/kg). Dose-
response curves for codeine were generated to determine the dose of codeine that was 
equi-effective as the codeine-S-(-)-nornicotine codrug, and to calculate ED50 value of 
codeine. A 65% MPE was exhibited by codeine. Similarly, time-response curves and 
dose-response curves were generated for S-(-)-nornicotine alone after oral dosing of the 
drug. Four doses (5, 20, 40, and 60 mg/kg) of S-(-)-nornicotine were used to generate 
dose-response curves for the calculation of ED50 values. The maximum possible effect 
shown by S-(-)-nornicotine alone was 45%. In a similar manner, time-response and dose-
response curves were generated for the codeine-S-(-)-nornicotine codrug. Fig. 3.11 shows 
the time-response curves for various doses (1, 5, and 10 mg/kg) of the codeine-S-(-)-
nornicotine codrug. Post-hoc Student Newman Keuls (SNK) analysis indicated that the 5 
and 10 mg/kg doses of the codrug showed an enhanced antihyperalgesic effect when 
compared to vehicle alone.  The maximum possible effect was achieved around 2 hours 
173 
 
post-dosing with the 15 mg/kg dose of the codeine-S-(-)-nornicotine codrug. The 
enhancement of the analgesic response caused by the codeine-S-(-)-nornicotine codrug is 
evident at several points in the time-response curves. 
 
Fig. 3.9: Time-response and dose-response curves for orally administered codeine in the 
CCI model. 
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Fig. 3.10: Time-response and dose-response curves for orally administered S-(-)-
nornicotine in the CCI model 
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Fig. 3.11: Time-response curves for orally administered codeine-S-(-)-nornicotine codrug 
and codeine in the CCI model. 
 
Fig. 3.12 illustrates the % MPE (Maximum Possible Effect) for the codeine-S-(-)-
nornicotine codrug and for codeine and S-(-)-nornicotine. The highest %MPE achieved 
by codeine is 65%. Increasing the dose further for codeine does not result in a further 
increase in the % MPE. The highest % MPE achieved by S-(-)-nornicotine is 45% by 40 
mg/kg oral dose of S-(-)-nornicotine. Increasing the dose from 40 to 60 mg/kg reduces 
the effectiveness of the drug. The 10 mg/kg dose of the codeine-S-(-)-nornicotine codrug 
produced the highest %MPE (85%). 85% MPE could not be achieved with any dose of 
codeine or S-(-)-nornicotine alone. This clearly demonstrates that codeine-S-(-)-
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nornicotine is much superior compared to either of the two parent drugs in terms of its 
antihyperalgesic activity.  
 
 
Fig. 3.12: Dose-response curves for orally administered codeine, S-(-)-nornicotine, and 
codeine-S-(-)-nornicotine codrug in the CCI animal model. 
 
The 10 mg/kg dose of the codeine-S-(-)-nornicotine codrug contains a 6.3 mg/kg 
dose of codeine and a 3.7 mg/kg dose of S-(-)-nornicotine. As is evident from the dose-
response curves for codeine and S-(-)-nornicotine, a 6.3 mg/kg dose of codeine is 
considered as a dose producing very low efficacy, and 3.7 mg/kg dose of S-(-)-
nornicotine is not even considered effective. Therefore, the analgesic effect shown by a 
6.3 mg/kg dose of codeine and 3.7 mg/kg dose of S-(-)-nornicotine when given in the 
form of the codeine-S-(-)-nornicotine codrug produces profound analgesia which cannot 
be achieved by the same respective doses of the individual drugs. In conclusion, the 
present data demonstrates that combining codeine with S-(-)-nornicotine in the form of a 
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codrug may enhance codeine effectiveness against neuropathic pain. Also the 
accompanying reduction of opioid dose will decrease the adverse effects associated with 
opioid therapy. 
 
3.5.3 3-O-Acetylmorphine-S-(-)-Nornicotine Codrug Antinociception (Tail-Flick 
Test) 
The antinociceptive effects of 3-O-acetylmorphine alone, S-(-)-nornicotine alone 
and various doses of 3-O-acetylmorphine-S-(-)-nornicotine codrug were characterized 
after the oral administration in the tail-flick test. The present data provides evidence 
(Figs. 3.13, 3.14, 3.15, and 3.16) that a codrug consisting of 3-O-acetylmorphine (low 
dose) and S-(-)-nornicotine (non-effective dose) significantly enhances effectiveness of 
the analgesic agents against acute nociception. In preliminary experiments, three doses of 
3-O-acetylmorphine (2.5, 5, 10 mg/kg) and four doses of S-(-)-nornicotine (5, 8, 15, 30 
mg/kg) were administered orally to rats to compare the analgesic effects of the two parent 
drugs and also to determine the ED50 values for the parent drugs. In separate experiments, 
five doses (0.5, 1.25, 2.5, 4, 8 mg/kg) of the 3-O-acetylmorphine-S-(-)-nornicotine codrug 
were administered orally and tail flick latencies were experimentally determined. 3-O-
Acetylmorphine and 3-O-acetylmorphine-S-(-)-nornicotine codrug tail-flick latency 
values were above baseline values, which indicated that both drugs exhibited analgesic 
effects.  
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Fig. 3.13: Time-response curves for orally administered 3-O-acetylmorphine (MOR) in 
the tail-flick animal model. 
 
 
Fig. 3.14: Time-response curves for orally administered S-(-)-nornicotine (NNIC) in the 
tail-flick animal model. 
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Fig. 3.15: Time-response curves for orally administered 3-O-acetylmorphine-S-(-)-
nornicotine codrug (MOR-NNIC) in the tail-flick animal model. 
 
Fig. 3.16 illustrates the %MPE (Maximum Possible Effect) at the peak of the time 
response curve for the 3-O-acetylmorphine-S-(-)-nornicotine codrug, 3-O-
acetylmorphine, and S-(-)-nornicotine. The highest %MPE achieved by 3-O-
acetylmorphine and the 3-O-acetylmorphine-S-(-)-nornicotine codrug is around 90%. The 
8 mg/kg dose of the 3-O-acetylmorphine-S-(-)-nornicotine codrug produced the highest 
%MPE among the codrug doses. The equi-effective dose of 3-O-acetylmorphine was 10 
mg/kg compared to an 8 mg/kg dose of the 3-O-acetylmorphine-S-(-)-nornicotine codrug. 
The 8 mg/kg dose of the 3-O-acetylmorphine-S-(-)-nornicotine codrug contains a 5.2 
mg/kg dose of 3-O-acetylmorphine. Therefore, the analgesic effect shown by a 5.2 mg/kg 
dose of 3-O-acetylmorphine when given in the form of the 3-O-acetylmorphine-S-(-)-
nornicotine codrug is equivalent to a 10 mg/kg dose of 3-O-acetylmorphine alone. On the 
other hand, S-(-)-nornicotine does not possess very good analgesic activity on its own. To 
achieve a %MPE similar to 3-O-acetylmorphine or codrug, a very high oral dose of S-(-)-
nornicotine is required, which can cause toxicity in the animal. The 8 mg/kg dose of 3-O-
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acetylmorphine-S-(-)-nornicotine codrug contains only 2.4 mg/kg dose of S-(-)-
nornicotine. A 2.4 mg/kg dose of S-(-)-nornicotine is completely ineffective as an 
analgesic. It can further be noticed that the dose-response curve for the codrug is shifted 
to the left compared to the dose response curves of 3-O-acetylmorphine and S-(-)-
nornicotine. Shifting of the dose response curve to the left signifies that a lesser amount 
of codrug dose is required to produce analgesic effects similar to those produced by the 
parent drugs. 
 
 
Fig. 3.16: Dose-response curves for 3-O-acetylmorphine, S-(-)-nornicotine, and 3-O-
acetylmorphine-S-(-)-nornicotine codrug in the tail-flick animal model. 
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3.5.4 ED50 values 
  The dose of a drug that is pharmacologically effective for 50% of the population 
exposed to the drug, or that shows a 50% response in a biological system that is exposed 
to the drug is defined as the ED50 value of the drug. To calculate ED50, time-response 
curve was converted to a dose-response curve. To develop dose-response curve, the 
maximum TFL for each dose was selected regardless of the time point. The maximum 
TFL for a dose at any time point was then converted to a %MPE using the formula to 
calculate %MPE. The %MPE value at the peak of the time-response curve is denoted as 
%MPE at peak time. Dose-response curve was generated by plotting %MPE (peak time) 
± SEM versus dose and 4-6 rats were used to obtain each point in the dose-response 
curve. In the dose-response curve a horizontal line was drawn at 50 %MPE intersecting 
the dose-response line. From the point of intersection, a vertical line was drawn on the X-
axis (Dose). The point of intersection on the X-axis gives the ED50 value for the analgesic 
agent. As the dose-response curve is a line, the obtained ED50 value is just a number 
without any SEM, but it should be kept in mind that 4-6 rats were used to generate each 
point on the dose-response curve. 
As can be seen in Table 3.1, the ED50 value for the codeine-S-(-)-nornicotine 
codrug in the tail-flick test, as well as in the CCI pain model is much lower than the ED50 
value of codeine and S-(-)-nornicotine in either test, which suggests that the use of a low 
dose combination of these two analgesics in a codrug structure is a valid and effective 
approach for improved treatment of both nociceptive and neuropathic pain. 
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Table 3.1: ED50 values of codrug and parent drugs in tail-flick and CCI models. 
 ED50 
Tail-flick model 
ED50 
C.C.I. model 
Codeine  12.4 mg/kg 
41.4 µmol/kg 
13.5 mg/kg 
45.1 µmol/kg 
S-(-)-Nornicotine 15.9 mg/kg 
107.3 µmol/kg 
16.9 mg/kg 
114.0 µmol/kg 
Codeine-S-(-)-Nornicotine 
Codrug 
8.5 mg/kg 
18.0 µmol/kg 
3.5 mg/kg 
7.4 µmol/kg 
 
Table 3.2 lists the ED50 values of 3-O-acetylmorphine, S-(-)-nornicotine, and 3-O-
acetylmorphine-S-(-)-nornicotine codrug in tail-flick model. It can be seen that the codrug 
is more effective for treating nociceptive pain compared to the parent drugs. Thus, 
combining an opioid with S-(-)-nornicotine in a single chemical entity can increase the 
efficacy of both the drugs. 
 
Table 3.2: ED50 values of morphine, 3-O-acetylmorphine, S-(-)-nornicotine, and 3-O-
acetylmorphine-S-(-)-nornicotine codrug in tail-flick model. 
 ED50 
Tail-flick model 
3-O-Acetylmorphine 3.6 mg/kg 
11.0 µmol/kg 
S-(-)-Nornicotine 15.9 mg/kg 
107.3 µmol/kg  
3-O-Acetylmorphine-S-(-)-
Nornicotine Codrug 
1.5 mg/kg 
3.0 µmol/kg 
 
 
183 
 
3.6 Analgesic Activity of N-Ethoxycarbonylgabapentin-Codeine Codrug (CG-4) 
3.6.1 Tail Flick Test (Measure of Analgesia/Antinociception) 
Tail flick latencies for several doses of codeine were previously determined and 
already discussed in this chapter. It has been previously reported in literature that 
gabapentin alone has no intrinsic effect in the tail flick test (Gilron et al., 2003). Thus, 
gabapentin was not tested for its efficacy in the tail flick test. The antinociceptive effect 
of the N-ethoxycarbonylgabapentin-codeine codrug (CG-4) was characterized after oral 
administration in the rat tail-flick test. Three doses (6.25, 12.5, and 25 mg/kg) of N-
ethoxycarbonylgabapentin-codeine codrug were administered and then tail flick latencies 
were experimentally determined. CG-4 codrug tail-flick latency values were above 
baseline values, which indicated that the codrug exhibits an analgesic effect. An 
equimolar physical mixture dose of codeine and gabapentin (14.3 mg/kg codeine + 8.2 
mg/kg gabapentin, total of 22.5 mg/kg physical mixture) equivalent to 25 mg/kg dose of 
the CG-4 codrug was also administered orally, and then time response curve for tail flick 
test was generated. The tail flick latency values of the physical mixture dose of 
gabapentin and codeine (14.3 mg/kg codeine + 8.2 mg/kg gabapentin, total of 22.5 mg/kg 
physical mixture) were above the baseline, and also the antinociceptive effect of the 
physical mixture was significantly different from that of the vehicle. Fig 3.17 illustrates 
the time-response curve for the three doses of the codrug along with the vehicle response. 
It can be noticed that the 25 mg/kg and 12.5 mg/kg doses of the codrug showed 
significant antinociceptive effects. It can further be noticed that the codrug showed a 
prolonged analgesic effect. The analgesic effect of the codrug did not come to baseline 
even after 24 hours in both the 12.5 and 25 mg/kg doses. To compare the analgesic 
efficacy of the codrug with an equimolar physical mixture of the two parent drugs a time-
response curve was generated for a 25 mg/kg dose of the codrug as well as 22.5 mg/kg 
dose of an equimolar physical mixture (14.3 mg/kg codeine + 8.2 mg/kg gabapentin, total 
of 22.5 mg/kg physical mixture. This dose is equivalent to 25 mg/kg dose of CG-4 
codrug). By comparing Figs. 3.17 and 3.18, it can be seen that the analgesic effect of the 
physical mixture reduces to baseline after 8 hours, while the same dose of the codrug 
remains effective for a much longer time period (30 hours). It can also be noticed that 
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even the 12.5 mg/kg dose of the codrug shows a much prolonged antinociceptive effect 
than the equimolar physical mixture dose. 
 
 
 
Fig. 3.17: Time-response curves for three oral doses of the N-ethoxycarbonylgabapentin-
codeine codrug and an equimolar physical mixture dose of codeine and gabapentin in the 
tail-flick animal model. 
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Fig. 3.18: Comparison of time-response curves for N-ethoxycarbonylgabapentin-codeine 
codrug and an equivalent physical mixture dose of the parent drugs. 
 
Fig. 3.19 illustrates the %MPE (Maximum Possible Effect) at the peak of the time 
response curve for the N-ethoxycarbonylgabapentin-codeine codrug and the equimolar 
physical mixture of codeine and gabapentin. The 25 mg/kg dose of the N-
ethoxycarbonylgabapentin-codeine codrug produced the highest % MPE among the 
codrug doses. The highest %MPE achieved by N-ethoxycarbonylgabapentin-codeine 
codrug is around 90%. 90% MPE could not be achieved with any dose of codeine alone. 
The 25 mg/kg dose of the N-ethoxycarbonylgabapentin-codeine codrug contains a 14.3 
mg/kg dose of codeine. From the dose response curve of codeine, it can be noticed that a 
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14.3 mg/kg dose of codeine alone would produce less than 60% MPE. Therefore, the 
analgesic effect shown by a 14.3 mg/kg dose of codeine when given in the form of the N-
ethoxycarbonylgabapentin-codeine codrug is much more profound compared to that 
afforded by the same dose of codeine alone. It can also be noticed from the dose-response 
curve of the N-ethoxycarbonylgabapentin-codeine codrug and an equimolar physical 
mixture of the two parent drugs, that when the two parent drugs are combined in a single 
chemical entity as a codrug, this chemical form is much more effective than 
administering a physical mixture of the two parent drugs. 
It can also be proven that the overall analgesic effect of the codrug is greater 
compared to that produced by the physical mixture by calculating the area under the 
curve (AUC) of the various doses of the codrug and the physical mixture. Table 3.3 lists 
the area under the curves until 8 hours (AUC0-8 hr) after the oral dosing of codrug and an 
equimolar physical mixture. By comparing the AUCs, it can be concluded that the overall 
effects of 12.5 and 25 mg/kg doses of the codrug are higher compared to the equimolar 
dose of the physical mixture. Thus the enhancement of the analgesic response of the two 
parent drugs when given in the form of a codrug is evident at several points in the time-
response curve, as well in the overall effect. 
 
Table 3.3: AUCs for different doses of the N-ethoxycarbonylgabapentin-codeine codrug 
and an equimolar physical mixture dose of codeine and gabapentin. 
Codrug and Physical Mixture Dose AUC0-8 hr (s * hr) 
6.25 mg/kg codrug 7.50 ± 1.60 
12.5 mg/kg codrug 18.50 ± 4.58 
25 mg/kg codrug 34.70 ± 5.01 
22.5 mg/kg equimolar physical mixture 16.90 ± 1.92 
 
ED50 values of the codrug were calculated from dose-response curves and then 
compared to the ED50 values of the parent drugs. It can also be noticed from the ED50 
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values that the codrug is more efficacious than the parent drugs, and that the opioid dose 
can be reduced by combining an opioid with gabapentin in a single chemical entity. 
Table 3.4: ED50 values of codeine, gabapentin, and N-ethoxycarbonylgabapentin-codeine 
codrug in the tail-flick animal model. 
 ED50 
Tail-flick model 
Codeine 12.4 mg/kg 
41.4 µmol/kg 
Gabapentin Non responsive 
N-ethoxycarbonylgabapentin-codeine 10.1 mg/kg 
19.2 µmol/kg 
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Fig. 3.19: comparison of % MPE at peak time for three different doses of the N-
ethoxycarbonylgabapentin-codeine codrug and an equimolar physical mixture dose of 
codeine and gabapentin in tail-flick test. 
 
Thus it can be concluded from the study of several opioid codrugs in different 
pain assays that combining an opioid with an adjuvant drug in the form of a codrug 
molecule can increase the analgesic potency of the opioid. This strategy can lead to 
reduced doses of the opioids for the treatment of pain and can significantly diminish the 
adverse effects associated with opioid therapy. It can also be noticed from the behavior of 
the studied codrugs that the codrugs showed longer period of action compared to the 
parent opioids or physical mixtures. Therefore, codrug strategy can also provide a 
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prolonged analgesia and can make the dosing regimen less frequent and can also increase 
the patient compliance. Another important outcome of the study is that, combination of 
an opioid molecule with an appropriate adjuvant analgesic in the form of a codrug can 
make the opioid molecule more effective in treating neuropathic pain. Codeine-S-(-)-
nornicotine codrug showed promising antihaperalgesic effect in the CCI model of 
neuropathic pain. Thus codrug strategy can be useful for treating a broader range of pain 
and making opioids more useful for the treatment of both nociceptive and neuropathic 
pain. 
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Chapter 4 
In Vitro Stability Study of the Codrugs 
 
4.1 Introduction 
Orally administered drug molecules experience a wide range of pH in the human 
body. Harsh acidic conditions are experienced in stomach (pH=1 to 2), mild acidic 
conditions are experienced at the beginning of small intestine (pH=4 to 5), and basic 
conditions are experienced in the small intestine and colon (pH=7 to 9). Also, blood 
plasma has a slightly basic pH of 7.4. Thus, therapeutic molecules need initially to be 
examined and analyzed in vitro at different pH conditions to determine their stabilities. In 
vitro evaluation of chemical stability is particularly important for prodrugs and codrugs, 
as they contain labile linkers. Along with the study of chemical stability of codrugs in 
different aqueous buffers, stability studies in the presence of different enzymatic 
conditions are also essential. Gastric juice contains hydrolytic enzymes, such as trypsin, 
pepsin, rennin, and mucin; intestinal fluid also contains hydrolytic enzymes such as 
pancreatin, and human plasma contains a large number of hydrolytic enzymes such as, 
cholinesterases, aldolases, lipases, dehydropeptidases, and alkaline and acid phosphatases 
(Piper et al., 1963; DeBeer et al., 1935). The primary object of performing stability study 
on a drug molecule in nonenzymatic and enzymatic assays is to predict the stability of the 
drug in the GI tract after oral dosing. The obtained hydrolytic profile of the drug can 
guide the structural modification of the drug to improve GI stability and optimize plasma 
bioavailability (Kern and Di 2008).  
In case of codrugs, in vitro stabilities of the molecules need to be studied in depth 
before starting the more expensive in vivo evaluation experiments. An ideal codrug 
should not be hydrolyzed to the parent drugs in the GI tract. After the codrug enters 
systemic circulation, it can behave in two different ways: the codrug may get hydrolyzed 
in blood to produce the parent drugs. In this scenario, the codrug serves the purpose of a 
chemical delivery system and provides both parent drugs in systemic circulation, usually 
191 
 
at higher concentrations than administering the parent drugs alone. In a different scenario, 
the codrug may not get hydrolyzed in the plasma and may target the site of action as a 
single chemical entity and then be hydrolyzed by tissue-specific enzymes present at site 
of action to produce the parent drugs concomitantly. In case of opioid codrugs, the site of 
action is the brain, since opioid receptors are mostly located in the central nervous system 
(CNS). Thus, to determine the hydrolytic profile of opioid codrugs in the GI tract, 
stability study should be performed under the following hydrolytic conditions: 
• Aqueous buffer of pH 1.3 
• Aqueous buffer of pH 5.0 
• Aqueous buffer of pH 7.4  
• Simulated gastric fluid (containing pepsin) (SGF) 
• Simulated intestinal fluid (containing pancreatin) (SIF) 
To determine the stability of opioid codrugs in the systemic circulation, stability 
studies should also be performed in plasma, and to determine the stability at the site of 
action, stability studies should also be performed in brain homogenate. Thus selected 
codrugs from each group of synthesized opioid codrugs were examined for the stability 
under the following hydrolytic conditions to model drug barriers to bioavailability: 
• Aqueous buffers (pH 1.3 to 7.4, 37 ºC) 
• Simulated gastric fluid (USP, 37 ºC) 
• Simulated intestinal fluid (USP, 37 ºC) 
• 80% rat plasma (37 ºC) 
• Rat brain homogenate (37 ºC) 
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4.2 Opioid-S-(-)-Nornicotine Codrugs 
Three of the synthesized opioid-S-(-)-nornicotine codrugs were studied under 
different hydrolytic conditions. The stability of codeine-S-(-)-nornicotine, 3-O-
acetylmorphine-S-(-)-nornicotine, and morphine-S-(-)-nornicotine codrugs were 
examined in different nonenzymatic and enzymatic conditions.  
 
Fig. 4.1: Structures of the opioid-S-(-)-nornicotine codrugs used in stability studies. 
 
4.2.1 Standard Curve and Quality Control Validation Solutions 
In the stability study of the codeine-S-(-)-nornicotine codrug, morphine was used 
as an internal standard and in the studies involving the 3-O-acetylmorphine-S-(-)-
nornicotine and the morphine-S-(-)-nornicotine codrugs, codeine was used as an internal 
standard. Stock solutions of codrugs, codeine, morphine, 3-O-acetylmorphine, and S-(-)-
nornicotine were prepared in methanol. Standard curves with eight different 
concentration points were generated and utilized in the quantitative analysis of the 
unknown samples. Calibration curves were obtained using quadratic least-squares 
regression of area-under-the-curve (AUC) ratios (analyte peak AUC/internal standard 
peak AUC) versus drug concentration. The amount of codrug, or parent drug, was then 
determined using the standard curves.  
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4.2.2 Kinetics of Hydrolysis of the Codrugs in Aqueous Solutions (Non-Enzymatic) 
  A 0.02 M hydrochloric acid buffer, pH 1.3, was used as a non-enzymatic 
simulated gastric fluid. A 0.02 M sodium acetate buffer, pH 5.0; and a 0.02 M phosphate 
buffer, pH 7.4 were also used in this study. The pH 5.0 simulates intestinal fluid present 
at the beginning of small intestine and the pH 7.4 represents pH of the small intestine and 
physiological pH (plasma). Reactions were initiated by adding 300 µL of 25 mM stock 
solution (in methanol) of the codrug to 9 mL of appropriate thermostated (37 ± 0.5 °C) 
aqueous solutions of the above buffer species. Aliquot-parts (250 µL) were removed from 
the codrug-buffer solutions at various time intervals, mixed with 50 µL of the 5 mM 
internal standard solution, and 10 µL of the resulting solution was immediately injected 
onto the HPLC-DAD analytical system for quantitative analysis.  Experiments were run 
in triplicate (Omar, 1998).  
 
4.2.3 Kinetics of Hydrolysis of the Codrug in Simulated Gastric Fluid (SGF) and 
Simulated Intestinal Fluid (SIF) (Enzymatic Conditions) 
Reactions were initiated by adding 300 µL of a 25 mM stock solution (in 
methanol) of the codrug to 9 mL of appropriate thermostated (37 ± 0.5 °C) SGF and SIF 
solutions. Aliquot-parts (250 µL) of the resulting solutions were removed at various time 
intervals, mixed with 50 µL of the 5 mM internal standard solution and 10 µL of the 
resulting solution was immediately injected onto the HPLC-DAD analytical system for 
quantitative analysis.   Experiments were run in triplicate.  
 
4.2.4 Kinetics of Hydrolysis of the Codrug in Rat Plasma (in vitro):  
Plasma from male Sprague-Dawley rats was obtained by centrifugation of blood 
samples at 12,000 rpm for 10-15 min. The supernatant plasma fractions (2 mL) were 
diluted with phosphate buffer (pH 7.4) to afford a total volume of 2.5 mL (80% rat 
plasma). Incubations were performed at 37 ± 0.5 °C in a water-bath with constant 
stirring. Reactions were initiated by adding 100 µL of the codrug stock solution (5 mM in 
194 
 
methanol) to 2.5 mL of preheated (37 ± 0.5 °C) 80% rat plasma. Aliquot-parts (100 µL) 
were removed at various times, mixed with 50 µL of the 5 mM internal standard solution, 
and then deproteinized by mixing with 600 µL of acetonitrile. After centrifugation for 10 
minutes at 12,000 rpm, the supernatant was separated, dried under nitrogen gas, the 
residue reconstituted with 300 µL of methanol, and the resulting solution was analyzed 
by HPLC-DAD.  
 
4.2.5 Kinetics of Hydrolysis of the Codrug in Rat Brain Homogenate 
Brain homogenate obtained from male Sprague-Dawley rats was obtained by 
homogenizing brain tissues with 3 volumes of 1.15%  KCl/g brain tissue for 2 minutes in 
a tissue homogenizer. Incubations were performed at 37 ± 0.5 °C in a water-bath with 
constant stirring. The reactions were initiated by adding 100 µL of the codrug stock 
solution (5 mM in methanol) to 2.5 mL of preheated (37 ± 0.5 °C) brain homogenate. 
Aliquot-parts (100 µL) were removed at various times, mixed with 50 µL of the 5 mM 
internal standard solution, and deproteinized by mixing with 600 µL of acetonitrile. After 
centrifugation for 10 minutes at 12,000 rpm, the supernatant was separated, dried under 
nitrogen gas, the residue reconstituted with 300 µL of methanol, and the resulting 
solution analyzed by HPLC-DAD. 
 
4.2.6 HPLC Analysis 
HPLC analysis was carried out on an Agilent 1100 series Quatpump, equipped 
with a photodiode array detector and a computer integrating apparatus. A Waters 
Symmetry ® C18 (5 µm, 3.9 x 150 mm) column protected with guard column (Nova-
Pak® C18; 3.9 x 20 mm; 4µ) was used as the stationary phase; a mixture of 0.16% 
aqueous solution of sodium heptane sulfonate (SHS) adjusted to pH 3.2 with 85% o-
phosphoric acid (solvent A)/methanol (solvent B)/was used as mobile phase. A 1 mL/min 
flow rate was used, and UV detection was carried out at 220 nm. This HPLC assay was 
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used for 3-O-acetylmorphine-S-(-)-nornicotine and morphine-S-(-)-nornicotine codrugs. 
Naltrexone was used as the internal standard. 
 
 
Fig. 4.2: HPLC chromatogram of morphine, S-(-)-nornicotine, naltrexone (IS), and 3-O-
acetylmorphine-S-(-)-nornicotine codrug. 
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Fig. 4.3: Individual HPLC Chromatograms of morphine, S-(-)-nornicotine, naltrexone 
(IS), and morphine-S-(-)-nornicotine codrug (in top to bottom order). 
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A specific 30 min time gradient program was used for the analysis of 3-O-
acetylmorphine-S-(-)-nornicotine and morphine-S-(-)-nornicotine codrugs as follows: 
0-11 min: 45% solvent A 
11-14 min: 45% to 7% solvent A 
14-20 min: 7% solvent A 
20-23 min: 7% to solvent A 
23-30 min: 45% solvent A 
For the codeine-S-(-)-nornicotine codrug a different HPLC assay was used. A Waters 
Symmetry ® C18 (5 µm, 3.9 x 150 mm) column protected with an appropriate guard 
column (Nova-Pak® C18; 3.9 x 20 mm; 4µ) was used as the stationary phase; 0.04% 
aqueous HFBA solution (solvent A)/0.04% heptafluorobutyric acid (HFBA) solution in 
methanol (solvent B) was used as mobile phase. A 0.5 mL/min flow rate was used, and 
UV detection was carried out at 280 nm. Morphine was used as the internal standard. 
A specific 20 min time gradient program was used for analysis of the codeine-S-(-)-
nornicotine codrug as follows: 
0-1 min: 76% solvent A 
1-17 min: 76% to 28% solvent A 
17-17.1 min: 28% to 76% solvent A 
17.1-20 min: 76% solvent A 
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Fig. 4.4: HPLC Chromatogram of S-(-)-nornicotine, morphine (IS), codeine, and codeine- 
S-(-)-nornicotine codrug (in order of elution). 
 
 4.3 Results  
4.3.1 Assay Validation  
Calibration curves were generated for each analyte and for each stability study. 
Table 4.1 summarizes the information regarding the linear range of each analyte. 
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Table 4.1: Standard curve analysis of the analytes. 
Analyte Linear Range R
2
 
Codeine  3.906-1000 µM 0.9994 
S-(-)-Nornicotine  31.25-2000 µM 0.9915 
Codeine-S-(-)-nornicotine 7.813-2000 µM 0.9991 
3-O-Acetylmorphine-S-(-)-
nornicotine 
23.36-996.9 µM 0.9942 
Morphine-S-(-)-nornicotine 7.813-2000 µM 0.998 
Codeine-Norketamine 31.25-2000 µM 0.992 
Morphine-Norketamine 31.25-2000 µM 0.9931 
CG-1 7.813-2000 µM 0.9994 
CG-2 7.813-2000 µM 0.9978 
CG-3 3.906-1000 µM 0.9834 
CG-4 2.047-1048 µM 0.9925 
 
4.3.2 Chemical and Enzymatic Stability Study 
 Chemical and enzymatic stability studies on the codeine-S-(-)-nornicotine, 3-O-
acetylmorphine-S-(-)-nornicotine and morphine-S-(-)-nornicotine codrugs were carried 
out in vitro. Chemical hydrolysis was examined utilizing buffers at pH 1.3, 5, and 7.4, 
and enzymatic hydrolysis was examined in simulated gastric fluid (SGF), simulated 
intestinal fluid (SIF), 80% rat plasma, and brain homogenate. Table 4.2 summarizes the 
results of the stability studies. 
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Table 4.2: Results of the stability studies of opioid- S-(-)-nornicotine codrugs. 
 codeine-S-(-)-
nornicotine 
3-O-acetylmorphine-
S-(-)-nornicotine 
morphine-S-(-)-
nornicotine 
pH 1.3 Stable Deacetylation only Stable 
pH 5.0 Stable Deacetylation only Stable 
pH 7.4 Stable Deacetylation only Stable 
SGF Stable Deacetylation only Stable 
SIF Stable Deacetylation only Stable 
80% Rat Plasma Stable Deacetylation only Stable 
Brain Homogenate Stable Deacetylation only Stable 
 
The data from the chemical hydrolysis studies at pH 1.3 and in SGF indicates that 
the codrugs are stable in these media, and thus are not likely to undergo chemical or 
enzymatic hydrolysis in the stomach when given orally. In fact, no observable 
degradation of the codrug occurred in these media over 24 hours. 3-O-Acetylmorphine-S-
(-)-nornicotine codrug underwent hydrolysis of the ester group, as expected, to produce 
morphine-S-(-)-nornicotine codrug, but no carbamate bond hydrolysis was observed. 
Thus, the codrugs should pass through the stomach after oral administration without any 
hydrolysis to produce the parent drugs. Additionally, at pHs 5.0 and 7.4, and in SIF, no 
hydrolysis of the codrugs to produce the parent drugs was observed for 24 hours. Thus, 
the codeine-S-(-)-nornicotine and morphine-S-(-)-nornicotine codrugs should be absorbed 
intact from the intestine and reach the systemic circulation as a single molecular entity, 
while the 3-O-acetylmorphine-S-(-)-nornicotine codrug will undergo ester bond 
hydrolysis to produce morphine-S-(-)-nornicotine codrug in the GI tract. 
In rat plasma, no significant hydrolysis of the codeine-S-(-)-nornicotine and 
morphine-S-(-)-nornicotine codrugs was observed, while 3-O-acetylmorphine-S-(-)-
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nornicotine codrug underwent instantaneous hydrolysis of the O-acetyl moiety to produce 
morphine-S-(-)-nornicotine. 
  
4.3.3 Stability Study in Brain Homogenate 
  The stability study of the codrugs in brain homogenate was carried out over 8 hrs 
and samples were analyzed by HPLC–DAD assay. The data from the enzymatic 
hydrolysis study in brain homogenate indicates that the codrugs are stable in brain with 
respect to carbamate bond hydrolysis, and thus are not likely to undergo enzymatic 
hydrolysis in the brain to produce the parent drugs. In fact, no observable generation of 
the parent drugs occurred over the 8 hours of the study. 
 
4.4 Opioid-Ketamine/Norketamine Codrugs 
Three codrugs were synthesized in this series. The structures of the synthesized 
codrugs are illustrated in Fig 4.5. Codeine-norketamine and morphine-norketamine 
codrugs were analyzed for their stabilities under the same hydrolytic conditions. Since 
racemic ketamine and racemic norketamine were used for the synthesis of the codrugs, 
diasteromeric mixtures of the resultant codrugs were obtained and these diastereomeric 
mixtures were studied for in vitro stability. The codeine-ketamine codrug was not studied 
as this codrug contains a secondary carbamate and from the stability study of the opioid-
nornicotine codrugs it was found that secondary carbamate linkages are very stable in the 
studied hydrolytic conditions.  
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Fig. 4.5: Structures of opioid-norketamine codrugs analyzed for in vitro stability. 
 
4.4.1 HPLC Assay 
HPLC assays were developed for the study of the stability of the above codrugs. 
A Waters Symmetry ® C18 (5 µm, 3.9 x 150 mm) column protected with guard column 
(Nova-Pak® C18; 3.9 x 20 mm; 4µ) was used as the stationary phase; 0.16% aqueous 
solution of sodium heptane sulfonate (SHS) adjusted to pH 3.2 with 85% o-phosphoric 
acid (solvent A)/methanol (solvent B) was used as mobile phase. A 0.8 mL/min flow rate 
was used, and UV detection was carried out at 220 nm. Morphine was used as the internal 
standard in case of the codeine-norketamine codrug, and naltrexol was used as internal 
standard for the study of the morphine-norketamine codrug.  
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Fig. 4.6: HPLC Chromatogram of Morphine (IS), Codeine, Norketamine, and 
Norketamine-Codeine codrug (2 peaks for the 2 diastereomers) (in order of elution). 
The following gradient program was utilized for the codeine-norketamine codrug stability 
study: 
0-10 min: 46% solvent A 
10-13 min: 46% to 30% solvent A 
13-35 min: 30% solvent A 
35-38 min: 30% to 46% solvent A 
min0 5 10 15 20 25 30 35
mAU
0
50
100
150
200
250
 DAD1 A, Sig=220,4 Ref=360,100 (UJJWAL\NORKET_CODRUGS 2010-06-06 22-20-26\0606105.D)
 5.5
66
 6.5
67
 11.
250
 22.
193
 23.
221
204 
 
 
Fig. 4.7: HPLC Chromatogram of Morphine, Naltrexol (IS), Norketamine, and 
Norketamine-Morphine codrug (2 peaks for the 2 diastereomers) (in order of elution). 
 
A very similar isocratic HPLC assay was utilized for the stability study of the 
morphine-norketamine codrug utilizing a 0.8 mL/min flow rate and 44.5% composition 
of solvent A. 
 
4.4.2 Assay Validation  
Calibration curves were generated for each analyte and for each stability study. 
Table 4.2 summarizes the information regarding the linear range of each analyte. 
 
4.4.3 Chemical and Enzymatic Stability Study 
 Chemical and enzymatic stability studies on the codeine-norketamine and 
morphine-norketamine codrugs were carried out in vitro. Chemical hydrolysis was 
examined utilizing buffers at pH 1.3, 5.0, and 7.4, and enzymatic hydrolysis was 
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examined in simulated gastric fluid (SGF), simulated intestinal fluid (SIF), and 80% rat 
plasma and brain homogenate. Table 4.3 summarizes the results of these stability studies. 
Figure 4.3: Results of stability studies of opioid-norketamine codrugs. 
 Codeine-Norketamine Morphine-Norketamine 
pH 1.3 Stable Stable 
pH 5.0 Stable Stable 
pH 7.4 Stable Stable 
SGF Stable Stable 
SIF Stable Stable 
80% Rat Plasma Stable Stable 
Brain Homogenate Stable Stable 
 
Both the opioid-norketamine codrugs failed to produce the parent drugs in any of 
the hydrolytic conditions.The codeine-norketamine codrug contains a carbamate linkage 
between a primary amine and an allylic alcohol moiety. On the other hand, the morphine-
norketamine codrug has a carbamate linkage between a primary amine and a phenol. 
These types of carbamate linkages are expected to be more prone towards hydrolysis, but 
the two codrugs did not hydrolyze in either the enzymatic or the nonenzymatic 
conditions. Thus, it can be concluded that these opioid-ketamine/norketamine codrugs 
will likely not behave as codrugs in vivo; rather, they will act as stable hybrids of two 
parent analgesic agents (i.e. opioid agonist and NMDA receptor antagonist). 
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4.5 Codeine-Gabapentin Codrugs 
Four different codrugs were synthesized that incorporated codeine and gabapentin 
or prodrugs of gabapentin. The structures of the 4 codrugs are shown in Fig 4.8. The CG-
1 codrug contained an ester linkage between codeine and gabapentin moieties and could 
only be isolated in the form of the HCl salt. As discussed in Chapter 2, the design of the 
codrug may be problematic. The pKa of the amino group in CG-1 is expected be about 8 
to 8.5. Thus, in slightly basic condition (e.g. small intestine or physiological pH, but not 
in the stomach), a significant amount of the free amino group of the gabapentin moiety 
may be generated as a consequence of deprotonation which will lead to the formation of a 
five-membered cyclic carbamate derivative. The five-membered cyclic carbamate form 
of gabapentin is expected to be very stable, and will likely not hydrolyze back to 
gabapentin after cleavage of the inter drug ester linkage, but will form the parent drug 
codeine and a stable derivative of gabapentin.   
   
Fig. 4.8: Structures of the codeine-gabapentin codrugs analyzed for their in vitro 
stabilities. 
 
4.5.1 HPLC Assay 
To examine the above possibility, codrug CG-1 was synthesized and its stability 
was studied in pH 7.4 phosphate buffer. An HPLC assay was developed to separate 
morphine (IS), codeine and CG-1. A Waters Symmetry ® C18 (5 µm, 3.9 x 150 mm) 
column protected with a guard column (Nova-Pak® C18; 3.9 x 20 mm; 4µ) was used as 
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the stationary phase; 0.04% aqueous HFBA solution (solvent A)/0.04% 
heptafluorobutyric acid (HFBA) solution in Methanol (solvent B) was used as mobile 
phase. A 0.5 mL/min flow rate was used, and UV detection was carried out at 280 nm. 
 
 
Fig. 4.9: HPLC Chromatogram of Morphine, codeine, and CG-1 codrug. 
 
The 22 min time gradient program used for the analysis of the codeine-S-(-)-nornicotine 
codrug was as follows: 
0-1 min: 70% solvent A 
1-18 min: 70% to 28% solvent A 
18-18.1 min: 28% to 70% solvent A 
18.1-22 min: 70% solvent A 
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4.5.2 Assay Validation  
Calibration curves were generated for each analyte and for each stability study. 
Table 4.1 summarizes the information regarding the linear range of each analyte. 
 
4.5.3 Chemical Stability Study 
At physiological pH (7.4), significant hydrolysis of the CG-1 codrug was 
observed and the kinetics of codrug disappearance with concomitant appearance of 
codeine was confirmed by HPLC-DAD analysis. The disappearance of the CG-1 codrug 
was correlated with pseudo first order kinetics. The hydrolytic rate constant and half-life 
value of the CG-1 codrug were obtained by regression analysis from slopes of semi-
logarithmic plots of concentration versus time. Thus the codrug is hydrolyzed at a 
relatively fast rate in the small intestine to produce codeine and the five membered cyclic 
carbamate analog of gabapentin. 
From the previous hydrolytic studies of the carbamate codrugs, it can be predicted 
that codrug CG-2, which combines codeine and gabapentin via a carbamate linkage, will 
likely be resistant to hydrolysis. To evaluate this possibility, the CG-2 codrug was 
analyzed for stability under different hydrolytic conditions. An HPLC assay was 
developed to study the stability of the codrug. A Waters Symmetry ® C18 (5 µm, 3.9 x 
150 mm) column protected with a guard column (Nova-Pak® C18; 3.9 x 20 mm; 4µ) was 
used as the stationary phase; 0.16% aqueous solution of sodium heptane sulfonate (SHS) 
adjusted to pH 3.2 with 85% o-phosphoric acid (solvent A)/ methanol (solvent B) was 
used as mobile phase. A 0.8 mL/min flow rate was used, and UV detection was carried 
out at 220 nm. Morphine was used as the internal standard. 
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Fig. 4.10: HPLC Chromatogram of morphine, codeine, and CG-2 codrug (in order of 
elution). 
 
The following gradient program was used for the CG-2 codrug stability study: 
0-5.5 min: 47% solvent A 
5.5-8.5 min: 47% to 39% solvent A 
8.5-27 min: 39% solvent A 
27-30 min: 39% to 47% solvent A 
As predicted from the results of the previous stability studies the CG-2 carbamate 
codrug did not hydrolyze to produce the parent drugs codeine and gabapentin in any of 
the enzymatic or nonenzymatic solutions examined. 
Codrugs CG-3 and CG-4 were synthesized by combining amide protected and 
carbamate protected gabapentin with codeine via a more labile ester linkage. These two 
codrugs were expected to undergo hydrolysis in several enzymatic and nonenzymatic 
buffers. It was expected that the more labile ester bond would hydrolyze at the fastest rate 
to produce codeine and a prodrug of gabapentin, and then the more resilient amide or 
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carbamate pro-moiety would be hydrolyzed at a slower rate to produce gabapentin. Since 
gabapentin does not contain a chromophore, it was only possible to follow the initial ester 
hydrolysis step was by HPLC-DAD assay; the hydrolysis of the pro-moiety of gabapentin 
could not be followed. [A subsequent in vivo study was performed using an LC-MS/MS 
assay to analyze the complete hydrolytic pattern of the codrugs in the rat (discussed in 
next chapter)]. 
 
 4.5.4 HPLC assay 
Initially, HPLC assays were developed to study the hydrolytic reactions of the 
above codrug molecules. The following HPLC assay was used for the stability study of 
the CG-3 codrug. A Waters Symmetry ® C18 (5 µm, 3.9 x 150 mm) column protected 
with a guard column (Nova-Pak® C18; 3.9 x 20 mm; 4µ) was used as the stationary 
phase; /0.16% aqueous solution of sodium heptane sulfonate (SHS) adjusted to pH 3.2 
with 85% o-phosphoric acid (solvent A)/Methanol (solvent B) was used as mobile phase. 
A 0.8 mL/min flow rate was used, and UV detection was carried out at 220 nm. 
Morphine was used as the internal standard. 
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Fig. 4.11: HPLC Chromatogram of morphine (IS), codeine, and CG-3 codrug (in order of 
elution). 
 
The following gradient program was used for the CG-3 codrug stability study: 
0-6 min: 43% solvent A 
6-9 min: 43% to 31% solvent A 
9-20 min: 31% solvent A 
20-23 min: 31% to 43% solvent A 
For the hydrolytic study of the CG-4 codrug, the following HPLC assay was used. 
A Waters Symmetry ® C18 (5 µm, 3.9 x 150 mm) column protected with a guard column 
(Nova-Pak® C18; 3.9 x 20 mm; 4µ) was used as the stationary phase; 0.04% aqueous 
HFBA solution (solvent A)/ 0.04% heptafluorobutyric acid (HFBA) solution in Methanol 
(solvent B) was used as mobile phase. A 0.5 mL/min flow rate was used, and UV 
detection was carried out at 280 nm. Morphine was used as an internal standard. 
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Fig. 4.12: HPLC Chromatogram of morphine (IS), codeine, and CG-4 codrug (in order of 
elution). 
 
The 20 min time gradient program used for CG-4 codrug was as follows: 
0-0.3 min: 65% solvent A 
0.3-10 min: 65% to 13% solvent A 
10-15 min: 13% solvent A 
15-15.1 min: 13% to 65% solvent A 
15.1-20 min: 65% solvent A 
 
4.5.5 Assay Validation  
Calibration curves were generated for each analyte and for each stability study. 
Table 4.1 summarizes the information regarding the linear concentration range for each 
analyte.  
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Table 4.4: Rate constants for hydrolysis of codeine-gabapentin codrugs. 
 CG-1 (hr
-1
) CG-2 CG-3 (hr
-1
) CG-4 (hr
-1
) 
pH 1.3 Not performed Stable 0.0018 ± 0.0002  0.0018 ± 0.0002 
pH 5.0 Not performed Stable 0 0 
pH 7.4 0.2220 ± 0.0003 Stable 0.0018 ± 0.0001  0.0012 ± 0.0002 
SGF Not performed Stable 0.0020 ± 0.0003 0.0022 ± 0.0001 
SIF Not performed Stable 0.0041 ± 0.0004 0.0048 ± 0.0002 
80% Rat 
Plasma 
Not performed Stable 0.0123 ± 0.0025  0.0134 ± 0.0021 
Brain 
Homogenate 
Not performed Stable 0.0052 ± 0.0019 0.0060 ± 0.0011 
 
4.5.6 Results 
Results from stability studies performed on the codeine-gabapentin codrugs are 
summarized in Table 4.4. Both CG-3 and CG-4 codrugs showed improved hydrolytic 
profiles compared to any of the other synthesized codrugs. Both codrugs underwent ester 
bond hydrolysis in 80% rat plasma to produce codeine and a prodrug of gabapentin. This 
data signifies that in the systemic circulation these codrugs will be cleaved to produce 
either parent drugs or parent drugs attached to a pro-moiety. The rates of hydrolysis in 
80% rat plasma were comparatively slow, which may result in CG-3 and CG-4 having 
prolonged effects (sustained release). In addition to hydrolysis in 80% rat plasma, CG-3 
and CG-4 were also hydrolyzed in pH 1.3 and pH 7.4 buffers and in SGF and SIF. These 
observations are not ideal for codrugs as it is not desirable to have significant hydrolysis 
of the codrugs in GI tract. It can be seen that these rates of hydrolysis in the above 
mentioned enzymatic and nonenzymatic conditions are very slow and the half-lives range 
from 144.38 hr to 577.5 hr. Since the mean residence time of a drug in the stomach is 
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roughly 30 min to 1 hr, it can be concluded that codrugs CG-3 and CG-4 will practically 
remain unhydrolyzed in stomach before being absorbed into systemic circulation. The 
same conclusion can be drawn in the case of probable hydrolysis of the codrugs in 
intestine, by observing the large half-life values of the codrugs at pH 7.4 and in SIF. It 
can also be seen that the CG-3 and CG-4 codrugs are hydrolyzed by brain homogenate at 
a relatively slow rate. This observation indicates that if the codrug molecules enter brain 
as a single chemical entity, they will be slowly hydrolyzed over time by enzymes present 
in brain to produce the parent drugs. 
Results of the comprehensive stability study of the synthesized codrugs in 
different nonenzymatic aqueous buffers and biological media demonstrate that carbamate 
linkages are not always ideal in codrug design. In literature codrugs and prodrugs 
containing carbamate linkage have been reported, but most of them are either a type of 
activated carbamate linkage, or a very simple carbamate of a primary amine and a 
primary alcohol (Das et al., 2010). Since the carbamate linked codrugs did not show any 
sign of hydrolysis in enzymatic and nonenzymatic media, it can be concluded that these 
codrugs will not cleave to the respective parent drugs inside the body, but will rather 
behave as stable hybrids of the two parent analgesic drug molecules. On the other hand, 
ester-linked codrugs showed promising hydrolytic behavior. Ester linkages were cleaved 
in the plasma to produce parent drugs at a slow rate, which allows these codrugs to act as 
a chemical reservoir of the parent drugs for a sustained period of time. Though the ester 
linked codrugs were hydrolyzed in both acidic and basic pH conditions, the rates of 
hydrolysis were relatively too slow to be significant. Thus, ester linked codrugs CG-3 and 
CG-4 are predicted to be stable enough in the GI tract when administered orally to be 
absorbed from GI tract as a single chemical entity. Hydrolysis of the ester linkages in 
80% rat plasma showed that such codrugs would hydrolyze in systemic circulation to 
produce codeine and a prodrug of gabapentin. 
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Chapter 5 
Pharmacokinetic Analysis of the Codrugs 
 
5.1 Introduction 
Pharmacokinetics is the study of the time course of drug concentration in different 
body compartments, such as plasma, blood, urine, cerebrospinal fluid, and tissues, and 
incorporates the processes of absorption, distribution, metabolism and excretion (ADME) 
after a specific route of administration of a drug (Smith et al., 2001).  
The drug can enter the body in a variety of ways. Drugs are mostly given orally 
for reasons of convenience and patient compliance. If the drug has been administered 
orally, then it first enters the gastrointestinal tract, and gets absorbed through the 
gastrointestinal mucosal wall into the bloodstream. It is then shunted via the portal vein 
through the liver, where the “first pass effect” takes place, and it then reaches the blood 
circulation. The first-pass effect is a phenomenon of drug metabolism whereby the 
concentration of a drug is immensely reduced before it reaches the systemic circulation. It 
is a fraction of the administered drug that gets absorbed, which mainly takes place in liver 
and gut wall. Therefore, the oral delivery of a drug involves an additional absorption step. 
The percentage of the administered dose reaching the circulation as the free drug is called 
the bioavailability of the drug. The drug then gets distributed to various tissues and 
organs in the body. The extent of this drug distribution depends on the structural and 
physicochemical properties of the drug. Some drugs might enter the brain and the central 
nervous system by crossing the blood–brain barrier. Finally, the drug will bind to its 
molecular target, for example, a receptor or an ion channel, and exert its anticipated 
action. If the drug is injected directly into the bloodstream (e.g. by the intravenous route), 
then it is totally available for distribution to the tissues. But if it is administered orally, 
then its bioavailability will usually be less than 100% (Smith et al., 2001).  
Once the drug is in the systemic circulation, a portion of it is available to illicit its 
pharmacodynamic effect; the rest may bind to plasma proteins in an inactive reversible 
protein-drug complex. Binding to plasma proteins is sometimes advantageous since the 
drug is continuously freed from the protein-drug complex and this can result in a 
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extended drug action (Smith et al., 2001). The unbound drug follows the concentration 
gradient and gets distributed into the peripheral tissues. These tissues may contain 
specific or non-specific binding sites. The non-specific binding sites can act as reservoirs 
for the drug molecule. This “total volume of distribution” determines the equilibrium 
concentration of a drug after administration of a specific dose (van de Waterbeemd and 
Gifford, 2003).  
Pharmacokinetic parameters are derived from the measurement of drug 
concentrations in bloodstream or plasma after administration. The key pharmacokinetic 
parameters are Volume of Distribution (Vd), Clearance (Cl), Half-life (t1/2) and Oral 
Bioavailability (F).  
 
Volume of Distribution (Vd) -- Volume of Distribution is defined as the apparent space or 
volume into which a drug distributes itself. It is a theoretical concept that relates the 
administered dose with the actual initial concentration (C0) present in the systemic 
circulation. If a drug is highly lipophilic in nature, then the drug will have a very high 
volume of distribution, because the drug specifically or non-specifically binds to tissues 
and stays there (Mehvar, 2004). 
 
Vd = Dose/C0 
 
Clearance (Cl) --Clearance of a drug from the body mainly takes place via the liver 
(hepatic clearance or metabolism, and biliary excretion) and the kidney (renal excretion).  
 
By plotting the plasma concentration against time, the area under the curve (AUC) relates 
to dose, bioavailability (F) and clearance. 
 
AUC = F x Dose/Cl 
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Half-life (t1/2) --Half-life is the time taken for the drug concentration in the plasma to be 
reduced by 50%. It is a function of the clearance and volume of distribution, and 
determines how often a drug needs to be administered. 
 
t1/2 = 0.693 Vd/Cl 
 
Intravenous (IV) bolus dosing (i.e, the entire drug dose is given as a rapid injection) 
captures the pure distribution and elimination processes. 
In the “first pass effect” the liver bio-transforms the drug into active or inactive 
metabolites, which can then be more easily excreted. Prodrugs are inactive chemical 
entities that get activated only after they are metabolized to an active drug. This is often a 
strategy utilized to improve pharmacokinetic properties and drug-likeness. Some drugs 
are excreted in the bile and eventually may pass out of the body in the feces, while some 
are filtered by kidney, where a portion undergoes reabsorption, with the remainder being 
excreted in the urine. Smaller amounts of drug are excreted in the tears, breast milk and 
sweat (Dingemanse and Dingemanse, 2007). 
 
5.2 Pharmacokinetic Profile of Codeine and Gabapentin  
Codeine is mostly metabolized in liver to seven metabolites: codeine-6-O-
glucuronide, norcodeine, norcodeine-glucuronide (6-O-), morphine, morphine-3-O-
glucuronide, morphine-6-O-glucuronide, and normorphine. It has been hypothesized that 
codeine exerts its moderate analgesic potency through partial biotransformation to 
morphine via oxidative N-demethylation. Apart from morphine, two other metabolites of 
codeine, morphine-6-O-glucuronide and normorphine were found to be analgesic. 
Morphine-6-O-glucuronide was found to be a much stronger analgesic than morphine 
(Thorn, 2009). 
218 
 
Orally administered gabapentin is absorbed slowly with maximum plasma 
concentration attained within 3-4 hours (Bockbrader et al., 2010). Plasma concentrations 
of gabapentin do not increase proportionally with increasing oral dose. The 
bioavailability of gabapentin is dose-dependent and the absolute bioavailability drops 
from 60% to 33% as the dosage increases from 900 to 3600 mg/day in humans (Eckhardt 
et al., 2000). Gabapentin does not bind to plasma proteins, and is excreted renally. 
Gabapentin is metabolized to N-methyl gabapentin in dogs. In mice, rats and humans it 
undergoes negligible metabolism, and the metabolites account for less than 1% of the 
administered dose (Rose and Cam, 2002). 
Pharmacokinetic studies on selected codrugs were performed in cooperation with 
Dr. Zaineb Albayati, Dr. Manjula Sunkara, and Mr. John May. 
 
5.3 Materials and Methods 
5.3.1 Chemicals and Reagents 
S-(-)-Nornicotine, 3-O-acetylmorphine-S-(-)-nornicotine codrug, morphine-S-(-)-
nornicotine codrug, CG-3 (amide protected gabapentin-codeine codrug) and CG-4 
(carbamate protected gabapentin-codeine codrug) were synthesized in the laboratory (see 
Chapter 2 for details). The reagents and buffer salts used in this study were of HPLC 
grade or equivalent quality. Acetonitrile and potassium chloride were obtained from 
Thermo Fisher Scientific (Pittsburgh, PA). Heparin sodium injection, 10,000 USP 
units/ml, was purchased from Baxter Healthcare Corporation (Deerfield, IL). Nembutal 
sodium (pentobarbital sodium injection, USP) was obtained from Abbott Laboratories 
(North Chicago, IL).  
 
5.3.2 Animals 
 All procedures involving animals were performed in compliance with the 
guidelines of the University of Kentucky Institutional Animal Care and Use Committee 
established by the National Institutes of Health‟s Guide for the Care and Use of 
Laboratory Animals (1996). Male Sprague-Dawley rats (200–250 g) were obtained from 
Harlan (Indianapolis, IN) and housed two per cage with ad libitum access to food and 
water in the Division of Laboratory Animal Resources at the University of Kentucky 
219 
 
College of Pharmacy. Body weights at the time of dosing were 280-360 g. Rats were 
anesthetized with pentobarbital (40 mg/kg i.p.) and surgically implanted with jugular and 
femoral vein cannulas for i.v. drug dosing and blood sampling, respectively. For the first 
3 to 4 days after surgery, the rats were observed for signs of infection at the surgical sites, 
yellowing of hair and hair texture, presence of blood around the eyes or nose, indications 
of loss of appetite, and decreased or absent fecal activity before the start of  i.v. dosing.  
 
5.4 In vivo Pharmacokinetic Study of 3-O-Acetylmorphine-S-(-)-Nornicotine Codrug 
5.4.1 Instrumentation 
Samples were analyzed for analyte-specific (149 m/z to 130 m/z, S-(-)-
nornicotine; 328 m/z to 211 m/z, 3-O-acetylmorphine; 460 m/z to 268 m/z, morphine-S-(-
)-nornicotine; 286 m/z to 201 m/z morphine; and 502 m/z to 310 m/z, 3-O-
acetylmorphine-S-(-)-nornicotine) and internal standard-specific (342 m/z to 324 m/z, 
naltrexone) transitions by LC/MS/MS utilizing reverse-phase chromatography and 
positive-mode ionization. The instrumentation consisted of a Varian LC system (ProStar 
210 pumps, Prostar 410 autoinjector) connected through an ESI source to a Varian 1200L 
triple quadrupole mass spectrometer with all components controlled by a Varian MS 
Workstation version 6.42. Individual analyte-dependent ESI-(+)-MS/MS parameters were 
optimized for signal intensity. 
  
5.4.2 HPLC and Mass Spectrometric Conditions 
 Individual analyte-dependent ESI-(+)-MS/MS parameters were optimized for 
signal intensity. These optimized parameters were subsequently used in the analysis of 
biological samples (CE = 11 V for S-(-)-nornicotine, 16.5 V for morphine, 22 V for 3-O-
acetylmorphine, 15.5 V for naltrexone, 19.5 V for morphine-S-(-)-nornicotine, and 20 V 
for 3-O-acetylmorphine-S-(-)-nornicotine). Briefly, 10 µL of the biological sample was 
injected onto a guard column protected (Nova-Pak® C18; 3.9 x 20 mm; 4µ) Nova-Pak® 
C18 analytical column (3.9 x 150 mm; 4 um). Analytes were eluted at 11.12 min 
(morphine), 13.36 min (S-(-)-nornicotine), 13.77 min (naltrexone, internal standard), 
14.38 min (3-O-acetylmorphine), 15.12 min (morphine-S-(-)-nornicotine), and 16.24 min 
(3-O-acetylmorphine-S-(-)-nornicotine) using water containing 0.04% HFBA (solvent A) 
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and methanol containing 0.04 % HFBA (solvent B), using a gradient program and a 0.3 
mL/min flow rate. The 36 min gradient program began with 75:25 solvents A: B for 0.5 
min followed by a 21.5 min linear ramp to 10:90 solvents A: B. This percentage was held 
constant for 4 min, and then returned to 75:25 solvents A:B over a 3 min linear ramp; and 
then held at 75:25 solvents A:B for an additional 9 min. Argon was used as a collision 
gas at 2.0 m Torr, and nitrogen was used as a drying gas at 300 °C. The needle voltage 
was 5000 V, the shield voltage was 600 V, and the capillary voltage was 40 V.  
 
5.4.3 Plasma Pharmacokinetics 
It was observed in in vitro stability studies performed on the 3-O-acetylmorphine-
S-(-)-nornicotine codrug, that the carbamate linkage joining the two parent drugs did not 
cleave under any enzymatic or non-enzymatic conditions. Thus, the 3-O-acetylmorphine-
S-(-)-nornicotine codrug was predicted to be quite stable in the GI tract as well as in 
systemic circulation, and would likely not hydrolyze to the parent drugs. This prediction 
was proven in a quick pharmacokinetic study. 3-O-Acetylmorphine-S-(-)-nornicotine 
codrug solution was prepared in 15% PEG-400 solution in saline and filtered through a 
0.2-µm filter. The animal was administered with 8 mg/kg oral dose of the codrug. Dose 
and route of administration were chosen on the basis of studies that evaluated the 
analgesic effect of 3-O-acetylmorphine-S-(-)-nornicotine codrug (Chapter 3). Blood 
samples (0.2 mL) were obtained at 5, 15, 35, 45 min, 1, 2, 4, 7, 10, and 26 hrs after oral 
dosing. The withdrawn blood was replaced with heparinized saline (0.2 mL). Blood 
samples were centrifuged at 1200 g for 15 min, and the plasma was separated. The 
separated plasma was frozen immediately on dry-ice and stored at −80 °C prior to 
analysis.  
 
5.4.4 Extraction Procedure 
 To isolate the analytes from rat plasma, 50 µL of plasma was transferred to 
polypropylene tubes to which 10 µl of working internal standard solution was added 
followed by vortexing for 1 min. 300 µL of acetonitrile was then added for 
deproteinization. The samples were then centrifuged for 15 min at 8000 rpm.  The 
supernatant was transferred into silylated micro-serts and evaporated to dryness under 
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nitrogen gas at 37 °C. Following drying, the residue was dissolved in 80 µl of mobile 
phase by vortexing for 1min; 10 µl of the sample was then injected into the LC-MS/MS 
unit. 
 
Fig. 5.1: Chromatograms of S-(-)-nornicotine, morphine, 3-O-acetylmorphine, naltrexone 
(IS), morphine-S-(-)-nornicotine, and 3-O-acetylmorphine-S-(-)-nornicotine (top to 
bottom order). 
222 
 
 
The in vivo study of 3-O-acetylmorphine-S-(-)-nornicotine codrug indicated that 
the carbamate linkage of the codrug did not undergo hydrolysis. The only analyte that 
was observed in the collected blood samples was the morphine-S-(-)-nornicotine hybrid 
resulting from O-deacetylation of the administered codrug. Thus, the predictions 
regarding in vivo stability of the 3-O-acetylmorphine-S-(-)-nornicotine codrug were 
correct. Under in vivo hydrolytic conditions, 3-O-acetylmorphine-S-(-)-nornicotine 
codrug exhibited only ester hydrolysis of the O-acetyl moiety and no evidence of 
carbamate bond hydrolysis was demonstrated.  
 
 
Fig. 5.2: AUC for the morphine-S-(-)-nornicotine codrug versus time plot after oral 
administration of O-acetylmorphine-S-(-)-nornicotine codrug. 
 
5.5 In vivo Pharmacokinetic Study N-Acetamidogabapentin-Codeine (CG-3) Codrug 
5.5.1 Instrumentation 
Samples were analyzed for analyte-specific (172 m/z to 154 m/z, gabapentin; 214 
m/z to 154 m/z, N-acetamidogabapentin; 300 m/z to 215 m/z, codeine; 286 m/z to 201 
m/z morphine, and 495 m/z to 282 m/z N-acetamidogabapentin-codeine (CG-3) codrug 
and internal standard-specific (342 m/z to 324 m/z, naltrexone) transitions by LC/MS/MS 
utilizing reverse-phase chromatography and positive-mode ionization. The 
instrumentation consisted of a Varian LC system (ProStar 210 pumps, Prostar 410 
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autoinjector) connected through an ESI source to a Varian 1200L triple quadrupole mass 
spectrometer with all components controlled by a Varian MS Workstation version 6.42. 
Individual analyte-dependent ESI-(+)-MS/MS parameters were optimized for signal 
intensity. 
 
5.5.2 HPLC and Mass Spectrometric Conditions 
 Individual analyte-dependent ESI-(+)-MS/MS parameters were optimized for 
signal intensity. These optimized parameters were subsequently used in the analysis of 
biological samples (CE = 7.5 V for gabapentin, 9.5 V for codeine, 7 V for N-
acetamidogabapentin, 8 V for naltrexone, 7.5 V for morphine, and 18.5 V for CG-3. 
Briefly, 10 µL of the biological sample was injected onto a guard column protected 
(Nova-Pak® C18; 3.9 x 20 mm; 4µ) Nova-Pak® C18 analytical column (3.9 x 150 mm; 4 
um). Analytes were eluted at 6.55 min (morphine), 9.87 min (codeine), 10.49 min 
(naltrexone, internal standard), 13.59 min (gabapentin), 19.52 min (N-
acetamidogabapentin), and 20.12 min (CG-3). 10 mM aqueous ammonium formate 
solution adjusted to pH 3.3 with formic acid (solvent A) and methanol containing 10 mM 
ammonium formate and formic acid (solvent B) were used as the mobile phases. A 
gradient program with 0.3 mL/min flow rate was used for the LC-MS/MS assay. The 36 
min gradient program began with 75:25 solvents A: B for 0.5 min followed by a 21.5 min 
linear ramp to 10:90 solvents A: B. This percentage was held constant for 4 min, and then 
returned to 75:25 solvents A:B over a 3 min linear ramp; and then held at 75:25 solvents 
A:B for an additional 9 min. Argon was used as a collision gas at 2.0 m Torr, and 
nitrogen used as a drying gas at 300 °C. The needle voltage was 5000 V, the shield 
voltage was 600 V, and the capillary voltage was 40 V. 
 
5.5.3 Plasma Pharmacokinetics 
CG-3 codrug was dissolved in a saline solution containing 15% concentration of 
PEG-400 and filtered through a 0.2-µm filter. A 10 mg/kg oral dose was administered to 
the animals. Blood samples (0.2 mL) were obtained at 5, 15, 30 min, 1, 2, 4, 6, 10, 11, 
and 29 hrs after oral dosing. The withdrawn blood was replaced with heparinized saline 
(0.2 mL). Blood samples were centrifuged at 1200 g for 15 min, and the plasma was 
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separated. The separated plasma was frozen immediately on dry-ice and stored at −80 °C 
prior to analysis. 
5.5.4 Standard Curves and Quality Control Validation Solutions  
Stock solutions of the analytes and internal standard (naltrexone) were prepared in 
methanol. Two stock solutions were prepared; one for generating the standard curve, and 
a second one for quality control (QC) and method validation. A standard curve with eight 
different concentration points was prepared for the analysis of unknown samples. 
Standard curve samples were prepared by spiking blank plasma with working solutions of 
all the different analytes. Calibration curves were obtained using quadratic least-squares 
regression of AUC ratio (analyte peak AUC/internal standard peak AUC) versus drug 
concentrations. The amounts of codrug, or parent drugs, were then determined. Three 
quality control samples with different concentrations were prepared to check the 
sensitivity of the instrument. The three concentrations chosen were: one towards the 
higher end of the standard curve concentrations, one towards the middle, and the third 
one towards the lower end of the standard curve concentrations.  
 
5.5.5 Extraction Procedure 
 To isolate the analytes from plasma, 50 µL of plasma was transferred to 
polypropylene tubes to which had been added 10 µl of working internal standard solution 
followed by vortexing for 1 min. 300 µL of acetonitrile were then added for 
deproteinization. The samples were then centrifuged for 15 min at 8000 rpm.  The 
supernatant was transferred into silylated micro-serts and evaporated to dryness under 
nitrogen gas at 37 °C. Following drying, the residue was dissolved in 80 µl of mobile 
phase by vortexing for 1 min; 10 µl of the sample was then injected onto the LC-MS/MS 
unit. 
   
5.5.6 Assay Validation  
Blank plasma samples were extracted and analyzed by reverse phase HPLC for 
potential interfering peaks within the range of the retention time for analytes and the 
internal standard, naltrexone. An 8-point calibration curve for each analyte was 
generated. Table 6.1 summarizes the information regarding the standard curves. 
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Table 5.1: Linear ranges of analytes in the LC-MS/MS assay. 
Analyte  Linear Range R2 
Morphine  20-500 ng/mL 0.9999 
Codeine 2-500 ng/mL 0.9997 
Gabapentin  2-500 ng/mL 0.9992 
N-acetylgabapentin 0.5-500 ng/mL 0.9986 
CG-3 0.5-500 ng/mL 0.9992 
 
5.5.7 Results 
Mean concentration versus time profile of the codrug and parent drugs is plotted 
in Fig. 6.3. It can be noticed from the concentration versus time profile that the ester 
linkage in the codrug undergoes hydrolysis to produce codeine and N-acetylgabapentin, 
but the amide pro-moiety is not cleaved from the gabapentin derivative to produce 
gabapentin. The codrug hydrolysis profile was studied for a time period of 29 hrs, but no 
gabapentin formation was observed over that time period. It can also be noticed that at 
any time point in the concentration profile, codrug is present at a higher concentration 
than codeine or N-acetylgabapentin. Thus, the ester bond hydrolysis is likely being very 
slow in both plasma and GI tract, and the N-acetylgabapentin product is stable to 
hydrolytic cleavage.  
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Fig. 5.3: Mean concentrations of the analytes versus time plot after oral dosing of CG-3 
codrug. 
 
5.6 In vivo Pharmacokinetic Study of N-Ethoxycarbonylgabapentin-Codeine (CG-4) 
Codrug 
5.6.1 Instrumentation 
Samples were analyzed for analyte-specific (172 m/z to 154 m/z, gabapentin; 244 
m/z to 154 m/z, N-ethoxycarbonylgabapentin; 300 m/z to 152 m/z, codeine; 286 m/z to 
152 m/z morphine, and 525 m/z to 282 m/z N-ethoxycarbonylgabapentin-codeine (CG-4) 
codrug and internal standard-specific (342 m/z to 324 m/z, naltrexone) transitions by 
LC/MS/MS utilizing reverse-phase chromatography and positive-mode ionization. The 
instrumentation consisted of a Varian LC system (ProStar 210 pumps, Prostar 410 
autoinjector) connected through an ESI source to a Varian 1200L triple quadrupole mass 
spectrometer with all components controlled by a Varian MS Workstation version 6.42. 
Individual analyte-dependent ESI-(+)-MS/MS parameters were optimized for signal 
intensity. 
  
5.6.2 HPLC and Mass Spectrometric Conditions 
 Analysis of codeine, N-ethoxycarbonylgabapentin, gabapentin, CG-4 codrug, 
morphine and naltrexone was carried out using a Shimadzu UFLC coupled with an AB 
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Sciex 4000-Qtrap hybrid linear ion trap triple quadrupole mass spectrometer in multiple 
reaction monitoring (MRM) mode. Naltrexone was used as an internal standard. Codeine, 
N-ethoxycarbonyl- gabapentin, gabapentin, CG-4 codrug, morphine and naltrexone were 
separated using a Zorbax Eclipse XDB C18 column, 5 µM, 4.6 X 150 mm column 
(Agilent). The mobile phase consisted of water containing 0.1% TFA (solvent A) and 
acetonitrile containing 0.1% TFA (solvent B). Analysis of these compounds was 
achieved by starting with 10 % solvent B for an initial 1 min, changing from 10% B to 
100 % B over the next 7 min, and maintained at 100% B for the last 4 min. The HPLC 
column was equilibrated back to the initial conditions over 3 min. The flow rate was 0.5 
mL/min with a column temperature of 30 °C. The sample injection volume was 10 µL. 
The mass spectrometer was operated in the positive electrospray ionization mode with 
optimal ion source settings determined by synthetic standards of codeine, N-
ethoxycarbonylgabapentin, gabapentin, CG-4 codrug, morphine and naltrexone with a 
curtain gas of 20 psi, ion spray voltage of 5500 V, ion source gas1/gas2 of 40 psi and 
temperature of 550 °C.  
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Table 5.2: Optimal ion source settings for each MRM transition monitored.  
  Q1 Q3 
DP 
(volts) 
CE 
(volts) 
CXP 
(volts) 
Codeine 300.197 152.2 56 87 8 
  300.197 165.2 56 59 8 
N-ethoxycarbonylgabapentin 244.081 154.1 46 27 8 
  244.081 226.1 46 13 14 
Gabapentin 172.118 154.1 51 21 8 
  172.118 137.1 51 25 6 
Gabapentin-Codeine Codrug 
(CG-4) 525.298 282 151 45 18 
  525.298 154.1 151 65 8 
Morphine 286.152 152.2 116 85 8 
  286.152 201 116 37 12 
Naltrexone 342.123 324.1 96 31 16 
  342.123 270.1 96 37 16 
N-ethoxycarbonylgabapentin 244.081 180.1 46 21 10 
  244.081 198.1 46 19 10 
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Fig. 5.4: LC-MS/MS chromatograms of morphine, codeine, naltrexone, gabapentin, N-
ethoxycarbonylgabapentin (gabapentin carbamate), and CG-4 codrug. 
 
5.6.3 Plasma Pharmacokinetics 
15% solution of PEG-400 in saline was used as the vehicle. The CG-4 codrug was 
dissolved in the vehicle and filtered through a 0.2-µm filter. The animals were 
administered with 12.5 and 25 mg/kg oral doses and 1 mg/kg iv dose. Blood samples (0.2 
mL) were obtained at 5, 15, 30 min, 1, 2, 4, 6, 9, 10, and 24 hrs after oral dosing and at 5, 
15, 30 min, 1, 2, 3, 5, 7, and 9 hrs after iv dosing. The withdrawn blood was replaced 
with heparinized saline (0.2 mL). Blood samples were centrifuged at 1200 g for 15 min, 
and the plasma was separated. The separated plasma was frozen immediately on dry-ice 
and stored at −80 °C prior to analysis. 
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5.6.4 Standard Curve and Quality Control Validation Solutions  
Stock solutions of the analytes and internal standard (naltrexone) were prepared in 
methanol. Two stock solutions were prepared; one for generating the standard curve, and 
a second one for quality control (QC) and method validation. A standard curve with eight 
points was prepared for the analysis of unknown samples. Standard curve samples were 
prepared by spiking blank plasma with working solutions of all the different analytes. 
Calibration curves were obtained using quadratic least-squares regression of AUC ratio 
(analyte peak AUC/internal standard peak AUC) versus drug concentrations. The 
amounts of codrug, or parent drugs, were then determined. Three quality control samples 
with different concentrations were prepared to check the sensitivity of the instrument. 
The three concentrations chosen were: one towards the higher end of the standard curve 
concentrations, one towards the middle, and the third one towards the lower end of the 
standard curve concentrations.  
 
Table 5.3: Linear ranges of the analytes in standard curves. 
Analyte  Linear Range R2 
Morphine  0.02-10 µM 0.9998 
Codeine 0.005-10 µM 0.9998 
Gabapentin  0.1-10 µM 0.9961 
N-ethoxycarbonylgabapentin 0.01-10 µM 0.9970 
CG-4 0.005-10 µM 0.9971 
 
5.6.5 Extraction Procedure 
  To isolate the analytes from plasma, 125 µL of plasma was transferred to 
polypropylene tubes to which 50 µL of working internal standard solution was added 
followed by vortexing for 1 min. 700 µL of acetonitrile was added for deproteinization. 
The samples were then centrifuged for 15 min at 8000 rpm.  The supernatant was 
transferred into silylated micro-serts and evaporated to dryness under nitrogen gas at 37 
°C. Following drying, the residue was dissolved in 50 µl of mobile phase by vortexing for 
1min; 10 µl of the sample was then injected onto the LC-MS/MS unit. 
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5.6.6 Assay Validation  
Blank plasma samples were extracted and analyzed by reverse phase HPLC for 
potential interfering peaks  within  the  range of  the  retention  time for  analytes and  the  
internal  standard, naltrexone. 
 
5.6.7 Results 
The mean concentration versus time profiles for 12.5 and 25 mg/kg oral doses and 
1 mg/kg iv dose of the codrug are shown in Figs. 6.5, 6.6, and 6.7. It can be noticed that 
in all of the oral and iv doses, the N-ethoxycarbonylgabapentin-codeine codrug (CG-4) is 
hydrolysed to codeine and N-ethoxycarbonylgabapentin (a prodrug of gabapentin). The 
rate of hydrolysis of the ester linkage joining the two parent drugs is slow, and the 
hydrolysis is not complete, as it can be noticed that at all time points CG-4 codrug is 
present in the plasma. These data also show a prolonged release of the parent drugs from 
the codrug over time. It can further be observed that the hydrolysis of the pro-moiety in 
the N-ethoxycarbonylgabapentin product is very slow and the concentration of 
gabapentin observed in the plasma is low. Along with the codrug, codeine, N-
ethoxycarbonylgabapentin, and gabapentin, presence of morphine can also be observed in 
the plasma samples from orally dosed rats. It has already been reported in literature that 
in the liver codeine is metabolized to morphine to some extent (Thorn, 2009). Morphine 
was not observed in the plasma samples of the rats that had been administered codrug via 
the iv route since the codrug and codeine do not get exposed to the liver enzymes.  
The pharmacokinetic parameters for codeine, N-ethoxycarbonylgabapentin, 
gabapentin, CG-4 codrug, and morphine are listed in Table 6.4. Following the oral 
administration of 25 and 12.5 mg/kg doses of codrug CG-4, plasma concentration of the 
codrug reached a maximum within 3 hours for both oral doses. Plasma concentrations of 
codeine, N-ethoxycarbonylgabapentin, gabapentin, and morphine reached the maxima at 
a later time, due to slow hydrolysis of the ester and the even slower hydrolysis of the 
carbamate moiety. The data clearly show a dose-dependent relationship, since the AUC 
for the codrug, as well as for the parent drugs, increases with increasing doses of codrug. 
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Fig. 5.5: Mean concentrations of the analytes versus time plot after administration of 25 
mg/kg oral dose of CG-4 codrug. 
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Fig. 5.6: Mean concentrations of the analytes versus time plot after administration of 12.5 
mg/kg oral dose of CG-4 codrug. 
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Table 5.4: Pharmacokinetic parameters of the codrug and parent drugs. 
Analyte Dose 
(mg/kg) 
AUC 
(hr*mg/mL) 
Tmax (hr) Cmax (mg/mL) T1/2 (hr) 
CG-4 Codrug 25 3.72 ± 1.15 2.67 ± 0.94 0.71 ± 0.09 1.88 ± 0.86 
12.5 1.65 ± 0.14 3.00 ± 2.16 0.24 ± 0.02 3.62 ± 2.50 
Codeine 25 0.58 ± 0.09 2.67 ± 0.94 0.08 ± 0.01 3.85 ± 1.11 
12.5 0.14 ± 0.02 3.33 ± 1.89 0.020 ± 0.003 8.88 ± 7.08 
N-
ethoxycarbonylgabapentin 
25 3.93 ± 0.64 2.98 ± 1.76 0.67 ± 0.26 5.40 ± 0.71 
12.5 2.47 ± 0.83 4.08 ± 2.44 0.26 ± 0.04 5.75 ± 0.48 
Gabapentin 25 0.28 ± 0.06 7.00 ± 1.41 0.04 ± 0.01 4.65 ± 2.67 
12.5     
Morphine 25 0.27 ± 0.03 2.67 ± 0.94 0.04 ± 0.01 3.73 ± 0.82 
12.5 0.07 ± 0.01 8.33 ± 1.70 0.0102 ± 
0.0004 
4.48 ± 2.91 
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Fig. 5.7: Mean concentrations of the analytes versus time plot after administration of 1 
mg/kg i.v. dose of CG-4 codrug. 
 
5.6.8 Bioavailability 
Bioavailabilities of codeine and gabapentin in rats are already reported in 
literature. Codeine has an oral bioavailability of 2.9 ± 1.4% (Holtman et al., 2006) and 
gabapentin has a dose-dependent oral bioavailability (Bockbrader et al., 2010). The oral 
bioavailability in rats after administration of gabapentin HCl salt was determined (Cundy 
et al., 2004) to be 83.8 ± 10.1 % at low dose (25 mg/kg) but decreased significantly to 
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47.5 ± 7.72 % at 200 mg/kg dose. This is explained by the saturation of the active 
transport pathway responsible for the absorption of gabapentin (Cundy et al., 2004). The 
clinical pharmacokinetics of gabapentin has also been studied in healthy volunteers and 
patients with epilepsy. Gabapentin oral bioavailability was found to be dose-dependent in 
humans and decreases from an average of 60% at a 300 mg dose to about 35% or less at 
doses used to treat neuropathic pain (Eckhardt et al., 2000). The reason for the decrease 
in oral bioavailability with increasing dose is believed to be the same as observed in rats, 
i.e. saturation of absorption pathways. The absorption pathway for gabapentin apparently 
achieves saturation at doses normally used to treat neuropathic pain. As a consequence, 
the plasma concentration of gabapentin in patients receiving Neurontin (brand name of 
gabapentin in the United States) is not dose-proportional and thus might not reach 
therapeutically useful levels in many patients. After oral absorption, gabapentin is 
excreted in the urine without significant metabolism. The plasma half-life of gabapentin 
in humans is relatively short, necessitating three to four times administration of 
gabapentin per day (Eckhardt et al., 2000). It has been shown that dosing regimens 
requiring three to four doses per day may lead to significant noncompliance in patients 
with epilepsy (Eckhardt et al., 2000). Thus a more prolonged, stable exposure to 
gabapentin will provide several clinical benefits, including greater efficacy and prolonged 
duration of action. 
The half-life of gabapentin in rats after oral dosing varies from 1.9 hrs for a dose 
of 25 mg/kg to 2.6 hrs for a dose of 200 mg/kg (Cundy et al., 2004). The half-life of 
gabapentin was found to be 4.7 hrs after orally administering the CG-4 codrug at a dose 
of 25 mg/kg (8.2 mg equivalent gabapentin/kg). Thus delivering gabapentin in the form 
of the CG-4 codrug significantly increases the half-life of gabapentin. Therefore, the 
codrug strategy appears to be a way to achieve a more prolonged exposure of gabapentin 
to patients and consequently a less frequent dosing regimen. Calculation of the oral 
bioavailability of the CG-4 codrug is not straight-forward because of the time-dependent 
hydrolysis of the codrug to the parent compounds in the plasma. Thus, two bioavailability 
values for the codrug can be calculated, i.e. the “actual” codrug bioavailability, and the 
“total” codrug bioavailability. The actual codrug bioavailability is based on the amount of 
actual codrug present in the plasma; whereas the total codrug bioavailability is calculated 
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assuming no hydrolysis of the codrug has taken place in the plasma. The total 
bioavailability value represents an approximation of the total amount of the codrug 
entering the systemic circulation after oral dosing. The actual codrug bioavailability was 
calculated to be 5.37 ± 1.45 %, and the total codrug bioavailability was found to be 16.32 
± 3.85 %. It should be noted that the total codrug bioavailabilty value may be 
underestimated, since the clearance parameters are not taken into account for the parent 
drugs. Since the actual and total codrug bioavailability is higher than the bioavailability 
of codeine after oral administration, this shows that a greater amount of codeine can be 
delivered orally in the form of the CG-4 codrug than codeine itself. The bioavailability of 
CG-4 codrug does not exceed the oral bioavailability of gabapentin. Thus more 
gabapentin cannot be delivered by utilizing this codrug strategy. By administering 
gabapentin in the form of the CG-4 codrug will increase the half-life of gabapentin. Thus 
the codrug strategy will cause prolong release of gabapentin and patients will need less 
frequent dosing of the codrug to maintain therapeutic level of gabapentin in plasma. Thus 
the frequent dosing regimen of gabapenting might be made simpler and patient 
compliance can be improved via a codrug strategy. 
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Chapter 6 
Summary 
 
6.1 Introduction 
There is an ongoing need for analgesic medications that are able to provide high 
efficacy pain relief and covering broader ranges of pain while providing more favorable 
pharmacokinetics and reducing the possibility of undesirable side effects. Enhancement 
of the analgesic effect of opioids when administered with S-(-)-nornicotine /ketamine or 
norketamine/gabapentin has been previously described and is well known in literature 
(see Chapter 1 for references). However, appropriate dosing of these analgesic agents to 
the site of action, e.g., the brain or spinal column, can be difficult because of their 
differential pharmacokinetics. Therefore, in the present dissertation, a codrug strategy is 
presented for orally administering opioids concomitantly with either nicotinic receptor 
agonists, NMDA receptor antagonists, or anticonvulsants, to provide a more favorable 
pharmacokinetic and analgesic profile than would be attainable by administering 
equimolar amounts of the parent drugs as a physical mixture. 
Codrugs are designed to overcome various barriers to drug formulation and 
delivery, such as poor or extreme aqueous solubility, chemical instability, insufficient 
absorption after oral administration, rapid pre-systemic metabolism, inadequate brain 
penetration, and toxicity and local irritation. The first chapter in this dissertation 
demonstrates the usefulness of the codrug strategy by discussing several reported 
examples. The codrug strategy is very useful when the physicochemical and/or 
pharmacokinetic properties of two synergistic drugs are not favorable for delivery as a 
physical mixture, but can be improved by chemical combination of the two drugs (Crooks 
et al., 2010). 
 
6.2 Opioid-S-(-)-Nornicotine Codrugs 
A series of codrugs were synthesized by conjugating an opioid molecule with the 
nicotinic receptor agonist, S-(-)-nornicotine. Codeine, morphine and 3-O-acetylmorphine, 
a prodrug of morphine, were used as the opioid and were conjugated to S-(-)-nornicotine 
via a carbamate linkage moiety. The structures of the five synthesized codrugs in this 
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series are shown in Fig. 6.1. The codrugs were synthesized by either converting the 
opioid molecule into an O-p-nitrophenoxy ester and then reacting the ester with S-(-)-
nornicotine; or by converting S-(-)-nornicotine into its p-nitrophenoxy derivative and then 
reacting this intermediate with the opioid molecule.  
 
 
Fig. 6.1: Structures of synthesized opioid-S-(-)-nornicotine codrugs. 
 
After their synthesis, some of the codrugs and parent drugs were analyzed for 
their analgesic actions in different pain models. The codeine-S-(-)-nornicotine codrug, 
codeine, and S-(-)-nornicotine were evaluated in the rat tail-flick pain model for their 
efficacy for treating nociceptive pain, and in the rat paw-pressure (CCI) pain model for 
their efficacy for treating neuropathic pain. The codrug and the parent drugs were 
administered orally in separate experiments. All three drug molecules showed analgesic 
activity to some extent in both pain models. Codeine is known to be effective in treating 
nociceptive pain (Loeser and Melzack, 1999) and the observed ED50 value for this opiate 
was 41.42 µmol/kg in tail-flick assay. S-(-)-Nornicotine was found to have very little 
efficacy in the tail-flick pain model and showed an ED50 of 107.29 µmol/kg in this assay. 
The codrug of codeine and S-(-)-nornicotine was found to be much more effective than 
either of the parent drugs in tail-flick pain model. The codrug had an ED50 of 17.95 
µmol/kg. The same trend was observed in CCI pain model. The codrug (ED50 = 7.39 
µmol/kg) was much more effective compared to either of the parent drugs (codeine, ED50 
= 45.10 µmol/kg, and S-(-)-nornicotine, ED50 = 114.04 µmol/kg). 
  Another codrug of 3-O-acetylmorphine and S-(-)-nornicotine was also evaluated 
in the tail-flick pain model and its activity was also compared with the parent drugs. This 
codrug was found to be very effective in the pain model for nociceptive pain. ED50 values 
of the codrug and parent drugs were determined from their dose-response curves. The 
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ED50 value of the codrug was found to be 2.99 µmol/kg, which is much lower compared 
to the parent drugs (3-O-acetylmorphine, ED50 = 11.00 µmol/kg, and S-(-)-nornicotine, 
ED50 = 107.29 µmol/kg).  
Thus it was observed that combing an opioid molecule with the nicotinic receptor 
agonist, S-(-)-nornicotine, in a single molecular entity enhanced the analgesic efficacy of 
both the opioid molecule and S-(-)-nornicotine. By utilizing the codrug strategy, the 
opioid dose can be reduced and the adverse side effects related to opioid therapy may be 
avoided. Also, the codeine-S-(-)-nornicotine codrug was found to be effective in the 
treatment of neuropathic pain. Opioids are known to have little or no effect in treating 
neuropathic pain (Woolf and Mannion, 1999). Thus, administering an opioid with S-(-)-
nornicotine in the form of a codrug may be useful in treating neuropathic pain. 
After synthesis and assay in the pain models, the stabilities of the codrugs were 
analyzed under different enzymatic and nonenzymatic conditions. In the different pain 
assays discussed in Chapter 3, the oral route was used as the route of administration, and 
the codrugs showed significant analgesic activity. Orally administered drug molecules 
experience the harsh conditions of GI tract, encountering encounter strongly acidic, 
mildly acidic, and basic conditions in different parts of the GI tract (Kern and Di, 2008). 
Within addition to experiencing acidic and basic environments, orally administered drug 
molecules also experience a variety of enzymes in GI tract. After the drug molecule is 
absorbed into systemic circulation (pH 7.4) a variety of hydrolytic enzymes in the plasma 
can interact with the therapeutic agents. Depending on the molecular weight and polarity 
of the drug molecule, permeation of the blood-brain barrier may occur and the drug will 
be taken up into brain, where it can also interact with different CNS enzymes. An ideal 
codrug should not undergo hydrolysis in the GI tract, and should get absorbed into 
systemic circulation as a single chemical entity (i.e. the original codrug molecule). In the 
plasma, the codrug may or may not undergo hydrolysis to produce the parent drugs. If the 
codrug does not undergo hydrolysis in the plasma to produce the parent drugs, it must 
undergo hydrolysis at the site of action (i.e. brain, in the case of opioid codrugs), 
otherwise, it will not have any pharmacological effect. To examine the stability of the 
codrug molecules, and to  determine if the codrug possesses the desired stability 
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characteristics as described above, the codrug was exposed to the following hydrolytic 
conditions: 
• Aqueous buffers (pH 1.3 to 7.4, 37 ºC) 
• Simulated gastric fluid (USP, 37 ºC) 
• Simulated intestinal fluid (USP, 37 ºC) 
• 80% rat plasma (37 ºC) 
• Rat brain homogenate (37 ºC) 
Three of the opioid-S-(-)-nornicotine codrugs (drawn in the color blue in Fig. 6.1) 
were analyzed in all of the above hydrolytic conditions. All of the three codrugs showed 
lack of hydrolysis in buffers at pH 1.3, 5.0, 7.4, and in SGF, and SIF, with the exception 
of the 3-O-acetylmorphine-S-(-)-nornicotine codrug. The 3-O-acetylmorphine-S-(-)-
nornicotine codrug underwent fast O-deacetylation to produce the morphine-S-(-)-
nornicotine codrug, however, no carbamate bond cleavage was observed. Thus, it can be 
predicted that all the analyzed codrugs will be absorbed into the systemic circulation 
without any hydrolysis to the parent drugs. The stability of the carbamate codrugs in 80% 
rat plasma and brain homogenate showed that the carbamate linkage was difficult to 
cleave in plasma, and thus, the codrugs in this series were not substrates for rat plasma 
esterases, and would likely not cleave hydrolytically to afford the parent drugs. To 
examine this likelihood, a quick pharmacokinetic study was performed with the 3-O-
acetylmorphine-S-(-)-nornicotine codrug. The codrug was administered orally to rat and 
blood samples were collected over a 24 hr time period. Plasma samples were analyzed by 
LC-MS/MS for both codrug and parent drugs. The only analyte observed in the blood 
samples was the morphine-S-(-)-nornicotine codrug; no parent drugs were detected. Thus, 
it was concluded from both the in vitro and in vivo studies on the opioid-S-(-)-nornicotine 
codrugs that a carbamate linkage between a secondary amine and an alcohol moiety is too 
stable  and will not be effective in liberating the parent drugs in the plasma. The enzymes 
present in GI tract, plasma, and brain are not capable of cleaving such a carbamate 
linkage; thus, even if the codrug entered the CNS it likely would not convert to the parent 
drugs via carbamate bond hydrolysis. Since the codrug molecules that incorporated an 
opioid molecule and S-(-)-nornicotine did not cleave to produce the respective parent 
drugs, these drug molecules are better termed drug hybrids rather than codrugs. The 
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analgesic activity exhibited by two of these “hybrid” drugs can only be explained by the 
hybrid molecules having significant analgesic activity of their own. Further experiments 
beyond the scope of this project are required to determine the mechanism of action of 
these hybrid drugs. 
 
6.3 Opioid-Ketamine and Opioid-Norketamine Codrugs 
Three codrugs were synthesized in this series following a similar synthetic 
strategy. Most pharmaceutical preparations of ketamine utilize the racemic form of the 
drug. Thus, racemic ketamine and racemic norketamine were used in the synthesis of the 
codrugs. Consequently, a mixture of diastereomeric codrugs was obtained in each case. 
In vitro stability studies were performed on the codrugs prior to analyzing the codrugs in 
the different pain models. Since the codeine-ketamine codrug contains a carbamate 
linkage between a secondary amine and an alcohol, as in the opioid-S-(-)-nornicotine 
codrug structures, a stability study under the different hydrolytic conditions was not 
performed. From the previous stability studies, it was shown that a carbamate linkage 
between a secondary amine and an alcohol is not readily hydrolysable in the plasma. 
Thus, the codeine-ketamine conjugate is an example of a drug hybrid between codeine 
and ketamine rather than a codrug. 
The codeine-norketamine conjugate contains a carbamate linkage between a 
primary amine and a secondary allylic alcohol, whereas the morphine-norketamine 
codrug contains a carbamate linkage between a primary amine and a phenolic hydroxyl 
group. These two codrugs were thought to be more likely to behave as classical codrugs, 
since they contain a more labile carbamate linker. A comprehensive stability study was 
performed on each of these codrugs to determine their hydrolytic profile. Both codrugs 
were resistant to hydrolysis under both enzymatic and nonenzymatic conditions, as well 
as in plasma and brain homogenate incubates, and did not afford any detectable amounts 
of the parent drugs in these in vitro stability studies. The reason for this might be the 
sterically hindered nature of the carbamate moiety as a consequence of the norketamine 
structure. Thus, it was predicted that in the in vivo experiments, the codeine-norketamine 
and morphine-norketamine conjugates would likely not undergo hydrolytic cleavage to 
produce the parent drugs. Since the codrugs will not be able generate the parent drugs, as 
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with the previous series of drug conjugates they are more correctly termed drug hybrids. 
In vivo pain model studies were not performed on the hybrid drugs from this series. 
 
Fig. 6.2: Structures of synthesized opioid-ketamine and opioid-norketamine codrugs. 
 
6.4 Codeine-Gabapentin Codrugs 
Four different codrugs were synthesized in this series (Fig. 6.3). Three of the 
codrugs contained ester linkers, which are known to be more prone to hydrolytic cleavage 
than carbamate linkers. The CG-1codrug was predicted to be very labile under neutral or 
slightly basic physiological condition and afford codeine and the cyclic carbamate of 
gabapentin in the small intestine or plasma, where the pH is 7.4. The stability of the CG-1 
codrug was studied in aqueous buffer at physiological (pH 7.4). The codrug was found to 
be cleaved hydrolytically at physiological pH; the rate constant for hydrolysis was 
determined to be 0.222 hr
-1
. Thus, the CG-1 codrug is not an ideal codrug, since it will be 
partly hydrolyzed in GI tract before being absorbed into systemic circulation. Also, it will 
not produce gabapentin, but rather the five-membered cyclic carbamate of gabapentin, 
which might be difficult to hydrolyze to gabapentin by plasma esterases.  
CG-2, CG-3, and CG-4 codrugs were studied extensively in different enzymatic 
and nonenzymatic buffers. Codrugs CG-3 and CG-4 are ester-linked codrugs, while CG-2 
is a carbamate- linked codrug. The CG-2 codrug did not cleave under any of the studied 
hydrolytic conditions. Thus, it can be predicted that the CG-2 codrug will not hydrolyze 
in plasma to produce the parent drugs, and thus is a hybrid drug. 
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Fig. 6.3: Structures of codeine-gabapentin codrugs. 
  
In the CG-3 and CG-4 codrugs, codeine is linked through an ester moiety with 
either an amide protected gabapentin molecule or a carbamate protected gabapentin 
molecule. Stability studies on these two codrugs were performed under the different 
enzymatic and nonenzymatic conditions previously described. The hydrolytic reactions 
were monitored by HPLC-DAD assay. Since gabapentin and gabapentin-protected 
hydrolytic products do not contain a chromophore, only the ester bond cleavage could be 
followed by HPLC assay. Amide bond hydrolysis in the amide-protected and carbamate-
protected gabapentin products could not be followed by HPLC assay. Both the CG-3 and 
CG-4 codrugs underwent ester bond hydrolysis at pH 1.3 and 7.4, and in SGF and SIF at 
a very slow rate to produce codeine and gabapentin or protected gabapentin. This is not 
an ideal rate of hydrolysis for codrugs, but since the rate of hydrolysis was very slow, it 
can be predicted that most of the codrug will be absorbed through the epithelial lining of 
the GI tract into the systemic circulation as a single chemical entity. The rates of 
hydrolysis of the ester linkages were comparatively faster in plasma and brain 
homogenate compared to the rates in simulated GI fluids. Thus, it can be predicted that 
after the codrugs are absorbed into the systemic circulation, they will be hydrolyzed in 
the plasma as well as in brain, to afford codeine and gabapentin or protected gabapentin.  
After the in vitro stability study was performed, the CG-3 codrug was evaluated in 
vivo in the rat to determine whether the codrug is hydrolyzed to the parent drugs codeine 
and gabapentin in the plasma. Codrug CG-3 was administered orally to rats and blood 
samples were collected over a time period of 24 hrs. The blood samples were analyzed by 
LC-MS/MS assay. The only analytes detected in plasma samples of the rats were 
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codeine, CG-3 codrug and N-acetylgabapentin; no gabapentin parent drug was detected. 
It was concluded that the ester linkages are labile enough to be hydrolyzed in the plasma, 
however, amide bonds that incorporate the primary amino group of gabapentin do not get 
hydrolyzed to gabapentin. Thus CG-3 codrug was not studied in relevant rat pain models. 
The pharmacokinetic profile of the CG-4 codrug was evaluated in the rat after 
oral administration. Rat plasma concentrations of the CG-4 codrug were determined after 
oral and i.v. administration utilizing an LC-MS/MS analytical methodology. Several 
groups have reported the low bioavailability of codeine (4 to 8%) after oral 
administration in rats, due to poor absorption from the gastrointestinal tract (Shah and 
Mason, 1990; Holtman et al., 2006). The oral bioavailability of gabapentin varies from 
83.8% to 47.5% (Eckhardt et al., 2000), and the bioavailability decreases with increasing 
dose. Gabapentin has a shorter half-life ranging from 1.9 to 2.6 hours (Cundy et al., 
2004). Because of shorter half-life value, repeated dosing is required to maintain 
therapeutically significant concentrations of gabapentin in the plasma.  
The CG-4 codrug, codeine, N-ethoxycarbonylgabapentin, gabapentin, and 
morphine were detected in the plasma of rats that had been administered with the CG-4 
codrug via the oral route. The codrug was detected in plasma samples at all time points 
up to and including 24 hrs. Thus, it can be concluded that ester bond hydrolysis occurs at 
a slow rate and that the codrug slowly releases codeine and N-ethoxycarbonylgabapentin. 
The N-ethoxycarbonylgabapentin product is then slowly hydrolyzed to afford gabapentin. 
Due to the relatively slow hydrolysis of the ester linkage of the codrug, and the even 
slower hydrolysis of the carbamate bond of the N-ethoxycarbonylgabapentin product, the 
parent drugs were generated at a slow rate, and were present in plasma for a long period 
of time. The actual codrug bioavailability was calculated to be 5.37%, and the total 
codrug bioavailability was found to be 16.32%. The bioavailability of the codrug was 
much higher compared to the parent drug codeine. Thus, a codrug strategy can be used to 
effectively improve the bioavailability of codeine. Also, due to the sustained release of 
codeine from the codrug, the dosing regimen of codeine or another structurally related 
opioid molecule can be made simpler by having a less frequent dosing of the codrug. 
However, this codrug strategy did not increase the oral bioavailability of gabapentin. 
Nevertheless, due to very slow release of gabapentin from the codrug, its half-life was 
246 
 
increased to 4.7 hrs. Thus, the codrug is effectively acting as a sustained release chemical 
delivery system for gabapentin, and the dosing regimen of gabapentin may be made less 
frequent by utilizing a codrug strategy. Interestingly, a significant amount of morphine 
was also detected in the plasma samples of rats after oral administration of the CG-4 
codrug. It is reported in literature that codeine is metabolized to morphine in liver. Some 
investigators believe that the analgesic activity of codeine is mainly due to its 
bioconversion to morphine, since codeine itself has little or no analgesic action when 
administered by iv injection to rats (Trescot et al., 2008). Generation of morphine in the 
plasma after oral administration of the CG-4 codrug would definitely contribute towards 
the analgesic efficacy of this codrug.  
Finally, the analgesic action of the CG-4 codrug was determined in the rat tail-
flick model after oral administration of the codrug. Tail-flick latencies of codeine were 
determined, and from the dose response curve ED50 value of codeine was calculated to be 
41.42 µmol/kg. It has been previously reported in literature that gabapentin alone has no 
intrinsic effect in the rat tail flick test. Thus, gabapentin was not tested for its efficacy in 
this pain model. Three doses (6.25, 12.5, and 25 mg/kg) of codeine-N-
ethoxycarbonylgabapentin codrug (CG-4) were administered orally and tail flick 
latencies were experimentally determined. A dose of an equimolar physical mixture of 
codeine and gabapentin equivalent to 25 mg/kg dose of the CG-4 codrug was also 
administered orally, and the time response curve for rat tail flick test was determined. The 
CG-4 codrug was found to be more effective than codeine in the tail-flick pain model 
with ED50 value of 19.17 µmol/kg. Thus, it can be concluded that the efficacy of codeine 
or another structurally related opioid can be improved by combining it with gabapentin in 
a single codrug molecule. This strategy can be utilized to reduce the opioid dose while 
treating pain, and the adverse side effects of opioids may be avoided. It was also found 
that a 25 mg/kg oral dose of the CG-4 codrug was more effective than the equivalent oral 
dose of a physical mixture of codeine and gabapentin. Thus the codrug strategy is more 
effective in treating pain than a drug combination strategy. 
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